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(and cost control staff) see red. It is also now 
increasingly more difficult for many hospital 
formulary committees to  be ab le  to strike an 
agreeable ba lance betw een effectiveness 
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QUILL ON SCALPEL This section provides a medium through which Canadian surgeons can declare themselves, 
briefly and informally, on the day-to-day affairs of surgery.
Autotranfusion Has Many Forms
S.E. Carroll, MD, FRCSC
Professor o f Surgery, University o f  Western Ontario, London, Ont.
S ince the advent of the AIDS epidemic, there has been much 
interest in using the patient’s own 
blood for transfusion. In this issue 
of the Journal (pages 458 to 462), 
Graham, Burdon and Symes de­
scribe a system of autotransfusion 
using suction, a cardiotomy reser­
voir and pump. This system is simi­
lar to ones that have been used by 
cardiac surgeons for several years, 
but there are others which might be 
considered.
Perhaps the simplest form of au­
totransfusion for elective surgery is 
to have patients to donate their own 
blood before operation. By making 
a second donation with exchange, 2 
or 3 units of the patient’s blood can 
be obtained. This system has been
instituted by the Red Cross Blood 
Bank in Ontario.
Another simple method is the 
Solcotrans system. A bottle contain­
ing anticoagulants is used during 
surgery and the blood is reinfused. 
This may be quite suitable for repair 
of an aneurysm of the abdominal 
aorta. The patient is usually hepari­
nized and the volume of blood re­
placed is relatively small.
During the past few years a cell 
saver system has been developed, 
using a suction apparatus to collect 
blood, washing the erythrocytes 
and restoring these to the patient. 
The apparatus costs approximately 
$35 000.00 and requires a techni­
cian for the operation. The rate of 
blood replacement is limited, so that
this system might be most useful 
for repair of an aneurysm of the 
descending thoracic aorta or thora­
coabdominal aorta.
The system described by the au­
thors is not so expensive as the 
cell saver, although a technician is 
still required. It has the added ad­
vantage of providing a high volume, 
rapid rate transfusion. It, therefore, 
may be the preferred method when 
larger volumes are required, as in 
repair of the abdominal aortic aneu­
rysm which has ruptured into the 
inferior vena cava, a large thora­
coabdominal aneurysm, or a pene­
trating injury of the abdominal 
aorta or inferior vena cava. Further 
developments in this field are an­
ticipated. ■
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QUILL ON SCALPEL
Aptitude Testing in Surgery
D. Michael Grace, MD, DPhil, FACS, FRCSC
Member, Editorial Board, Canadian Journal o f  Surgery. Associate Professor, Department o f 
Surgery, University o f  Western Ontario, University Hospital, London, Ont.
I n this issue (pages 467 to 470), Squire and colleagues have 
added a new worry to those of 
senior surgeons, faced with failing 
eyesight, stamina and memory, in 
their finding that surgical consul­
tants performed more poorly than 
surgical or medical residents in 
tests of manual dexterity. I can hear 
surgeons across the country stir­
ring with indignation and preparing 
to challenge our medical colleagues 
or surgical residents to a shootout 
on the golf course! On further 
reflection, the paper raises impor­
tant issues. What makes a good 
surgeon and how do you measure 
performance? How should surgical 
residents be selected and surgical 
performance predicted? How can in­
terest in surgery among medical 
students be stimulated and techni­
cal skills in medical and surgical 
fields be encouraged?
Squire and colleagues conclude 
that manual dexterity should not be 
used in assessing candidates for 
surgical residency training posi­
tions. The same conclusion was 
reached by Schueneman and associ­
ates,1 who stated that “pure psy­
chomotor skill (manual dexterity) is 
not the major dimension distin­
guishing the proficient surgical per­
formance from the mediocre”. Abili­
ty to tolerate stress and complex 
visuospatial organization correlated 
much better with assessments of 
operative skill.1 Others2 have agreed 
that older residents may show “less 
speed and coordination and more 
caution” but no difference in rated 
surgical skills. Although specific 
tasks may be performed more slow­
ly, surgical experience does result
in quicker operations and reduced 
postoperative complications.3 Many 
factors other than pure technical 
skill influence success in surgery. 
Spencer4 stated that a skilfully per­
formed operation is 75% decision­
making and 25% dexterity.
The desirable qualities of a good 
surgeon are open to debate. A 
group of surgical faculty and resi­
dents rated the qualities of surgical 
house officers;5 their list included 
admission of errors, good discipline, 
considering all facts, high motiva­
tion, consistency, ability to listen, 
decisiveness, teamwork, flexibility 
and a positive attitude. Non-sur­
geons might have other ideas. The 
aim is to obtain the maximum num­
ber of positive qualities in surgical 
trainees, realizing that some of us 
already in the field may be deficient 
in a few of these attributes.
Traditional methods of resident 
selection are based on academic 
records, personal interviews, refer­
ences, and often direct observation 
on the ward or in the operating 
room. Academic records may pre­
dict ability to pass examinations but 
correlate poorly or even negatively 
with surgical skills.1 Unstructured 
group interviews may be no more 
successful than random selection in 
assessing ability, motivation and 
personality, which predict later per­
formance.6 References are rarely 
critical or detailed enough to be of 
real help in selection. Direct obser­
vation during electives or internship 
may be helpful, but, unfortunately 
for the student, the elective is used 
to impress surgical selection com­
mittees rather than to gain experi­
ence in varied medical fields. An
opportunity to travel is lost and 
those who need medical and cultur­
al breadth of knowledge become yet 
narrower in outlook. A standardized 
selection procedure less dependent 
on interviews and impressing the 
selection committee might allow a 
return to broadly based electives in 
clerkship and internship and more 
accurate prediction of surgical suc­
cess.
In England, surgeons have begun 
aptitude testing67 and have de­
scribed the present system as “sub­
jective and haphazard”.7 Yet selec­
tion becomes more important as 
residency positions decline and ap­
plications increase. The problem is 
to get the right people into the 
right jobs. In a symposium on per­
sonality assessment and aptitude 
testing in the selection of surgical 
trainees, it was pointed out that 
such testing is now widely used in 
industry and in assessing suitability 
for military service.6 Clarke and 
Wigton,8 in the United States, rated 
applicants under five criteria: 
knowledge, judgement, work hab­
its, interpersonal skills and techni­
cal skills. However, this system may 
be more helpful in organizing infor­
mation than in predicting future 
success, and technical skills could 
not be assessed accurately. The 
Dutch9 have used an initial detailed 
questionnaire to grade prospective 
surgical residents. They assess ver­
bal, spatial and numerical reasoning 
with paper and pencil and use com­
puter testing to assess manual dex­
terity and stress tolerance. Candi­
dates are rated according to intelli­
gence, operative skill, stability and 
organization (stress tolerance, corn-
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mon sense, time management), 
work attitudes (motivation, accura­
cy, energy), and cooperation (team 
spirit, leadership, self-criticism and 
empathy). A psychologist aids sur­
geons in the selection process. By 
this technique, 10% to 20% of appli­
cants are selected, although far 
more are judged suitable for train­
ing. The Dutch emphasize that 
there is room for individuals and no 
single profile of the ideal surgeon.
Are surgical skills innate or 
learned? Neuropsychologic testing 
designed by Schueneman and col­
leagues1 and the Dutch9 attempts to 
determine innate skills and avert 
technical skill problems late in sur­
gical residency. However, more can 
be done to encourage technical 
skills during residency. Some sur­
geons, such as the late Dr. A.D. 
McLachlin, are renowned for their 
emphasis on teaching and encour­
aging good surgical technique. The 
system of graded responsibility en­
courages technical experience but 
defers it to the later years of resi­
dency when the early years may be 
of crucial importance for acquiring 
basic skills.10 The recent develop­
ment of microvascular laboratories 
in many centres has encouraged the 
learning of fine motor skills. In the 
past, operations on animals allowed 
residents to acquire surgical skills, 
but such opportunities have de­
creased as a result of opposition to 
the use of animals for experimenta­
tion. Many ingenious alternatives 
can be developed in the laboratory 
for teaching fundamental surgical 
skills to surgical residents,10 and 
such methods can also be applied to 
medical students. Orthopedic sur­
geons have been pioneers in evalu­
ating and teaching surgical 
skills.1112
In these days of limited training 
positions and hospital resources, it 
is important that we select the right 
candidates for residency and a ca­
reer in surgery. Squire and col­
leagues have shown that assess­
ment of manual dexterity should 
not, by itself, be used to select 
prospective surgeons. However, 
methods of predicting technical 
skills and determining aptitude for a 
surgical career are being developed 
in other countries. We should con­
tinue this process in Canada.
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SESAP VI Question
Item 222
For a patient with a superficial femoral artery occlusion with only 
posterior tibial artery runoff, which of the following signs or symptoms 
would be the WEAKEST indication for femorotibial bypass?
(A) Nonhealing ischemic ulcer
(B) Ischemic rest pain of the forefoot
(C) Severely limiting intermittent claudication of the calf
(D) Gangrene of the great toe
(E) Cyanotic toes secondary to ischemia
For the question above, select the one answer that is best of the five 
given.
For the critique of Item 222 see page 444.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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QUILL ON SCALPEL
T h e  CJS — Yesterday, Today and 
Definitely Tomorrow
C.B. Mueller, MD, FRCSC; L.D. MacLean, MD, FRCSC
Coeditors, Canadian Journal o f Surgery
Events of the past 2 or 3 years, and particularly those of the 
spring and summer of 1989, have 
forced the Canadian Journal o f Sur­
gery to review its status, its man­
date and its support. Your coeditors 
take this opportunity to review the 
past, describe the present and pres­
ent some personal thoughts about 
Canada, its surgical community and 
its national identity.
A Bit of History
In 1957, the first volume of the 
Canadian Journal o f Surgery was 
published by the Canadian Medical 
Association. It appeared quarterly 
in a 7 X 9-inch format. Dr. R.M. 
Janes, chairman of the Department 
of Surgery at the University of 
Toronto was the first editor and 
chaired an editorial board composed 
of the chairmen of all the university 
departments of surgery in Canada. 
The editorial policy was for the 
Journal to be a publication of recent 
scientific activities within Canadian 
surgical departments. A full-time 
editorial assistant and a part-time 
associate editor were appointed, and 
the Journal was distributed on a 
subscription basis. In 1964, Dr. 
Janes relinquished the editorship to 
Dr. Fred Kergin, also of Toronto. 
By 1971, the frequency of publica­
tion had increased to six issues per 
year and the circulation had grown 
to 1500. In 1972, Dr. Kergin gave 
up his editorial responsibilities,
partly because the editorial offices 
were being moved from Toronto to 
Ottawa. Drs. L.D. MacLean and 
C.B. Mueller then accepted the re­
sponsibility of coeditorship.
About the same time, a commit­
tee of the Royal College of Physi­
cians and Surgeons of Canada, with 
representation from the Canadian 
Medical Association, the Canadian 
Society for Clinical Investigation 
and l’Association des medecins de 
langue franqaise du Canada agreed 
that it “was desirable to try to 
ensure the survival of the Canadian 
Journal of Surgery...perhaps broad­
en it to include greater coverage of 
the surgical specialties...an affilia­
tion with or sponsorship by 
RCPSC...would merit serious con­
sideration”.
In 1973, a proposal to the Coun­
cil of the Royal College suggested 
that it should send “CJS to its 
surgical members as a function of 
membership...arrange for it to re­
late to all members...for purposes of 
continuing education, a chance to 
disseminate information of general 
interest and be a medium of com­
munication”. With Council approv­
al, the following policies were estab­
lished:
•  The publication would be a 
joint undertaking.
•  The CMA would own the 
Journal.
•  The Royal College would set 
editorial policy, appoint the editors 
and the editorial board and receive 
periodic reports.
•  The CJS would be sent to 
every Fellow in the Division of 
Surgery and any Fellow in the Divi­
sion of Medicine who desired it.
•  A board of management would 
be appointed from the two organi­
zations.
•  An annual grant of money 
from the Royal College would be 
provided to the CMA to help cover 
expenses.
•  The Royal College would pro­
vide a mailing list.
The CMA portion of this arrange­
ment was to provide office space, 
reimbursement for the coeditors 
and editorial staff, manuscript pro­
cessing, copy editing and prepara­
tion of manuscripts for publication, 
journal production with respect to 
layout, style and format, contract­
ing for printing and mailing, and 
advertising sales staff. By 1974, a 
new editorial board had been consti­
tuted and a new position created in 
the CMA editorial office. This ar­
rangement has continued to the 
present. The circulation of the Jour­
nal is now 9000 per issue, the 
annual budget is approximately 
$300 000 per year, and, in 1988, 
the cost to the Royal College for 
this arrangement was approximate­
ly $2.00/yr per Fellow.
The Events of 1989
In May 1989, the Council of the 
Royal College voted to “ ...support 
financially only one journal and that
398 CJS, VOL. 32, NO. 6, NOVEMBER 1989
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journal be the Annals”. The Royal 
College agreed to continue financial 
support for a short period, but 
fiscal pressures now weigh heavily 
upon the Canadian Medical Associa­
tion. From a net gain of approxi­
mately $50 000.00 in 1984, the 
CJS showed a net loss of approxi­
mately $100 000.00 in 1987 and 
1988. This deficit, absorbed by the 
CMA at approximately $3.00/yr 
per member, is partly explained by 
rising costs, but it results chiefly 
from a major decrease in advertis­
ing revenue — an item which must 
create 50% to 60% of the Journal’s 
income. The CMA General Council 
in a recent action narrowly defeated 
a motion to discontinue publication 
of the CJS. Thus, discomfort with 
the present arrangement within the 
Royal College and a deficit in the 
Journal’s budget have brought the 
CJS to the point where a new look, 
new ideas and new arrangements 
are in order.
Personal Thoughts
This is an appropriate time to 
acknowledge the productive associ­
ations of the past as we contem­
plate the future of CJS. It has been 
a stimulating and rewarding experi­
ence for us, your coeditors, for we 
have enjoyed many warm relation­
ships with the editorial board and a 
host of reviewers over the past 17 
years.
The Journal has grown both in 
the amount and quality of editorial 
material, which reflects the in­
creased interest of an ever-increas­
ing number of authors. The Journal 
reflects the excellence of Canadian 
surgery in many areas, including 
transplantation, critical care, trau­
ma, cardiovascular surgery and co­
lorectal surgery. We hope this Jour­
nal will encompass the interests of 
all surgeons in the future.
Royal College support permitted 
us to circulate the Journal to over
9000 surgeons. Many changes in 
format, together with this large 
circulation, have made the Journal 
attractive to a wide audience on 
which readership surveys are excel­
lent.
The staff of the communications 
committees of both the Royal Col­
lege and CMA have been most help­
ful. We have enjoyed full rein in all 
editorial matters, but the time has 
come for the CJS to take the next 
step in development. The Journal 
must appeal to all surgeons in Can­
ada, and it must do this with a 
balanced budget.
We must offer more than good 
science, we must be a sounding 
board for the many issues that 
uniquely affect surgeons. Some of 
these issues are physician liability, 
reimbursement, the management of 
hospitals where we do most of our 
work, quality control and audit of 
surgical practice in and outside the 
hospital, the inadequate financial 
support available for research in 
areas of surgical interest, the pro­
motion of research related to health 
care policy with focus on outcome 
analysis in all surgical disciplines. 
We should promote the develop­
ment of multidisciplinary clinical tri­
als across this great nation.
How can this be accomplished at 
a time when the CMA can no longer 
absorb deficits in the budget and 
the Royal College has made the 
decision to support only one jour­
nal, the Annalsl
We need an umbrella organiza­
tion which has appeal to all surgical 
specialties, an organization that 
would set editorial policy, appoint 
the editors and editorial board.
The Canadian Conjoint Council 
on Surgical Education and Re­
search, which is now being consti­
tuted, has as its contemplated func­
tions and goals many of the above 
requirements for the future of the 
CJS.
Members of the provisional exec­
utive committee of this new organi­
zation responsible for developing an 
inaugural meeting in September 
1989 were Drs. Jean R. Brunette, 
Jean Couture, John Duff, Robert 
McMurtry, David S. Mulder and 
Bryce Weir. The founding organiza­
tions include the following:
Canadian surgical chairmen 
Royal College of Physicians and 
Surgeons of Canada 
Canadian Society of Cardiovascu­
lar & Thoracic Surgeons 
Canadian Critical Care Society 
Canadian Association of General 
Surgeons
Canadian Neurosurgical Society 
Canadian Orthopaedic Associa­
tion
Canadian Society of Otolaryngol­
ogy
Canadian Association of Paediatr­
ic Surgeons
Canadian Society of Plastic Sur­
geons
Canadian Society for Surgery of 
the Hand
Trauma Association of Canada 
Canadian Urological Association 
Canadian Society for Vascular 
Surgery
Canadian Ophthalmological Soci­
ety
Society of Obstetricians and Gy­
naecologists of Canada.
A journal of surgery is a national 
obligation for a country of 26 mil­
lion with a unique health delivery 
system at a time of enormous 
change in patterns of health care 
delivery, many of which affect sur­
geons very specifically. A new, more 
broadly based Canadian Journal o f  
Surgery with input, control, even 
ownership, by all branches of sur­
gery should play an important role 
in our future. We hope the new 
Canadian Conjoint Council on Sur­
gical Education and Research and 
the Canadian Journal o f Surgery 
can prosper together for the benefit 
of our patients and the welfare of 
all surgical disciplines.*
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Coeditor Recipient of 1989 Gairdner Foundation Award
Dr. L.D. MacLean, coeditor of 
the Canadian Journal o f Surgery, 
has been named winner of the 
1989 Gairdner Foundation 
Wightman Award. He received 
the award from Dr. J.C. Polanyi, 
the president of the Foundation, 
at a ceremony in Toronto on 
Oct. 20, 1989.
The Gairdner International 
Foundation, which was estab­
lished in 1957, recognizes, annu­
ally, outstanding contributions 
to medical science. This year 
eight scientists (three from Cana­
da, two from the United States, 
one from Belgium and two from 
West Germany) received five 
awards amounting to more than 
$250 000. Of the 205 scientists 
so far honoured, 33 have sub­
sequently received a Nobel prize.
The Wightman Award is giv­
en, from time to time, to a 
Canadian who has shown out­
standing leadership in medicine 
and medical science.
In his citation, Dr. R.B. Salter 
stated: “Dr. MacLean is eminent­
ly suited to be a recipient of the 
Gairdner Foundation Wightman 
Award which is given, from time 
to time, ‘to a Canadian who, in 
the opinion of the Foundation, 
has demonstrated outstanding 
leadership in medicine and medi­
cal science consistent with the 
purposes of the Foundation’. He 
is being recognized as Canada’s 
most outstanding surgeon-scien­
tist-teacher-administrator over a 
long and productive career. As a 
general surgeon, his clinical 
skills are widely respected
throughout Canada. As a surgi­
cal scientist, he has consistently 
conducted exciting and signifi­
cant basic research on shock and 
the nutritional needs of surgical 
patients. As a teacher, he has 
taught surgery and surgical re­
search to undergraduate and 
postgraduate students over a pe­
riod of 27 years. As an adminis­
trator, he has served with great 
distinction as professor and 
Chairman of the Department of 
Surgery at McGill University, and 
Surgeon-in-Chief of the Royal 
Victoria Hospital, Montreal, for 
27 years.”
Dr. C.B. Mueller, coeditor of 
the Journal, and the editorial 
staff offer their congratulations 
to Dr. MacLean on winning this 
prestigious award.
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HOW I DO IT
Hidden Loop Colostomy
S. Walfisch, MD; H. Stern, MD, FRCSC; K. Witkowski, RN
A lthough one-stage operations for obstructing cancer of the 
colon have become popular, loop 
colostomy is frequently the proce­
dure of choice for inoperable colon­
ic cancer or unresectable abdominal 
cancer, invading the distal colon.1 3 
It may also be indicated when ob­
struction is imminent. The rationale 
for this is the avoidance of another 
operation and the morbidity associ­
ated with the creation of a colosto­
my.4 This is particularly true for 
patients who have advanced disease. 
The purposes of a “hidden colosto­
my” are to allow the option of a 
colostomy if obstruction occurs, 
which can be simply done with only 
local anesthesia, and to delay the 
need for colostomy for as long as 
possible.5 In some patients, death 
from systemic disease occurs first 
and the need for the colostomy is 
avoided entirely.
Surgical Technique
Transverse or sigmoid colon may 
be used. In addition to the midline 
laparotomy incision, another stan­
dard, small, transverse incision is 
made for the colostomy, usually in 
the left upper or lower quadrant of 
the abdominal wall. An opening is 
made in the mesocolon and the loop 
of colon is pulled through the fas­
cial opening as for construction of a 
standard loop colostomy. The colon 
is retracted with a Penrose drain 
and, underneath, the fascia is loose­
ly approximated with 0 Prolene 
sutures through the opening in the 
mesocolon (Fig. 1). The colon 
should rest loosely on the Prolene- 
fascial bridge. The skin is then 
reapproximated above the loop. It is 
most important to create the loop 
without tension on the fascia. If the 
bowel becomes obstructed it is im­
portant to ascertain whether the 
obstruction is in the small or large 
bowel. If the obstruction is colonic, 
the patient is given a local anesthet­
ic at the bedside, then the skin is 
incised over the hidden loop. The 
dilated colon will bulge into the 
wound. The colonic loop is opened 
across the antimesenteric border 
and sutured to the skin (Fig. 2).
Discussion
We believe this procedure is 
probably best suited to elderly, 
blind, arthritic patients or to those 
who would find it difficult to adjust 
to life with a colostomy, and in 
whom complete obstruction is im­
minent. This is clearly a subjective 
finding at laparotomy, but support­
ive evidence can be gained from 
barium x-ray films. There are no
From the Department o f  Surgery, Mount Sinai Hospital, and the University o f  Toronto, Toronto, 
Ont.
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absolute contraindications, but 
clearly there are no advantages to 
the procedure if the colon is com­
pletely obstructed at the initial lapa­
rotomy.
A hidden loop colostomy is easily 
constructed and is simple to open 
whenever needed. We have per­
formed this procedure on three pa­
tients and in two, opening the co­
lostomy was delayed several 
months. We recommend that con­
struction of this type of colostomy 
be considered in the appropriate
FIG. 1. (Top) Loop of colon resting on 
fascial bridge. (Bottom) Lateral view.
FIG. 2. When obstruction occurs, skin 
and bowel are opened along antime­
senteric border.
CJS, VOL. 32, NO. 6, NOVEMBER 1989 401
WALFISCH, ET AL.
patients with impending obstruc­
tion.
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BOOK REVIEWS
AORTIC SURGERY. Edited by John J. 
Bergan and James S.T. Yao. 574 pp. 
Illust. W.B. Saunders Company Cana­
da Limited, Toronto, 1989. $142.75. 
ISBN 0-7216-2914-8.
This text continues a well-established 
series of multiauthored books on select­
ed vascular subjects. The successful 
format has been combined and contin­
ued with the contributions of some 
excellent authors.
The chapters are clear and concise, 
the illustrations good and the refer­
ences up to date, it was satisfying to 
see a chapter on historical perspectives, 
which reminds us of how much we owe 
to the pioneers in aortic surgery.
Rare problems in aortic disease, in 
particular Takayasu’s disease, arteri- 
omegaly, aortic lesions in children and 
Marfan’s syndrome, are well covered, as 
is the excellent chapter on urologic 
injuries, a rare problem.
The chapters on basic considerations, 
development of atherosclerosis and an­
eurysm formation are particularly inter­
esting. The sections on concomitant 
surgical procedures and on the contro­
versial areas of concomitant coronary 
artery surgery, cholelithiasis and com­
bined aortic and renal reconstruction 
are handled well and are informative. 
Up-to-date information is given on alter­
native aortic surgical procedures, and 
the chapter on the use of descending 
thoracic aorta for arterial reconstruc­
tion is particularly concise, clear and 
well illustrated. Complications of aortic 
surgery are well covered, particularly 
the management of the acutely ischemic 
limb and sexual dysfunction.
A minor drawback to this book is 
that some of the chapters overlap with 
other books in the series. This is to be 
expected, and the other chapters more 
than make up for this minor problem.
Aortic Surgery should be read by 
all vascular surgeons and will make an 
excellent addition to any library.
F. Michael Ameli, MB, ChB,
FRCS(Edin), FRCSC, FACS
Ste. 313,
E.K. Jones Building. 
160 Wellesley St. E. 
Toronto, Ont. 
M4Y1J3
INDICATIONS IN VASCULAR SUR­
GERY. Edited by Roger M. Green- 
halgh. 446 pp. Illust. W.B. Saunders 
Company, Philadelphia; W.B. Saun­
ders Company Canada Limited, Toron­
to, Ont., 1988. $136.95. ISBN
0-7216-2623-8.
This book, a collection of papers pre­
sented by authors who are recognized 
experts in their fields, helps to fill a gap 
between a traditional textbook and 
journal articles. Because it covers vas­
cular surgery in its entirety, it is an 
invaluable aid to those who wish to 
have these indications in one succinct 
book.
The section on cerebrovascular dis­
ease is excellent; carotid disease is 
divided into all its categories and each 
is reviewed in detail, all recent impor­
tant journal articles being noted. With
the ongoing criticism of carotid endar­
terectomy, it is imperative that the 
vascular surgeon have these facts and 
figures at hand.
The presentation of upper-limb prob­
lems is interesting; the section on sub­
clavian and brachial artery occlusions is 
presented clearly with many good dia­
grams and angiograms. The chapter on 
cervical and first-rib excisions helps to 
place in perspective the elusive thoracic 
outlet syndrome.
The section on lower-limb ischemia is 
the longest and possibly the most con­
troversial. The chapter on intra-arterial 
thrombolytic therapy is a review of the 
author’s personal experience, and the 
advocated technique of thrombolytic 
therapy on the ward may not be accept­
able in Canada.
In the chapter on surgery of the deep 
femoral artery, the author states that 
“even when the superficial femoral ar­
tery is patent, lesions of the profunda 
should be corrected prophylactically in 
relation to aorto-femoral reconstruc­
tions”, but this may not be standard 
practice for all vascular surgeons. Also, 
most vascular surgeons would not be 
willing to use the “pulse-rise time as 
measured by a hand-held pressure 
transducer over the femoral artery” 
instead of angiography to detect aor- 
toiliac inflow disease preoperatively.
Although the section on venous dis­
ease is short, it is well written and 
presents a clear view of venous opera­
tive indications.
In summary, this readable textbook 
summarizes most indications in vascu-
continued on page 427
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Symposium on the Management of 
Carcinoma of the Esophagus: a Continuing 
Controversy 
1. Introduction
R.J. Ginsberg, MD, FRCSC
The management of carcinoma of the esophagus continues to 
be controversial. Despite advances 
in all disciplines associated with the 
management of the disease, the 
overall survival and cure rates for 
patients suffering from carcinoma 
of the esophagus remain dismal. 
Unfortunately, in North America 
this disease usually presents late 
when the patient is already suffer­
ing from local or distant metastases 
and the cure rate is poor. Until 
methods are found to make an early 
diagnosis, medical oncologists, radi­
otherapists and surgeons will find 
themselves challenged in attempt­
ing to treat patients with relatively 
advanced tumours.
A symposium on management of 
esophageal cancer was held at the 
1988 annual meeting of the Royal 
College of Physicians and Surgeons 
of Canada under the auspices of the 
Canadian Society of Cardiovascular
Accepted for publication Feb. 9, 1989
and Thoracic Surgeons. We were 
fortunate in having four distin­
guished lecturers present their 
views on the current management 
of carcinoma of the esophagus, and 
their papers are presented in the 
following pages. Dr. Andre Duran- 
ceau (Montreal) outlines the current 
controversies in surgical manage­
ment (pages 415 to 419). Dr. 
David Skinner (New York) empha­
sizes his preference for radical surg­
ical excision in early stage disease 
(pages 420 to 423). Dr. David 
Kelsen (New York) reviews the role 
of adjuvant treatment in carcinoma 
of the esophagus, indicating the 
need for prospective randomized tri­
als to find out whether neoadjuvant 
chemotherapy and radiotherapy 
should play a role in the manage­
ment of this disease (pages 410 to 
414). Dr. Albino Flores (Vancou­
ver) reviews the experience of the 
Cancer Control Agency of British
Columbia in managing patients with 
carcinoma of the esophagus, utiliz­
ing a combination of brachytherapy 
and external beam irradiation; for 
patients whose disease was in its 
early stage this was combined ulti­
mately with surgical resection 
(pages 404 to 409).
From these articles, it is obvious 
that there are more questions than 
answers related to management of 
carcinoma of the esophagus. The 
answers to these controversial is­
sues will only be achieved by ade­
quate staging of patients before 
their treatment and by utilizing ran­
domized, controlled, clinical trials 
to pose questions concerning the 
best management of this disease. 
Unfortunately, as yet, this type of 
studied approach to carcinoma of 
the esophagus has not been done. 
Because of the relatively low inci­
dence of this disease in North 
America, any type of clinical trial 
with meaningful results will require 
the cooperation of many centres 
throughout the continent. We hope 
that the various disciplines involved 
in treatment can reach suitable 
compromises so that these very 
necessary studies can be done. Until 
then, the management of carcinoma 
of the esophagus will remain con­
troversial. ■
From the Department o f Surgery, Mount Sinai Hospital, University o f  Toronto, Toronto, Ont.
Presented as part o f a symposium on Carcinoma o f  the Esophagus by the Royal College in 
cooperation with the Canadian Society o f  Cardiovascular and Thoracic Surgeons, at the 57th 
annual meeting o f  the Royal College o f Physicians and Surgeons o f Canada, Ottawa, Ont., Sept. 
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2. Cancer of the Esophagus and Cardia: Overview of Radiotherapy
A.D. Flores, MD, FRCPC
Cancers of the esophagus and cardia are aggressive; they behave similarly and are 
associated with an extremely poor prognosis. Because current treatments (surgical 
esophagectomy and irradiation) have failed to cure the disease, critical analysis is 
needed to determine the reasons for this failure. The following problems in disease 
management have been identified: (a) most patients are old, frail, undernourished 
and have locally advanced disease at the time of diagnosis, (b) 80% of patients die of 
locally recurrent disease and aspiration pneumonia caused by the persisting cancer, 
(c) there is no consensus as to what constitutes the optimum curative treatment for 
the disease and (d) there is no agreement on the technical aspects and extent of the 
surgical treatment required or on radiotherapy.
Les cancers de l’oesophage et du cardia sont des tumeurs agressives. Ils se 
comportent de fafon similaire et sont lies a un tres mauvais pronostic. Comme les 
traitements actuels (oesophagectomie chirurgicale et irradiation) se sont reveles 
inefficaces a guerir cette maladie, une analyse critique s’impose si Ton veut 
determiner les raisons de cet echec. Les problemes suivant propres au traitement de 
cette maladie ont ete identifies: a) la plupart des patients sont ages, fragiles, 
sous-alimentes et souffrent d’un cancer localement etendu au moment du diagnostic, 
b) 80% des patients meurent d’une recidive locale et de pneumonie de deglutition 
causee par la persistance du cancer, c) il n’y a pas consensus sur ce qui represente le 
traitement a visee curative optimum de cette maladie et d) on ne s’entend pas sur les 
aspects techniques et sur I’etendue de la chirurgie requise ou sur la radiotherapie.
I n this paper I review the experi­ence of the Cancer Control Agen­
cy of British Columbia with the 
overall management of cancer of 
the esophagus and cardia, discuss 
our recommended radiotherapy pro­
tocol (combined intracavitary and 
external irradiation) based on that 
experience, and describe the results 
in a series o f patients who received 
this treatment.
Accepted fo r publication Feb. 9, 1989
Historical Cases
Between 1970 and 1980, 483 
patients with cancer of the esopha­
gus and cardia were seen at the 
Cancer Control Agency of British 
Columbia by a joint esophageal tu­
mour group, comprising surgeons 
as well as radiation oncologists. 
These patients made up 60% of the 
total number of cancer cases regis­
tered in British Columbia during 
that period. Of the total group, 401 
patients had tumours larger than 5 
cm (T2), and in 288 (60%) the 
disease had extended beyond the 
esophageal wall (T3). Eighty-nine 
(18.4%) presented with distant me­
tastasis. The overall 5-year survival 
rate for the 331 patients who had 
locally advanced disease and were 
treated by external beam radiother­
apy was only 9%; a selected group 
of 70 patients who had lesser dis­
ease and were treated by esophagec­
tomy had a 5-year survival rate of 
20% (Figs. 1 and 2). The 121 
patients who had radical external 
beam radiotherapy had a similar 
overall 5-year survival (Fig. 3). 
Analysis of the pattern of failures in 
these cases showed that most pa­
tients died of persistent disease at 
the primary site and that the main 
cause of death was aspiration pneu­
monia due to obstruction caused by 
the persisting cancer (Table I).
FIG. 1. Survival curve for all patients 
treated.
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RADIOTHERAPY FOR ESOPHAGEAL CANCER
Combined Intracavitary and 
External Irradiation
Rationale
The radiobiologic effect on the 
tumour is directly proportional to 
the dose of radiation given. At­
tempts to improve local control by 
increasing the dose of external radi­
ation have not been successful be­
cause this exceeds the tolerance of 
the adjacent normal tissues (spinal 
cord, heart, lung) and has led to 
serious complications. The dosime­
try provided by a 10-cm linear 
source for esophagus is shown in 
Fig. 4. The short distance from the 
radioactive material to the tumour 
(4 mm) results in a high dose at the 
surface of the tumour but gives 
much lower doses at depth, thereby 
sparing the adjacent normal tissue 
from unnecessary radiation. The 
combination of intracavitary irradia­
tion and external irradiation is very 
attractive for esophageal tumours
because the most exophytic, super­
ficial and necrotic intraluminal dis­
ease can be irradiated to higher 
doses by the intracavitary compo­
nent without substantially affecting 
normal tissue; external irradiation 
provides a deeper dose to a portion 
of the tumour which is probably 
better oxygenated and hence the 
more sensitive portion of the eso­
phageal cancer (Fig. 5).
Method
Placement of the esophageal bou­
gie for intracavitary radiation at our 
institution is a very simple outpa­
tient procedure done under local 
anesthesia or with the patient only 
mildly sedated.1 Treatment is stan­
dard for all patients. A cylinder 
measuring 2 X 2 X 10 cm was 
exposed to 1.5 Gy over 1.5 hours. 
A course of external irradiation was 
started on an outpatient basis; it 
was applied to three fields, one 
anterior and two posterior oblique,
and a cylinder measuring 6 X 6 X 
16 cm was exposed to 4.0 Gy in 
15 treatments over 3 weeks, at 100 
cm source axis distance (SAD). For 
patients with potentially resectable
FIG. 3. Survival for patients treated by 
radiotherapy.
T a b le  1. C ause  o f D eath
Cause N o. of 
c a s es
P ne u m o n ia  (a s p ira tio n , f is tu la ) 3 4 9
C e re b ro va sc u la r 32
B leed ing 15
S uic ide 5
P o s to p e ra tiv e  c o m p lic a t io n s 2 3
Tota l 4 2 4
FIG. 4. Isodose distribution for 
brachytherapy in esophagus.FIG. 2. Survival for patients with adenocarcinomas.
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disease (lower esophagus and 
cardia), the external beam radio­
therapy was the same, but the oper­
ative procedure was arranged 6 
weeks after the last treatment.
Patients
From February 1985 to June 
1988, 211 patients were treated at 
our institution by a combination of 
intracavitary and external irradia­
tion. Of these, 171 patients were 
followed up for at least 10 months 
and were available for an analysis of 
tolerance, quality of life and surviv­
al. The youngest was 43 years of 
age and the oldest 89- years (median 
68 years). One hundred and ten 
patients had squamous cell car­
cinomas and 59 had adenocar­
cinomas of the lower esophagus or 
cardioesophageal junction (Table 
II). One had an adenocarcinoma of 
the middle portion of the esophagus 
and another had similar disease in 
the upper esophagus. Computed to­
mography revealed advanced dis­
ease with extension beyond the eso­
phageal wall in 131 patients. Twen­
ty-two (12.9%) had distant metasta- 
ses at the time of presentation, but 
all are included in the analysis.
Forty-three patients underwent 
surgery after the radiotherapy. 
Twenty-six underwent resection, 
but 17 had abdominal carcinomato­
sis or liver metastasis (worse surgi­
cal stage). The remainder of the 
patients had tumours in the upper 
(20) or middle portion (50) of the 
esophagus or had inoperable cancer 
located in the lower third of the 
esophagus or cardia (47).
Treatment Results
No patient died of complications 
related to the procedure. One pa­
tient died 3 months after the in­
tracavitary treatment as a conse­
quence of possible radiation-induced
pneumonitis. This was a patient 
with advanced chronic pulmonary 
disease who was treated for recur­
rent disease 6 months after the 
initial radical external beam radio­
therapy. The complication was 
thought to be unrelated to the 
intracavitary component of the 
treatment. Radiation esophagitis, al­
though common, was only mild in
most cases, but was severe in 25 
patients (14%), and it persisted until 
death in all of them. This complica­
tion was, however, superimposed 
on, and confused with, the persis­
tent and progressive malignant con­
dition. None of the patients suffered 
tracheo- or bronchoesophageal fis­
tulas as a consequence of the thera­
py, but in eight patients a fistula
PORT 1
□ 3000
10 cm ^  1500---------------- 1 □ 750
FIG. 5. Isodose distribution for combined treatment.
T a b le  II. S ite  D is tr ib u tio n
CCABC
S ite No. of pa tien ts c la ss ifica tio n *
C erv ica l eso p h a g us 11
U p p e r th o ra c ic 9 67
M id -th o ra c ic 50
L o w e r th o ra c ic 42 104
C ard ia 59
T o ta l 171
'C a n c e r  C on tro l A g e n c y  o f B rit ish  C o lu m b ia , cancers above  and b e lo w  tra ch e a l b ifu rc a tio n .
T a b le  II I .  Q ua lity  o f  L ife  -  P e rfo rm a n ce  S ta tu s *
G ra d e t before  trea tm en t a fte r  trea tm en t
0 ( 9 0 -  100) _
1 ?  ]  (7 5 % )1 (7 0  -  80) 27
2 (5 0  -  60) 85  (7 5 .9 % ) 28
T o ta ls 112 112
'E a s te rn  C o o pe ra tive  O n co lo g y  G roup  (E C 0G ) sys te m . 
■(Bracketed n u m b e rs  in d ica te  K a rn o fs ky  leve l.
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did occur subsequently, 6 months 
after therapy, and was probably 
related to progression of the dis­
ease. An early analysis of the quali­
ty of life (Tables III to VI) of 112 
patients at 6 months after therapy 
in relation to their performance sta­
tus, swallowing ability, weight and 
pain showed substantial improve­
ment in all areas. Ninety-seven of 
171 patients (56%) had complete 
restoration of their swallowing abili­
ty for solids. Most patients (154 of 
171 [90%]) had improved swallow­
ing lasting for 3 to 4 months, 
although 60 (35%) required dila­
tions later to maintain their nutri­
tional status.
Of the 171 patients, 61 (35%) 
were alive at 10 months after treat­
ment, 30 of 90 (33%) at 1 year, 14 
of 55 (26%) at 2 years and 5 of 26 
(19%) at 3 years after combined 
intracavitary and external irradia­
tion. All patients who had metasta­
sis died within 8 months.
Of the 43 patients considered 
suitable for preoperative irradiation, 
only 26 actually underwent resec­
tion after exploratory laparotomy. 
Of these patients, 19 (73%) were 
alive from 10 to 30 months. Of the 
17 patients who underwent explora­
tion only, 8 were dead within 6 
months. Eight died between 10 and 
16 months after treatment and one
T a b le  IV. Quality o f Life -  Swallowing*
S w a llo w in g Before After
ab ility tre a tm e n t, no. trea tm en t, no.
None (complete obstruction) 5 -
Clear fluids 52 3
Blended food 25 13
Soft food 26 32
Any food 4 (3%) 64 (57.1%)
Totals 112 112
*EC0G system.
T a b le  V. Quality of Life -  W eight*
Body w e ig h t, %
B efore
tre a tm e n t, no.
After
trea tm en t, no.
Loss
5 17 25
10 30 10
20 28 1
>20 27 -
Same weight 5 38
Gain
5 - 19
10 - 8
15 - 2
20 - 1
Totals 107 104
*EC0G system.
T a b le  V I. Quality of Life -  Pain Related to Swallowing *
Before A fter
Pain tre a tm e n t, no. trea tm en t, no.
None 67 93 (83%)
Sometimes present 23 16
Always present 22 3
Totals 112 112
*EC0G system.
was still alive at 36 months. All had 
good swallowing almost to the time 
of their death. The overall survival 
for all patients who underwent re­
section and for those having radio­
therapy only is shown in Fig. 6, 
although this also includes patients 
who had distant metastases, and 
although only a few patients have 
lived beyond 3 years, the trend 
suggests possible improvement in 
the overall survival rates. This trend 
is even more noticeable in those 
who underwent resection after irra­
diation, although the follow-up is 
still short (30 months). Of the 171 
patients treated with intracavitary 
and external irradiation and fol­
lowed up for 10 months, 61 pa­
tients were still alive and of those 
who died, only 31 (18%) died of 
pneumonia, which is proportionally 
less than in historical cases (Table 
I). Twenty-two patients (13%) died 
of abdominal carcinomatosis, but 
without dysphagia, which was com­
mon in the past (Figs. 7 and 8). We 
did not have any operative deaths. 
The resected specimens from 26 
patients were available for review. 
Eighteen were adenocarcinomas 
and 8 squamous cell carcinomas. 
Even though most tumours were 
large and locally advanced adeno­
carcinomas, the changes after ra­
diotherapy were dramatic. In 23 of 
the 26 specimens, there was no 
recognizable gross tumour (Fig. 9). 
The microscopic findings did con-
20 ■
------ 1----- 1----- 1------ 1------- 1
O 7 t4 22 29 36
Time, mo
FIG. 6. Survival for patients treated by 
combined intracavitary and external 
irradiation.
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firm the absence of residual disease 
in the intraluminal component of 
the specimen where the higher dose 
of irradiation was given. Deeply, in 
the submucosa, there were marked 
changes with pyknosis and cell de­
generation with questionable viabili­
ty (Fig. 10).
Discussion
Although there is no consensus 
as to whether the primary treatment 
for patients who have esophageal 
cancer should be surgery or radio­
therapy, it appears that a combina­
tion of the two could provide better
FIG. 7. Before treatment with com­
bined intracavitary and external beam 
irradiation.
survival for patients who suffer 
from a disease that usually cannot 
be controlled locally. From the sur­
geon’s viewpoint, an adjuvant treat­
ment program is desirable, one that 
would not increase operative mor­
bidity or mortality but would im­
prove resectability and prevent local 
recurrence. The radiation oncolo­
gist would like to enhance the ther­
apeutic ratio (i.e., to increase the 
amount of radiation and increase 
the effect but without increasing 
morbidity to normal tissues).
Although many investigators2-5 
are actively trying to improve the 
therapeutic ratio of external irradia­
tion by new fractionation schedules, 
radiation sensitizers, hyperthermia 
and other radiation modifiers, in­
tracavitary irradiation is a well- 
established and recognized method 
of treatment. It is of proven value in
FIG. 8. After treatment.
other organ systems (uterus), and 
recent technologic advances have 
facilitated its application in other 
hollow organs (esophagus and 
bronchus).
The simplicity of intracavitary ir­
radiation, convenience of the short 
treatment time and the safety pro­
vided by the remote after-loading 
system make this treatment ideal 
for palliation in cancer of the esoph­
agus. Our clinical experience over 
the past 3 years, using the combi­
nation of intracavitary and external 
beam irradiation has demonstrated 
that this treatment is safe, has low
FIG. 9. Gross specimen after treat­
ment.
FIG. 10. Microscopic findings show 
changes in submucosa with pyknosis 
and cell degeneration (hematoxylin and 
eosin, original magnification X 40).
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morbidity and appears to provide 
reasonable palliation. Intracavitary 
irradiation improves the therapeutic 
ratio of external beam radiotherapy 
alone by delivering higher doses to 
the more exophytic, more hypoxic, 
intraluminal portion of the esopha­
geal disease, while sparing the nor­
mal tissues. External beam irradia­
tion provides sufficient dose in 
depth to the better oxygenated, 
more peripheral, probably more sen­
sitive portion of the cancer. The 
palliative potential is certainly supe­
rior to surgery in metastatic or 
unresectable disease, and since it 
does not increase the morbidity or 
mortality associated with eso­
phagectomy, it provides a better 
selection of patients by limiting re­
section to only potentially curable 
cases.
Patients who have tumours 
below the tracheal bifurcation 
should be considered for surgery 
with adjuvant programs using irra­
diation preoperatively, and patients 
with tumours above the tracheal 
bifurcation should be allocated for 
radiotherapy with adjuvant pro­
grams which could involve chemo­
therapy, hyperthermia or sensitiz­
ers.
Our recent experience leads us to 
suggest that the combination of 
intracavitary and external beam ir­
radiation should be the optimal ra­
diotherapy treatment arm for these 
clinical trials, either as primary 
treatment for upper esophageal le­
sions or as adjuvant therapy for 
potentially operable cancers, partic­
ularly those in the lower esopha­
gus, below the tracheal bifurcation.
Conclusions
Intracavitary irradiation when 
combined with external beam radio­
therapy is an acceptable treatment 
for malignant disease of the esopha­
gus and cardia and is associated
with low morbidity. The potential 
benefits of this combined therapy 
are as palliative treatment of all 
cases, as a potentially curative 
treatment for upper esophageal can­
cer and as an adjuvant preoperative 
treatment for cancers of the lower 
esophagus and cardia. Trials are 
needed to further enhance the ther­
apeutic ratio using radiation sensi­
tizers, chemical modifiers or hyper­
thermia.
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3. Neoadjuvant Therapy of Esophageal 
Cancer
David Kelsen, MD, FACP
Neoadjuvant (preoperative) chemotherapy, with or without radiotherapy, is under 
intense study. There are theoretical and practical reasons for the preoperative use of 
systemic therapy: (a) laboratory studies support the use of preoperative treatment in 
animal models, (b) the relapse pattern of esophageal cancer is primarily systemic and 
(c) the impact on palliation if response is associated with an improved resection rate.
Three techniques involving systemic therapy are currently under investigation:
(a) chemotherapy alone followed by a planned surgical procedure; (b) chemotherapy 
and concurrent radiotherapy followed by a planned surgical procedure; (c) 
chemotherapy and radiotherapy without surgery. Phase II trials of the first 
technique have demonstrated its feasibility without an increase in operative 
morbidity or mortality. Two small-scale phase III trials have confirmed 
chemotherapy’s efficacy but have not clearly demonstrated an impact on survival. 
Large-scale phase III trials are under way, or about to begin, to test definitively the 
hypothesis that neoadjuvant chemotherapy improves disease-free and overall 
survival in operable patients.
The second technique has also been tested in small-scale phase II trials. Most 
recently, a large-scale phase II trial has been reported which suggests that this 
technique has not had a major effect on resection rates or on long-term survival for 
most patients.
These treatment plans are tolerable if careful attention to detail is given.
Definitive phase III trials testing the superiority of multimodality treatments over 
radiotherapy alone or surgery alone are under way.
La chimiotherapie (preoperatoire) neoadjuvante, associee ou non a la radiotherapie, 
fait l’objet d’une recherche intensive. II existe des motifs theoriques et pratiques 
pour administrer une therapie preoperatoire systemique: a) des etudes sur des 
animaux de laboratoire soutiennent l’utilisation d’un traitement preoperatoire, b) 
dans le cancer de l’oesophage, 1’evolution caracteristique de la recidive est avant 
tout systemique et c) une reponse therapeutique s’accompagne d’une amelioration 
tant au plan palliatif qu’a celui du taux de resection.
Trois techniques faisant appel a une therapie systemique sont presentement a 
l’etude: a) la chimiotherapie seul suivie d’une intervention chirurgicale planifiee; b) 
la chimiotherapie accompagnee d’une radiotherapie concomitante et suivie par une 
intervention chirurgicale planifiee; c) la chimiotherapie avec radiotherapie, mais 
sans chirurgie. Les essais de phase II de la premiere technique ont demontre qu’elle 
pouvait etre employee sans augmentation de la morbidite ou de la mortality 
operatoire. Deux petites etudes de phase III ont confirme l’efficacite de la 
chimiotherapie sans toutefois demontre d’effet net sur la survie. D’importants essais 
de phase III sont presentement en cours ou sur le point de demarrer; ils visent a 
verifier de fa?on definitive l’hypothese voulant que la chimiotherapie neoadjuvante 
ameliore la survie jusqu’a la recidive et la survie totale chez les patients operables.
La deuxieme technique a aussi fait l’objet de petits essais de phase II. On a 
recemment rapporte les resultats d’une vaste etude de phase II qui indiquent que 
cette methode n’a pas eu d’effet important sur le taux de resection ou sur la survie a 
long terme de la plupart des patients.
Ces modalites de traitement sont supportables a condition d’accorder une 
attention minutieuse aux details. Des etudes de phase III presentement en cours, 
tenteront d’etablir de fa?on definitive si les traitements multiples sont superieurs a 
la radiotherapie seule ou a la chirurgie seule.
Preoperative chemotherapy has been used as part of the treat­
ment for patients with “localized” 
esophageal carcinoma, because of 
the disappointing results achieved 
using surgery and radiotherapy,12 
which are aimed only at the local 
process. These methods fail because 
many patients have disseminated 
disease at the time of diagnosis. 
The extent of the disease has been 
studied in several autopsy series.3' 5 
It was found that in spite of a short 
duration of illness, the majority of 
patients, with or without residual 
local tumour, had disseminated can­
cer. The major sites of metastatic 
disease were the lung, liver and 
lymph nodes. Thus, chemotherapy 
as an early part of a multimodality 
approach has a strong rationale.
Neoadjuvant chemotherapy trials 
can be divided into three groups: (a) 
chemotherapy alone followed by a 
planned surgical procedure, (b) con­
current chemotherapy and radio­
therapy followed by a planned sur­
gical procedure and (c) chemothera-
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py and radiotherapy without opera­
tive intervention.
There are theoretical advantages 
to chemotherapy before surgery: 
first, its superiority has been dem­
onstrated by laboratory studies;6 
second, preoperative treatment, 
when the metastatic burden is low, 
may minimize spontaneous drug re­
sistance as postulated by Goldie and 
Coldman.7 Since surgery is usually 
performed within 4 to 8 weeks of 
induction chemotherapy, removal of 
the primary tumour (containing the 
bulk of tumour burden) may help to 
decrease the emergence of a drug- 
resistant tumour recurrence.
In esophageal cancer, there are 
two more practical advantages. 
First, reducing the size of the pri­
mary tumour may increase the re­
section rate, and this has important 
implications for both palliation and 
cure. Second, chemotherapy, when 
given as a single modality allows an 
in-vivo assessment of the effective­
ness of a drug or drug combination.
The rationale for using chemo­
therapy and radiotherapy concur­
rently is that radiotherapy alone has 
at least some effectiveness. A num­
ber of the chemotherapeutic agents 
chosen have both cytotoxic and 
radiosensitizing properties. By com­
bining chemotherapy and radiother-
micrometastases. The risks of con­
current chemotherapy plus radio­
therapy are that toxicity may be 
increased, and objective tumour re­
sponse rates cannot be ascribed to 
either modality alone.
Almost all of the studies reported 
to date can be characterized as 
phase II nonrandomized trials. They 
have demonstrated the feasibility of 
this approach and the toxicities 
associated with it but have not 
proven a survival advantage over 
conventional therapy.
Chemotherapy Followed by 
Surgery
At least 13 studies of chemother­
apy followed by a planned operative 
procedure have been reported and a 
total of 312 patients treated.8 As for 
combinations used in advanced dis­
ease, cisplatin is the common de­
nominator. There appears to be 
little difference between the various 
drug regimens with respect to re­
sponse rate (Table I9~17). Operability 
and resectability rates were fre­
quently not reported. With the ex­
ception of one study, operative mor­
tality did not appear to be increased 
over that reported with surgery 
alone (range from 5.6% to 11.7%).
months. The follow-up period for 
most of these trials was short, so 
that long-term survival was rarely 
available. One exception is the 
phase II trial reported by Kelsen 
and associates11 in which 34 pa­
tients were treated with one or two 
cycles of a combination of cisplatin, 
vindesine and bleomycin before eso­
phagectomy. The minimum follow­
up for this study is now 6.5 years; 
the 5-year survival rate was 17.6%. 
No relapses were seen after 
3V2 years.
At present, a number of such 
randomized trials are under way. 
They compare chemotherapy fol­
lowed by surgery to surgery alone, 
or chemotherapy followed by sur­
gery to radiotherapy followed by 
surgery. Preliminary data are avail­
able from two studies. Roth and 
colleagues18 gave cisplatin, bleomy­
cin and vindesine for two cycles and 
followed chemotherapy by a 
planned operation and then mainte­
nance chemotherapy. The standard 
arm underwent surgery and did not 
receive chemotherapy postopera- 
tively. Radiotherapy was given to 
selected patients in both groups. 
The response rate to chemotherapy 
was 47%. The operative death rate 
was 11.7% and the median duration 
of survival was 21 months. There
apy, it may be possible to enhance 
local control and destroy systemic
Median duration of survival, when 
reported, ranged from 17 to 24
were no statistical differences in 
operative morbidity (which was less
T a b le  1. Selected Phase II Trials of Chemotherapy-Surgery*
S eries
reference
Cell
type
D rug
com bination
No. pa tien ts  
en tered
No. p a tien ts  
eva lu a te d
R esponse  
ra te , %
Op,
no.
Res,
no.
Op ra te ,% R es ra te°/o Op d ea th  ra te , % S u rv iva l,m o
9 E DDP, BLE 34 34 17 34 26 100 76 11 1010 E DDP, MIT, BLE 15 15 55 12 NS 80 NS 45 NS11 E DDP, DVA, BLE 34 34 53 34 28 100 82 6 1612 E DDP, FU, VLB 20 20 NS 20 18 100 90 6 NS
13 E DDP, DVA, BLE 23 23 43 20 18 87 78 19 NS
14 E DDP, FU 24 24 54 22 19 92 79 4 NS
15 E DDP, DVA, MGB 14 14 NS 13 12 93 86 7 8
16 B DDP, VLB, MGB 29 27 44 25 25 86 86 0 14
17 E DDP, FU 26 25 44 24 10 96 38 0 18
'Adapted from Kelsen D: Chemotherapy of esophageal cancer. In Orringer MB, Zuidema G: (eds): Surgery o f the Alimentary Tract: The Esophagus,
Saunders, Philadelphia (in press).
'Some patients received definitive radiotherapy without surgery.
MIT =  mitomycin C, DDP =  cisplatin, FU =  fluorouracil, BLE =  bleomycin, MGB =  mitoguazone, VLB =  velban, Op =  operability, Res =  resection, E 
=  epidermoid, B =  both epidermoid and adenocarcinoma, NS =  not stated.
CJS, VOL. 32, NO. 6, N O V E M B E R  1989 41
KELSEN
in the chemotherapy arm) or in 
survival. In a subgroup analysis, 
survival for patients responding to 
chemotherapy was compared with 
that of the whole group. The medi­
an duration of survival was signifi­
cantly (p < 0.05) longer for re­
sponding patients than nonrespond­
ing patients. However, this type of 
analysis has its drawbacks.
At our institution, 96 patients 
with local regional epidermoid car­
cinoma of the esophagus were ran­
domly assigned to receive either 
radiotherapy (RT) preoperatively 
(55 Gy over 5 to 6 weeks) or two 
cycles of cisplatin, vindesine and 
bleomycin chemotherapy (CT).19 
Surgery was performed on day 56. 
Postoperative crossover to the op­
posite arm depended on the findings 
at surgery. The objective response 
rate to CT and RT was measured by 
barium esophagography and as­
sessed by an independent radiolo­
gist. The preliminary findings 
showed similar complete and partial 
response rates on the two arms 
(55% CT and 64% RT, respectively). 
There was also no difference in the 
operability or resectability rates; 
75% of patients underwent surgery 
and 60% had resection. Local fail­
ure was seen in 20% of resectable 
patients; an additional 11% of pa­
tients had unresectable cancer. 
Thus, surgery was unable to con­
trol local disease in a total of 31% 
of patients. Toxicity was acceptable.
Because many patients receive post­
operative therapy in this trial, dis­
ease-free or overall survival as a 
function of initial therapy cannot be 
analysed. At present, approximately 
20% of the 96 patients are alive and 
disease-free with a median follow-up 
of 34 months.
A third trial supported by the 
European Organization for the Sta­
tistical Study of Oesophageal Dis­
eases (OESO) is a three-arm study 
comparing surgery alone, surgery 
followed by radiotherapy and neoad­
juvant chemotherapy. This trial has 
accrued approximately 200 patients 
and is ongoing.
Preoperative Chemotherapy 
Plus Concurrent Radiotherapy
As for trials involving chemother­
apy as a single modality before an 
operation, studies in this area have 
been of the phase II single-arm 
type. Except for two early trials 
(using methotrexate plus radiother­
apy or bleomycin plus radiothera­
py), recent studies have involved 
combination chemotherapy with cis­
platin and fluorouracil, mitomycin 
and fluorouracil, or cisplatin and 
other agents. To date, trials involv­
ing 483 patients have been report­
ed. The dose of concurrent radio­
therapy ranged from 20 to 45 Gy. 
The majority of trials used approxi­
mately 30 Gy, given during the first
3 weeks. Preliminary reports from 
Wayne State University suggested 
that in one study,20 there may have 
been an improvement in long-term 
survival and perhaps in cure rate, 
but there was a high (27%) opera­
tive mortality. However, in a recent 
report, using chemotherapy plus ra­
diotherapy but no operation, Leich- 
man and associates21 noted that all 
patients in the original study with 
complete remission subsequently 
died of recurrent disease.
In a single-arm phase II trial, 
the Southwest Oncology Group 
(SWOG) extensively tested the 
Wayne State University regimen, 
consisting of cisplatin-5-fluorouracil 
(5-FU) plus concurrent radiothera­
py. The only change in the treat­
ment plan was to decrease the cis­
platin dosage to 75 m g/m 2. This 
study22 was recently reported in 
final form (Table II20’22-26). In all, 
113 patients were available for 
study. Initially all were believed to 
have operable disease; however, at 
the end of the radiotherapy and 
concurrent chemotherapy, only 62% 
of patients underwent operation. 
The resection rate was 48% and 
included 14% of patients in whom 
the tumour was described as being 
“debulked”. It is important to note 
that the most recent surgery-only 
series2 have reported resection rates 
of 60% to 80%. The operative death 
rate was 11%. Seventeen percent of 
patients had no histologic evidence
Table II. Selected Studies of Chemotherapy Plus Radiotherapy Before Surgery*
Series
reference
Cell
type
RT dose, 
Gy
RT
duration,
wk Concur
Drug
combination
No.
patients
entered
No.
patients
evaluated
Op,
no.
Res,
no.
Op
rate,
%
Res
rate,
%
Op death 
rate, %
Survival,
mo
20 E 30 3 Y DDP, FU 21 21 19 15 90 71 27 18
22 E 30 3 Y DDP, FU 128 113 71 37 63 33 11 12
23 E 30 4 Y BLE 70 65 38 35 58 54 NS 6
24 B 30 3 Y MIT, FU 89 89 43 31 48 35 10 NS
25 E 20 1 N MTX 93 93 55 NS 59 NS 15 26
26 E 30 3 Y MIT, FU 37 37 36 27 97 73 11 NS
‘ Adapted from Kelsen D: Chemotherapy of esophageal cancer. In Orringer MB, Zuidema G (eds.): Surgery o f the Alimentary Tract: The Esophagus 
Saunders, Philadelphia (in press)
RT =  radiotheraphy, E =  epidermoid, A =  adenocarcinoma, Concur =  concurrent radiotherapy, Y =  yes, N =  no, DDP =  cisplatin, FU =  fluorouracil, 
MTX =  methotrexate, MIT =  mitomycin C, BLE =  bleomycin, OP =  operability, Res =  resection.
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of residual cancer. The median du­
ration of survival for the entire 
group was 12 months, no better 
than that associated with surgery 
alone.
The potential toxicity of concur­
rent radiotherapy and chemothera­
py before surgery was further dem­
onstrated by Adelstein and associ­
ates.27 They treated a small group 
of eight patients using cisplatin, a 
fluorouracil infusion and metho­
trexate. Concurrent radiotherapy to 
a total dose of 30 Gy was given 
over 3 weeks. Although major re­
sponses were seen in all patients 
and although during the operative 
procedure the fractional intake of 
oxygen (F,02) was carefully con­
trolled, severe pulmonary toxicity 
developed in five patients, three of 
whom died. The authors concluded 
that the use of simultaneous che­
motherapy and radiotherapy led to 
an unacceptable surgical morbidity 
and mortality.
In summary, there are to date no 
randomized trials that demonstrate 
superiority of chemotherapy plus 
concurrent radiotherapy followed 
by an operation over surgery alone. 
Although one randomized study 
using bleomycin as the only chemo­
therapeutic agent was a negative 
trial, this is not surprising in view 
of the extremely low level of activity 
seen with that agent. More disap­
pointing is the large scale SWOG 
trial that gave dismal results. The
approach of neoadjuvant chemo­
therapy before surgery (without 
concurrent radiotherapy) should be 
considered experimental.
Chemotherapy Plus 
Radiotherapy Without Surgery
There have been two approaches 
to chemotherapy plus radiotherapy 
trials for esophageal cancer: in one, 
chemotherapy is given first (for one 
or two cycles) then definitive radio­
therapy (50 to 60 Gy); in the other, 
chemotherapy and radiotherapy are 
given concurrently. Most of these 
trials are single-arm, phase II pilot 
studies, involving fewer than 50 
patients; many involve fewer than 
20 patients. However, there are 
several older prospective random­
ized studies.
In the largest phase III trial, the 
Eastern Cooperative Oncology 
Group28 compared bleomycin given 
concurrently with 50 to 60 Gy of 
radiation with the same dose of 
radiation alone in a group of 77 
patients. There was no difference in 
survival (median 6.2 months for 
chemotherapy plus radiotherapy 
and 6.4 months for the radiothera­
py alone) (Table I I I 2128-32).
More recently, the results of sev­
eral multidrug regimens plus con­
current radiotherapy have been re­
ported.
Several groups have used cis-
Table III. Esophageal Cancer: Chemotherapy Plus Concurrent Radiotherapy
Series
reference
Drug
combination
Radiotherapy,
Gy
No. patients 
evaluated CR, %
Survival,
mo
21 DDP-FU 30 20 NS 22
BLE-MIT
28 BLE 5 0 -6 0 40 NS 6.2
- 37 NS 6.4
29 FU-MIT 60 30 87 21
50 20 NS 8
30 MIT-FU 45 15 NS 12
NS 12
31 DDP-MIT 3 0 -5 0 17 NS 8
32 ADR, BLE 40 15 20 NS
ADR =  Adriamycin, BLE =  bleomycin, DDP =  cisplatin, FU =  fluourouracil, MIT =  mitomycin C, 
CR =  complete response, NS =  not stated.
platin or mitomycin C plus a 5-FU 
infusion with concurrent radiother­
apy. Coia and colleagues29 have 
treated both adenocarcinoma and 
epidermoid carcinoma with concur­
rent radiotherapy, mitomycin-C and 
5-FU. In a recent update, the re­
sults in 50 patients were de­
scribed;29 30 patients who had no 
distant metastases received chemo­
therapy plus 60 Gy radiotherapy; 
20 who had more extensive disease 
received the same chemotherapy 
plus 50 Gy of radiotherapy. The 
median duration of follow-up was 
24 months. Of the 30 patients 
treated for potential cure, 87% 
achieved complete response as seen 
by barium swallow roentgenogra­
phy and endoscopy. Seven patients 
had local recurrence, either alone or 
with simultaneous distant metasta­
ses. Nine others had distant disease 
only. The median time to relapse 
was 10 months. Although Coia and 
colleagues reported a 32% 5-year 
survival, only three patients were 
actually at risk for 5 years. Of the 
total of 50 patients, 5 required 
hospitalization because of severe 
esophagitis. There was one treat­
ment-related death.
Similar results have been seen, 
using different radiotherapy and 
chemotherapy schedules, by Keane 
and associates30 and John and col­
leagues.31
Taylor and associates33 in a re­
cent study evaluating the use of 
cisplatin with 5-FU plus concurrent 
radiotherapy questioned the as­
sumption that the local control rate 
is high. They treated 17 patients 
(14 squamous cell, 3 adenocarcino­
ma) and found that although 76% 
of patients had complete or partial 
responses, 8 of 15 recurrences were 
local. The median time to recur­
rence was 7 months, no better than 
that with radiotherapy alone.
As with studies of neoadjuvant 
chemotherapy before surgery, pre­
liminary results suggest benefit but
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also the potential for severe toxici­
ty.21 Carefully controlled prospec­
tive randomized studies of radio­
therapy alone versus radiotherapy 
and chemotherapy (either sequential 
or concurrent) are required before 
accepting this technique as superior 
to standard care.
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4. Controversies in Esophageal Cancer 
Surgery
Andre Duranceau, MD, FRCSC
The current management of esophageal cancer is controversial. Parenteral nutrition 
in selected patients resulted in lower complication and death rates than in untreated 
patients. With respect to surgical management, esophagectomy without thoracotomy 
has given survival rates similar to more radical operations. The pattern of 
recurrence as well as morbidity and mortality necessitate a well-planned assessment 
in order to compare it with esophagectomy using a standard approach. An 
esophageal anastomosis in the neck seems to be at a higher risk for fistula 
formation than reconstruction in the chest. An instrument-made anastomosis results 
in fewer fistulas but a higher stricture rate than hand-made anastomosis. A large 
proportion of patients with esophageal cancer will receive only palliative benefit 
because of nonresectability; esophageal bypass offers a good quality of survival but 
is associated with high morbidity and mortality. Palliative intubation seems to offer 
the quickest and simplest method of restoring reasonable swallowing.
Despite improvements in the in­vestigation and operative and 
postoperative management of eso­
phageal cancer, overall long-term 
survival rates remain dismal. In this 
paper, I evaluate current manage­
ment methods and review current 
thinking on the subject in an at­
tempt to determine what is the 
safest approach in treating this dif­
ficult problem.
L’approche du patient porteur d’un cancer oesophagien demeure discutable sous 
plusieurs aspects. L’alimentation parenterale totale chez des groupes selectionnes 
de ces patients entraine une diminution de la morbidite et de la mortalite lorsque 
compares a des patients non traites. L’approche chirurgicale demeure sujet de 
controverse: l’oesophagectomie sans thoracotomie montre des survies comparables a 
celles des operations plus radicales. Le site des recidives ainsi que la morbidite et la 
mortalite des deux approches demande des etudes bien planifiees avant de conclure 
aux avantages de l’une sur l’autre. L’anastomose oesophagienne cervicale semble 
s’accompagner d’une plus grande incidence de fistule anastomotique que lorsque la 
reconstruction est intrathoracique. La compilation de series publiees revele que les 
anastomoses oesophagiennes completees par autosutures entrainent moins de 
fistules mais plus de stenoses anastomotiques. Une proportion importante de 
patients porteurs de cancer oesophagien ne pourront beneficier que de moyens 
palliatifs en raison de non resequabilite. Le court-circuitage avec reconstruction 
proximale a la tumeur resulte en une morbidite et une mortalite elevee. L’intubation 
oesophagienne palliative semble etre la methode la plus rapide et la plus simple 
pour obtenir une qualite de deglutition acceptable.
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Parenteral Nutrition
Whenever patients with esopha­
geal cancer cannot get adequate 
nutrition through the gastrointesti­
nal tract, parenteral nutrition is 
indicated. If access to the gastroin­
testinal tract remains acceptable 
and nutrients can be given, even 
through a nasogastric tube, paren­
teral nutrition should not be of­
fered. It is important not to procras­
tinate in restoring a normal nutri­
tional balance in these patients.
Holter and Fischer1 reported that 
parenteral nutrition could be benefi­
cial in preoperative management if 
administered to selected patients for 
at least 72 hours. Grant2 proposed 
that the intravenous support should 
be for at least 5 days. Patients who 
have suffered a 20% weight loss 
due to lack of dietary intake and in 
whom an additional 12 to 15 days 
of nutritional restriction is expect­
ed, should be considered for nutri­
tional support before treatment is
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initiated. If assessment of inspi­
ratory and expiratory muscle pres­
sure is completed in these patients, 
marked improvement may be seen 
within 2 weeks of instituting ag­
gressive nutritional support.2 A 
weight of 80% to 90% of the ideal is 
considered mild weight loss. At 70% 
to 80% of the ideal weight a patient 
is considered to have moderate mal­
nutrition. When the weight is less 
than 70% of normal, severe malnu­
trition is considered to be present. 
Shizgal and colleagues3 noted that 
when malnutrition was evaluated as 
a percentage of weight loss only, 
there was a marked underestima­
tion of the nutritional depletion, 
since the extracellular fluid volume 
actually increases with starvation.
The nutritional assessment as 
studied by weight, percentage 
weight loss, albumin, transferrin 
and total protein levels, mid-arm 
muscle circumference, triceps skin­
fold thickness, lymphocyte count 
and delayed hypersensitivity reactiv­
ity were reported by Buzby and 
colleagues.4 From their findings, if 
a predicted risk was less than 30%, 
the incidence of the complications 
was 11.7% and the death rate 2%. If 
the predicted risk factor was 30% to 
50%, the complication rate was 
36.8% and the death rate 7.9%. 
When the predicted risk was above 
59%, morbidity reached 81% and 
the mortality 59%. Prognosis was 
evaluated in patients who under­
went a variety of surgical proce­
dures. Generally, patients who are 
to undergo an esophagectomy and 
who are in a state of severe to 
moderate malnutrition should be 
given preoperative nutritional sup­
port and be maintained postopera- 
tively with intravenous nutrition 
until an adequate oral diet is re­
sumed.
The use of parenteral nutrition 
perioperatively in unselected pa­
tients who undergo major surgery 
is not justified. However, high-risk
patients may benefit. Severely mal­
nourished patients without evidence 
of metastatic disease who undergo 
an elective esophagectomy should 
receive parenteral nutrition. Moder­
ately malnourished patients, previ­
ously well, whose investigation and 
surgery will result in a period of 10 
or more days of inadequate nutri­
tion, should receive nutrients 
through a feeding tube or a jeju- 
nostomy but not total parenteral 
nutrition, which should be used if 
subsequent postoperative complica­
tions limit access to the alimentary 
tract.5 These recommendations are 
based on statistical evaluation of 11 
randomized studies. Groups of pa­
tients receiving parenteral nutrition 
had substantially lower complica­
tion and death rates than a non- 
treated group. In most studies, fail­
ure to restrict entry to malnour­
ished patients only may have limited 
the ability of these trials to show 
the true effectiveness of periopera­
tive parenteral nutrition. More re­
cently, Warnold and associates6 re­
ported that total parenteral nutri­
tion in moderately malnourished pa­
tients with stable disease did not 
promote synthesis of the majority 
of body proteins, and skeletal mus­
cle remained in negative protein 
balance even at high loads of total 
parenteral nutrition.
Transhiatal or Transthoracic 
Esophagectomy?
What is the evidence favouring a 
radical operation that follows the 
principles of a “good” cancer oper­
ation over an operation done 
through the mediastinum without 
thoracotomy and without systemat­
ic dissection of the lymphatic 
chains? Is survival of the patient 
with esophageal carcinoma related 
more to the nature of the tumour 
and its stage at operation than to 
the extent of resection?
The most extensive experience of 
transhiatal esophagectomy is that 
reported by Orringer7 on 152 pa­
tients. The most frequent complica­
tions were recurrent laryngeal nerve 
palsy (24%), anastomotic leaks (6%) 
and chylothorax (2%). The death 
rate was 6%, and 88% of the pa­
tients left the hospital in 21 days or 
less. Peracchia and colleagues8 re­
ported their experience with 127 
patients. In their study, blood losses 
were minimal, recurrent laryngeal 
nerve palsy was seen in 12% of 
patients and anastomotic leaks be­
came clinically evident in 8.7%; 34 
additional patients also had a radio- 
logically evident anastomotic leak. 
Their hospital mortality was 12.5%. 
Zilberstein and associates9 and Gur- 
kan and associates10 reported anas­
tomotic leakage in 23% and 6% of 
patients with a hospital death rate 
of 13.5% and 6% respectively. 
Teichman and colleagues11 in their 
study reported a 38% incidence of 
cervical anastomotic fistula in the 
neck. Only Orringer7 has reported a 
cumulative survival: 52% at 1 year, 
32% at 2 years, 22% at 3 years and 
17% at 4 years.
If the esophagectomy is complet­
ed through the chest, using a stan­
dard dissection technique or a radi­
cal en-bloc resection followed by an 
intrathoracic anastomosis, the over­
all reported survival varies. In Post- 
lethwait’s review12 of over 12 000 
patients, there was a 4.6% overall 
5-year survival in those series in 
which this could be determined. In 
large series, in which the carcinoma 
was resected, the survival rates 
showed a progressive improvement 
over the decades during which this 
operation was carried out. The im­
proved survival was possibly due to 
better selection of patients, surgical 
and anesthesia techniques and post­
operative management. Most large 
series have shown that esophagec­
tomy still carries an 8% to 30% 
death rate and a 5-year survival of
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3% to 20%. In an updated experi­
ence, Skinner13 reported 11 deaths 
in a group of 111 patients who 
underwent a systematic en-bloc dis­
section of the mediastinum. This 
operation helped to classify the pa­
tients by extension of the tumour, 
depth of wall penetration and the 
number of positive nodes. Results 
in these carefully staged patients 
showed an overall 5-year survival of 
25% with documented mediastinal 
recurrences in 5%. Survival depend­
ed on wall penetration and node 
status. When there was neither full­
thickness wall penetration nor in­
volved lymph nodes, the 5-year sur­
vival was 55%. When the esopha­
geal wall was fully invaded but 
there was no lymph-node metasta­
sis, the 5-year survival was 15%. 
When there was full-thickness pen­
etration and when the lymph nodes 
were involved, the 5-year survival 
was less than 10%. One-third of all 
patients had full-thickness wall pen­
etration and more than five positive 
nodes; not one of them survived 5 
years.
Although there is little controver­
sy about the feasibility of eso­
phagectomy using a radical tech­
nique or an approach through the 
neck and the abdomen, without a 
thoracotomy, it remains to be estab­
lished that esophagectomy without 
thoracotomy causes less morbidity 
and mortality. The natural evolu­
tion of the disease may not be 
affected and depends on the stage 
of the disease when resection is 
carried out. A radical, systematic 
dissection seems to offer excellent 
local and regional control of the 
disease along with a careful stag­
ing. The “blunt” approach needs to 
be assessed for the quality of its 
staging and the number of early 
and late mediastinal recurrences. 
These questions must be answered 
in order to compare both the early 
and late results of these two tech­
niques.
Neck or Chest Reconstruction?
Does neck reconstruction follow­
ing an esophagectomy mean less 
morbidity and mortality? Richelme14 
studied the length of resected 
esophagus obtained by both ap­
proaches. When the anastomosis is 
completed in the right apex, 2 to 5 
cm more of esophagus is needed to 
complete the reconstruction, de­
pending on whether it is completed 
high in the pleural dome or midway 
between the azygos vein and the 
apex. This is important when the 
resection margin from the upper 
border of the tumour is less than 10 
cm. Wong and Tam15 reported that 
47% of anastomotic recurrences 
were detected when the esophagus 
was transected less than 6 cm from 
the tumour but none when a mar­
gin of more than 10 cm was ob­
tained. Therefore a cervical ap­
proach is recommended for recon­
struction when a safe margin can­
not be obtained through a thoracot­
omy approach. They also found 
that the curative or palliative nature 
of the operation and the lymph- 
node status did not influence the 
frequency of anastomotic recur­
rences.
Despite the intent of the opera­
tion, if anastomosis is carried in the 
neck, it is much more likely to leak. 
The O.E.S.O. survey16 showed that 
19% of cervical anastomoses result­
ed in fistula formation, as opposed 
to 12% of thoracic anastomoses. 
Huang and colleagues17 reported 
fistulas in 23.5% and leaks in 3.5% 
of 1305 intrathoracic anastomoses. 
Ancona and associates18 also 
showed increased leakage with cer­
vical anastomoses (19.6%) as op­
posed to chest anastomoses (11%). 
Launois (personal communication, 
1987) studied a group of 123 pa­
tients, randomized to receive either 
thoracic or cervical stapled anasto­
moses; fistulas occurred in 26% of 
neck anastomoses compared with
leakage in only 4% of chest anasto­
moses. The death rate was 9% for 
the cervical approach and 14% for 
the chest. These reports showing a 
high incidence of complications 
with neck reconstruction must be 
taken in perspective with the large 
series of Orringer7 and Akiyama 
and associates19 who, with the sys­
tematic approaches that they have 
developed, reported an incidence of 
anastomotic fistulas of 6% and 
5.2%, respectively. Delicate manipu­
lation of tissues, intact circulation 
for the remaining esophagus and 
proximal stomach, and the absence 
of tension on the anastomosis prob­
ably remain the most important 
factors accounting for these differ­
ences.
Is the esophageal anastomosis 
more morbid than other digestive 
reconstructions, and is there an 
anastomotic technique that offers 
better success with less morbidity? 
It remains true that 50% of deaths 
after esophagectomy are due to 
failure of the anastomosis. Howev­
er, a careful approach with meticu­
lous handling of tissues can be 
followed by superior results.20 Ma- 
thisen and colleagues20 reported no 
cases of fistula and a 2.9% death 
rate in a series of 104 patients 
whose reconstruction was through 
the chest using a two-layer anasto­
motic technique. In the O.E.S.O. 
survey in 1984,16 one aspect of the 
investigation was the making of the 
anastomosis. It was found that a 
majority of the surgeons in Europe­
an countries used the hand-made 
anastomosis. When a single-layer 
anastomosis was made, a fistula 
occurred in 9% of cases, usually 
within 5 days. If the anastomosis 
was made in two layers, the rate 
was 19%, half appearing within 5 
days of operation. Of the 200 pa­
tients who had a stapled anastomo­
sis, 10% presented with a fistula. 
Postlethwait,12 from an extensive 
review of the literature and his own
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experience, reported a definite de­
crease in the frequency of leakage 
with stapled anastomoses. The 
overall rate of leakage with hand­
made anastomoses was 8%. In over 
500 patients with stapled sutures, 
the rate was 2%. This low incidence 
of fistula is acquired at the expense 
of a higher frequency of anastomot­
ic stricture, presumably because of 
the persistence of a mucosal gap 
after esophagogastric apposition 
and a resultant delay in healing.
Palliation: Surgery or 
Intubation?
The selection of a means for 
palliation in esophageal cancer is 
difficult. There is no simple method 
that will restore swallowing and 
prevent pulmonary and nutritional 
complications.
Conlan21 offered patients with 
mediastinal infiltration and a medio­
cre general status a total gastric 
bypass. The death rate was 11.4%. 
Most patients died of respiratory 
complications, sepsis resulting from 
an anastomotic fistula or complica­
tions related to the excluded esoph­
agus. Of the 78 patients, 69 left the 
hospital and 53% were followed up; 
43% survived 6 months and 21% 1 
year. None lived for more than 18 
months. Comparable series in North 
America do not contain such pa­
tient numbers and show a higher 
operative death rate — in the range 
of 35% to 40%.22 Wong and col­
leagues23 reported on 142 Kirsch- 
ner operations in which a Roux- 
en-Y anastomosis is added to de­
compress the distal esophagus. 
From an initial death rate of 41.5% 
they now obtain good palliation 
with a death rate of 9%. The mean 
survival is 5 months. Manned24 pub­
lished a series of 54 substernal 
gastric bypasses with three deaths.
The main advantage of the total 
gastric bypass is the technical sim­
plicity of the operation and the 
improved quality of life for these 
patients. The obvious disadvantage 
is the postoperative morbidity and 
mortality. Angorn and Haffejee25 
compared pulsion intubation with 
retrosternal gastric bypass in 106 
patients who had unresectable tu­
mour. Successful swallowing was 
restored in both groups. The post­
operative pulmonary complications 
were comparable in both groups. 
The hospital stay for the bypass 
group was three times that of the 
intubation group and the death 
rates were identical. Consequently, 
these authors prefer intubation.
Palliative intubation has been 
used since the early 1930s. Long 
tubes like the Mousseau-Barbin 
and the Celestin have a distal exten­
sion to pull the tube into position 
through the tumour. They are usu­
ally fixed in place with a nonabsorb­
able suture, anchoring the tube to 
the stomach. Push-through tubes 
have been developed to be placed 
transorally with the esophagoscope 
following dilatation of the strictured 
area over a guide wire. Cusumano 
and colleagues26 reported on 693 
patients with inoperable esophageal 
carcinoma who underwent intuba­
tion at the University of Padua; 334 
had a surgical pull-through proce­
dure and 359 an endoscopic push- 
through. They described a learning 
curve in applying the method and 
reducing morbidity and mortality. 
The most frequent complications 
for both types of tubes were perfo­
ration (2% to 4%), prosthesis migra­
tion (3% to 13%) and gastrointesti­
nal hemorrhage (2.4% to 0.8%). 
The death rate was 7.5% for the 
pull-through intubation and 2.8% 
for the push-through. In their insti­
tution, 70% of all inoperable eso­
phageal cancers are now treated by 
intubation, preferably using the 
push-through method.
Girardet and colleagues27 and 
Postlethwait12 reviewed the compli­
cations and mortality of palliative 
esophageal intubation. In over 
2000 patients they found a death 
rate of 26.5% for pull-through 
tubes and 14.1% when the prosthe­
sis was installed endoscopically. 
Complications occurred in 30% of 
pull-through tubes and in 28% of 
push-through intubations. Perfora­
tions were seen in 4% of all intuba­
tions and tube migration in 9.9%; 
bleeding was seen in 2.8% of all 
cases and was managed conserva­
tively in most. Other complications 
included tube obstruction (8.6%), 
fistula formation (9.6%), aspiration 
pneumonia (17.2%) and wound in­
fection (25.8%).
When esophageal carcinoma is in 
an advanced state, intubation seems 
to be the quickest and simplest 
method of restoring a reasonable 
ability to swallow.
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5. Choices in Treating Carcinoma of the 
Esophagus
David B. Skinner, MD, FACS*
A number of treatment regimens are now available for patients with esophageal 
carcinoma. They include several surgical procedures, chemotherapy and 
radiotherapy programs, either separate or combined, laser treatments, intubation 
and other palliative methods. Some of these programs are rigorous and are intended 
to be curative, others are purely palliative. Thus, each patient needs to be assessed 
by careful staging to select the most appropriate treatment. Analysis demonstrates 
that the factors principally and independently influencing prognosis are the depth of 
malignant penetration through the esophageal wall and the number of involved 
lymph nodes in addition to distal metastases. Modern staging techniques should be 
used to identify these prognostic factors preoperatively and at surgery before final 
decisions about treatment are made.
De nombreux traitements s’offrent maintenant aux patients souffrant de cancer de 
l’oesophage. On compte plusieurs techniques chirurgicales, des programmes de 
chimiotherapie et de radiotherapie separes ou associes, des traitements au laser, 
l’intubation ainsi que d’autres methodes palliatives. Certains de ces programmes 
sont rigoureux et sont a visee curative, alors que d’autres sont purement palliatifs. 
En consequence, le stade clinique de chaque patient doit etre etabli avec soin afin de 
choisir le traitement le plus approprie. L’analyse demontre que les facteurs qui 
influencent principalement et independamment le pronostic sont la profondeur 
d’envahissement de la paroi oesophagienne et le nombre de ganglions lymphatiques 
atteints, en plus des metastases distales. Les techniques modernes de classement du 
stade clinique doivent etre utilisees afin d’identifier ces facteurs pronostiques avant 
et a l’operation, avant qu’une decision finale soit prise quant au traitement.
Recent advances in surgical treatments, among others, havetechniques, radiotherapy, che- widely extended the range of thera-
motherapy, intubation and laser py available for patients suffering
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from esophageal carcinoma. Dys­
phagia, the most common present­
ing symptom, is a late development, 
indicating incurable disease in most 
cases. However, methods for early 
detection, especially cytologic meth­
ods, are identifying some patients 
with local or regional disease who 
can be cured. When a localized 
tumour favourable for cure is iden­
tified, surgical techniques employ­
ing en-bloc removal of an envelope 
of normal tissue surrounding the 
tumour are indicated to increase the 
chances for complete extirpation.1 
Similarly, radiotherapy for poten­
tially curable esophageal cancer 
often involves a different dosage 
and plan of delivery from that for 
patients requiring palliative radio­
therapy.2 On the other hand, surgi­
cal bypasses, intubation and laser 
resections to maintain a lumen are 
purely palliative and do not prolong 
life or offer any prospects of long­
term cure. Patients who present 
without obvious metastases should 
undergo careful staging of the dis­
ease before deciding whether treat­
ment should be for cure or pallia­
tion.
Factors Determining Prognosis
Our earlier studies34 indicated 
that only the depth of esophageal 
wall penetration and the presence 
and number of lymph-node metasta­
ses, in addition to systemic metasta­
ses, independently influenced the 
prognosis of esophageal squamous
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cell carcinoma or adenocarcinoma. 
From a multivariate analysis, tu­
mour size, degree of differentiation, 
cell type and location at varying 
levels in the esophagus did not 
independently influence survival. 
These findings, also reported from 
other centres,5 have recently been 
included in the international staging 
system for esophageal cancer.6 In 
this respect, staging for esophageal 
carcinoma is similar to that of the 
modified Dukes’ system for staging 
colonic cancer, with the emphasis 
placed entirely on depth of wall 
penetration and lymph-node metas- 
tases.7
Survival
Patients with carcinoma limited 
to the mucosa or submucosa and 
with uninvolved lymph nodes have 
an 80% chance of surviving 2 years 
after an en-bloc surgical resection 
and an approximately 55% chance 
of surviving 5 years.4 Those with 
tumour limited to the mucosa or 
submucosa and one to four positive 
regional lymph nodes have a better 
than 60% 2-year survival and ap­
proximately 30% are alive at 5 
years. If lymph nodes are free of 
cancer but the tumour has penetrat­
ed the esophageal muscle, more 
than half are alive at 2 years and 
approximately 20% at 5 years after 
an attempted curative resection. 
However, if lymph nodes are in­
volved and the tumour has pene­
trated the esophageal wall, less 
than 10% will be alive at 2 years in 
spite of en-bloc resection. These 
differences in prognosis are suffi­
ciently great that careful staging 
must be done before the effects of 
preoperative or postoperative adju­
vant chemotherapy or radiotherapy 
can be accurately assessed. For pa­
tients in the most favourable cate­
gory, the prognosis of curative sur­
gery alone is sufficiently good in
our experience, and those of oth­
ers,8 that neoadjuvant or postopera­
tive therapy is unlikely to be de­
monstrably beneficial. In such 
cases, the risk of chemotherapy or 
radiotherapy should be avoided.
Staging
Because of the importance of 
staging in treatment selection, 
much research has been done to 
determine appropriate techniques 
for staging. The value of chest and 
abdominal computed tomography, 
bone scanning, gallium scanning 
and liver-spleen scanning in addi­
tion to the evaluation of symptoms 
and physical findings has been as­
sessed for systemic metastases. 
Computed tomography is by far the 
most useful single test; it is excel­
lent for detecting lung, liver and 
adrenal metastases as well as re­
mote enlarged lymph nodes. Galli­
um scanning is occasionally positive 
for remote metastases if the primary 
tumour has a strong uptake. In 
approximately 5% of patients, the 
bone scan detects an unsuspected 
bony metastasis in a patient who 
otherwise appears curable.
For wall penetration, endoscopic 
ultrasonography is currently under 
evaluation and shows great promise 
of being the most sensitive for 
defining the depth of tumour. If the 
outlines of the tumour mass are 
irregular or blurred on the comput­
ed tomogram and the interpretation 
is wall penetration, computed to­
mography has proved to detect 
more than 90% of cases of full­
thickness wall penetration.4 If inter­
pretation of wall penetration is re­
stricted to the observation that pe­
riesophageal fat lines are obliterated 
or the tumour appears to engulf 
adjacent structures such as the aor­
ta, the value and sensitivity of the 
computed tomogram is much more 
limited. In advanced cases, gallium
scanning, showing intense uptake 
at the primary tumour location, 
barium swallow axis views or azy­
gos venography also confirm full­
thickness wall penetration, but 
these studies are less sensitive than 
computed tomography and are 
deemed unnecessary.
For lymph-node metastases only, 
the detection of nodes larger than 2 
cm by computed tomography or 
other techniques allows the predic­
tion of nodal metastases. Unfortu­
nately, at least 50% of patients who 
prove to have positive lymph nodes 
after surgical resection do not have 
glands large enough to be detected 
preoperatively.
Current Treatment
Our current preoperative evalua­
tion of patients who have esopha­
geal carcinoma includes computed 
tomography of the chest and abdo­
men, barium swallow evaluation of 
the upper digestive tract, endoscopy 
with biopsy and bone scanning, in 
addition to cardiopulmonary evalua­
tion. Additional studies or biopsies 
are determined by these initial find­
ings. During the evaluation, nutri­
tional therapy is provided as indicat­
ed by the degree of weight loss and 
level of serum albumin. Among pa­
tients presenting with established 
dysphagia as the principal symp­
tom, about 40% are found to have 
definite evidence of systemic metas­
tases, full-thickness esophageal wall 
penetration or remote, enlarged 
lymph nodes, and they are not 
considered candidates for curative 
therapy. In these cases, the thera­
peutic decision is based solely upon 
the extent of the patient’s symp­
toms and the most appropriate way 
of providing relief. Often this con­
sists of a standard esophagectomy 
or esophagectomy without thora­
cotomy if the tumour location and 
size are such that palliative radia-
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tion, intubation or laser therapy are 
unlikely to provide relief. Of the 
remaining 60% of patients with dys­
phagia who are potentially curable 
based on preoperative evaluation, 
another 10% to 15% are found to 
have more advanced disease at the
time of surgical staging; they un­
dergo a palliative resection. The 
techniques of en-bloc esophagecto­
my are reserved for those patients 
who appear to have localized dis­
ease both preoperatively and at the 
time of surgical exploration.
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Arterial Reconstruction to the Foot 
Vessels: Is It Worth the Trouble?
Raymond Labbe, MD, FRCSC; Yvan Douville, MD, FRCSC; Henri-Paul Noel, MD, FRCSC
Between 1974 and 1988, 32 patients with severe rest pain and ischemic ulcerations 
of lower extremities underwent 34 arterial reconstructions to the foot vessels, using, 
in the majority of cases, the in-situ vein technique. There were 10 early graft 
failures, resulting in the loss of five extremities. The indication for surgery, 
presence of diabetes and type of bypass were not predictive of early thrombosis. 
Five-year primary and secondary patency rates were 52.8% and 62.6%, with a foot 
salvage rate of 74%. Although a number of these long bypass grafts fail early 
because of the severity of tibial disease, this procedure appears to be durable in a 
selected group of patients.
De 1974 a 1988, 34 reconstructions arterielles au niveau du pied ont ete effectuees 
chez 32 patients presentant de la douleur de repos severe ou des ulcerations 
ischemiques, en utilisant dans la majorite des cas la technique du pontage veineux in 
situ. II y a eu 10 thromboses precoces de greffons, resultant en cinq amputations. 
L’indication pour la chirurgie, la presence de diabete et le type de pontage n’ont pas 
ete predictif d’une thrombose precoce. Les permeabilites primaire et secondaire a 5 
ans ont ete de 52.8% et 62.6%, avec un taux de sauvetage du pied de 74%. Bien 
qu’un certain nombre de ces pontages longs soit perdu precocement en raison de la 
severite de l’atteinte tibiale, il semble que ce soit une procedure durable avec un 
effect benefique a long terme dans un groupe selectionne de patients.
leolar arteries, concluded that pro­
cedures to the ankle and foot are 
effective and durable, and should be 
performed with autogenous vein. 
Others4-6 have promoted the use of 
distal vein bypasses for limb sal­
vage.
In an attempt to evaluate our 
results with arterial reconstructions 
to the foot vessels and to determine 
if such procedures have any long­
term benefit, we reviewed our expe­
rience with bypasses to the posteri­
or tibial artery, distal to the internal 
malleolus, to the plantar arch and 
to the dorsalis pedis artery, leaving 
out grafting to tibial vessels above 
the level of the malleoli.
S evere tibial disease remains a major challenge to vascular 
surgeons; in limb-salvage situa­
tions, arterial reconstruction to the 
foot may be the only alternative, 
short of a major amputation.
According to Buchbinder and col­
leagues,1 limb salvage has been ap­
preciably increased by femoral-foot 
bypass using in-situ vein and by 
popliteal-foot bypass using re­
versed vein.
In 1986, Grant2 presented his 
experience with distal in-situ vein 
grafts, including bypasses to tarsal 
and plantar arteries, with a follow­
up at 36 months; in his series, 
longer grafts with smaller distal 
anastomotic sites and outflow beds 
did not represent important factors 
in late failure.
Recently, Andros and associates,3 
reporting in June 1988 an impor­
tant series of bypasses to paramal-
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Patient Data and Methods
Between January 1974 and June 
1988, 32 patients underwent 34 
bypasses to the foot because of 
atherosclerosis. Two patients had 
bilateral procedures at 1- and 3-year 
intervals. This group represents 3% 
of all infrainguinal bypasses done at 
l’Hopital du Saint-Sacrement de 
Quebec during the same period.
The mean age of the patients was 
64.7 years (range from 40 to 83 
years) and 81% were men.
Seventeen patients (53%) had dia­
betes and 22 (68.7%) were smokers 
or previous smokers. Hyper­
lipidemia was documented in only 
four patients (12.5%) and 16 had 
coronary artery disease or hyperten­
sion, or both.
All operations were performed for
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foot salvage; in 18 cases there was 
ischemic ulceration and gangrene, 
in 13 cases debilitating rest pain 
and in 3 cases acute tibial thrombo­
sis.
There were 20 femoral to dorsalis 
pedis artery bypasses — 18 using 
in-situ saphenous vein and 2 using 
reversed saphenous vein; 13 bypass­
es were femoral to plantar arch or 
posterior tibial artery — 12 using 
the in-situ technique and 1 a mixed 
vein technique; only 1 popliteal to 
dorsalis pedis artery bypass was 
done, using reversed saphenous 
vein.
The mean vein diameter was 5.2 
± 0 . 12  mm proximally and 3.6 ± 
0.07 mm distally (mean ±  SEM).
Procedures with in-situ veins 
were performed essentially by the 
same technique over the years. The 
proximal anastomosis is completed 
first, then, using arterial inflow to 
distend the lumen, retrograde ever­
sion of the valves is done, using 
Cartier’s valvulotome.7 The arterio­
venous fistulas, identified with the 
help of the electromagnetic flow 
meter, are ligated; we accept a
FIG. 1. Intraoperative arteriogram of 
in-situ femoral-dorsalis pedis artery 
bypass with visualization of complete 
plantar arch.
minimal residual flow of fistulas. 
The distal anastomosis is then car­
ried out. Heparin is used locally or 
systemically, according to the sur­
geon’s preference, and maintained 
in an intravenous infusion for 48 to 
72 hours so that the partial throm­
boplastin time is slightly elevated.
Only a few patients underwent 
pre- or post-bypass angiography 
during the operation, but this has 
now become routine (Fig. 1).
Follow-up information was ob­
tained at 6-month intervals, and 
graft patency was assessed by ar­
terial Doppler examination. The rec­
ommendations of Rutherford and 
colleagues8 were followed to calcu­
late primary and secondary patency 
rates and foot salvage rate, using 
life-table analysis. Comparisons be­
tween subgroups were analysed by 
the x2 test.
Results
One patient died of massive pul­
monary embolism in the early post­
operative period. Morbidity was es­
sentially related to wound-healing 
problems, as reported by others.9
The primary patency was 69.8% 
at 30 days and 52.8% at 5 years 
(Fig. 2). Three grafts were success­
fully thrombectomized, and second­
ary patency was 75.8% at 30 days 
and 62.6% at 5 years (Fig. 3). Two 
bypasses are still patent 10 and 13 
years respectively after the bypass 
procedure. The foot salvage rate 
was 81.3%o at 30 days and 74% at 5 
years (Fig. 4). However, due to the 
small number of patients, the stan­
dard error is larger than 10% after 
2 years.
Because early graft failure is the 
major determinant of long-term pat­
ency, we focused our attention on 
the 10 grafts lost in the early 
postoperative period. The indication 
for surgery (Table I), the presence 
of diabetes (Table II) and the site of 
distal anastomosis (Table III) were 
not associated with a greater risk of 
failure; one graft in each of the last 
two groups was thrombectomized 
the day after surgery and was still 
patent at 6 months and years 
later respectively.
Vein diameter and intraoperative 
blood flow (ml/min) through the 
bypass, as measured by the flow 
meter, were not predictive of paten­
cy or failure.
The 10 failures resulted in five 
amputations, one performed a few 
months after surgery.
Thirty-three of the 34 procedures 
were long femorodistal bypasses.
100
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FIG. 2. Cumulative life-table primary patency rate for 34 femorodistal bypasses. 
Number of grafts at risk at beginning of each time interval is shown. Dotted line is 
used for standard errors larger than 10%.
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Grafts to dorsalis pedis artery did as 
well as grafts to the posterior tibial, 
with 3-year primary patency rates of 
61% and 44% respectively. The pop­
liteal dorsalis pedis bypass (the only 
short graft in this series) was patent 
at 2V‘i years.
Diabetes mellitus was not an ad­
verse factor. Surprisingly, diabetic 
patients did better than nondiabetic 
with respect to primary patency. 
Three nondiabetic patients had their 
thrombosed graft saved, upgrading 
their secondary patency rate to 
50.8% at 3 years.
Evaluation of arterial run off was 
difficult because of poor preopera­
tive angiographic documentation of 
tibial and foot vessels in many 
cases, mainly because of severe ar­
terial disease. Many patients had 
their dorsalis pedis or posterior tibi­
al artery, or both, explored surgical­
ly to confirm the patency or occlu­
sion of these vessels before bypass 
or amputation.
Discussion
In-situ saphenous vein bypass 
has allowed surgeons to reach vas­
cular beds as far distal as the 
forefoot. Although its superiority to
reversed saphenous vein bypass still 
has to be demonstrated,1011 it ap­
pears to be an ideal conduit when 
severe tibial disease is present and a 
more distal revascularization proce­
dure is required. Femorodistal by­
pass to the foot vessels proved to be 
a useful technique in this series; a 
5-year primary patency rate of 
52.8% is acceptable with respect to 
the type of arterial disease and is in 
agreement with that reported in the 
current literature.3-12 A foot salvage 
rate of 81.3% at 30 days reflects the 
severity of the disease: five limbs 
were lost among the 10 early graft 
failures; however, the foot salvage 
rate remained at 74% at 5 years, 
suggesting that the bypass was a 
durable one.
Although shorter bypasses seem 
to have better patency to disadvan­
taged outflow tracts,13 only one 
patient underwent a popliteal to 
dorsalis pedis artery bypass in our 
series. We have no experience with 
the composite sequential bypasses 
to the ankle level or more distally, 
even though Verta14 indicated good 
results.
It is interesting that the presence 
of diabetes did not have an adverse 
effect on graft patency or limb
Table 1. Early Graft Failure: Indication for 
Surgery
Indication No./no. in group
Ischemic ulceration +
gangrene 5/18
Debilitating rest pain 4/13
Acute tibial thrombosis 1/3
Table II. Early Graft Failure in Diabetes 
No./no. in group
Diabetic 3/18
Nondiabetic 7/16
Table III. Early Graft Failure According to 
Type of Bypass
Bypass type No./no. in group
Femoral-dorsalis pedis 5/20
Femoral-distal posterior
tibial 5/13
CUMULATIVE
PATENCY
80
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FIG. 3. Cumulative life-table secondary patency rate for 34 femorodistal bypasses to 
foot. Number of grafts at risk at beginning of each time interval is shown. Dotted 
line is used for standard errors larger than 10%.
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FIG. 4. Foot salvage rate by life-table analysis. Number of extremities at risk at 
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salvage. This observation has been 
reported by others,15'17 suggesting 
that a difference should not be 
anticipated between diabetic and 
nondiabetic patients in these re­
spects.
Early graft failure was seen in 10 
cases; two grafts were saved by a 
secondary procedure (thrombecto­
my), but five extremities were ulti­
mately lost. We were not able to 
identify the factors associated with 
a higher risk of early thrombosis. 
However, preoperative angiographic 
documentation of distal vascular 
beds was not adequate in the major­
ity of the patients, and this may 
represent a major determinant of 
early patency. Emphasis should be 
placed on peroperative angiogra­
phy, which should be routine dur­
ing distal vascular procedures.
Although long distal reconstruc­
tion to the foot vessels, using in- 
situ saphenous vein bypass, is tech­
nically demanding and carries a 
significant risk of early thrombosis, 
we believe it is worth doing for limb 
salvage; it should be performed 
when severe popliteal and tibial dis­
ease is present and a vessel is open 
in the foot.
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lar surgery, although some are contro­
versial. It will be particularly useful for 
those preparing for their fellowship ex­
aminations in vascular surgery and for 
vascular surgeons who require “facts 
and figures” for a particular procedure. 
We recommend it without hesitation.
Carman M. Iannicello, MD, FRCSC
Allan R. Downs, MD, FACS, FRCSC
Rm. GC405,
General Hospital,
820 Sherbrook St.,
Winnipeg, Man.
R3A 1R9
ROB & SMITH’S OPERATIVE SUR­
GERY. Paediatric Surgery. 4th edition. 
Edited by Lewis Spitz and H. Home- 
wood Nixon. 703 pp. Illust. Butter- 
worths, Stoneham, Mass., 1988. 
$250.00 (US). ISBN 0-407-00666-4.
This multiauthored text is the pediatric 
section of Rob & Smith’s Operative 
Surgery series. Pediatric general sur­
gery is well covered, but the only 
subspecialties included are plastic sur­
gery, urology and neurosurgery.
This book tries to bridge the gap 
between an atlas and a textbook. There 
are 65 contributors and the quality of 
each chapter is variable. The introduc­
tory chapters, which are theoretical and 
basic, may be of value to resident staff. 
There is no operative demonstration or 
discussion of venous access. The details 
in chapters discussing such topics as 
hair lip and cleft palate are highly 
specialized. The discussion is somewhat 
excessive in some chapters, such as 
those on empyema thoracis (14 pages) 
and inflammatory bowel disease (32 
pages), whereas operative descriptions 
of meconium ileus and exomphalos, for 
example, are controversial and superfi­
cial. The 16 pages on Hirschsprung’s 
disease represent a more balanced ap­
proach, which should have been the 
guiding principle for the rest of the 
text.
continued on page 432
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Comparison Between Transcutaneous 
Oximetry and Ankle-Brachial Pressure 
Ratio in Predicting Runoff and Outcome in 
Patients Who Undergo Aortobifemoral Bypass
F. Michael Ameli, MB, ChB, FRCS(Edin), FRCSC, FACS; Moni Stein, BA, MD; John L. Provan, MS,
FRCS, FRCSC, FACS; Loris Aro, RN; Robert Prosser, MA; Eugene L. St. Louis, MD, FRCPC
In a prospective study, transcutaneous oxygen tension and ankle-brachial pressure 
index (ABI) were measured pre- and postoperatively in 105 symptomatic patients 
who underwent aortobifemoral bypass to compare the ability of these two 
measurements to reflect the runoff status, determined by angiography, and to 
predict the outcome of surgery.
Postoperatively, ABI better reflected the runoff status. The difference in mean 
ABI for good versus poor runoff was 0.17 (p < 0.05). The difference in mean 
transcutaneous oxygen tension below the knee for the two runoff categories was 
relatively small (6.3 mm Hg, p < 0.05). Post- minus preoperative increases in ABI 
reflected the runoff status better than increases in transcutaneous oxygen tension. 
For good runoff, the mean ABI increase was 0.25 and for poor runoff it was only 
0.14 (p < 0.05).
Runoff and transcutaneous oxygen tension were found to be the best predictors of 
symptomatic recurrence. Poor runoff was associated with a relative risk of 2.5 (p =  
0.017) and transcutaneous oxygen pressure of less than 40 mm Hg implied a 
relative risk of 2.3 (p =  0.029) for symptomatic recurrence. The most important 
predictor of graft failure was preoperative ABI.
Transcutaneous oxygen tension and the ankle-brachial pressure index appear to 
be valuable noninvasive techniques for vascular assessment, offering different 
insights and different predictions for management and prognosis of peripheral 
vascular disease.
Au cours d’une etude prospective, on a mesure la tension d’oxygene transcutanee et 
l ’indice bras-cheville (IBC) chez 105 patients symptomatiques qui subirent un 
pontage aortobifemoral, dans le but de comparer l ’utilite de ces deux mesures pour 
donner un aperfu de la permeabilite vasculaire, telle qu’etablie par angiographie, et 
pour predire les resultats de la chirurgie.
L ’ lBC postoperatoire s’est avere un meilleur indicateur de la permeabilite. La 
difference entre 1’IBC des patients ayant un bon debit et celui des patients qui 
avaient un mauvais debit a ete de 0.17 (p < 0.05). La difference pour les deux 
categories de patients entre les tensions d’oxygene transcutanees moyennes prises 
sous le genou etait relativement faible (6.3 mm Hg, p < 0.05). Par rapport aux 
valeurs preoperatoires, l’augmentation de 1’IBC a donne une meilleure idee de la 
permeabilite vasculaire que l’augmentation de la tension d’oxygene transcutanee. 
Pour un bon debit, l’augmentation de 1’IBC moyen a ete de 0.25 par rapport a 
seulement 0.14 pour un mauvais debit (p < 0.05).
Le debit et la tension d’oxygene transcutanee ont ete meilleurs pour predire une 
recidive symptomatique. Un mauvais debit a ete associe a un risque relatif 2.5 fois 
plus eleve (p =  0.017) et un tension d’oxygene transcutanee inferieure a 40 mm Hg 
supposait un risque relatif de 2.3 (p =  0.029) de recidive symptomatique. Le facteur 
le plus important pour predire l ’echec du pontage a ete 1’IBC preoperatoire.
La tension d’oxygene transcutanee et l’ indice bras-cheville apparaissent comme 
deux methodes non sanglantes utiles pour evaluer le systeme vasculaire. Elies 
offrent des perspectives differentes et contribuent des facteurs previsionnels 
differents face au traitement et au pronostic des maladies vasculaires peripheriques.
Noninvasive vascular tests are playing an increasingly impor­
tant role in the diagnosis and man­
agement of patients with peripheral 
vascular disease. Doppler segmental 
limb systolic pressures are widely 
accepted as the standard for nonin­
vasive evaluation of peripheral vas­
cular disease. The ankle-branchial 
index (ABI) (the ratio of ankle to 
brachial systolic pressure1’2) is most 
frequently used to express the ankle 
systolic pressure. It can detect dif­
ferences between normal limbs, dis­
eased viable limbs and nonviable 
limbs.2 The technique is reproduci­
ble,3-5 and a change in the pressure 
ratio of more than 14% usually 
indicates disease.6 The ABI reflects 
mainly the hemodynamic status in 
relatively large vessels. However, 
under certain circumstances, it can 
be associated with some problems. 
For example, older diabetic patients 
tend to have calcific medial stenosis 
which falsely elevates the ABI.7 In 
addition, the pressures in large ves­
sels do not necessarily reflect blood
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flow to ischemic areas of the skin, a 
factor that is often more relevant 
clinically. Finally, ankle surgery 
may interfere with safe postopera­
tive pressure measurements.
Transcutaneous oximetry is a de­
pendable noninvasive technique for 
assessing peripheral oxygen deliv­
ery.8 It is gaining popularity in 
vascular surgery because of its sen­
sitivity in detecting limb vascular 
occlusive disease9 and its ability to 
reflect different degrees of isch­
emia.10'11 It has also been used 
successfully to predict the outcome 
of arterial reconstruction,12 and of 
stump healing after amputation.13-15 
Transcutaneous oximetry has been 
criticized for being influenced by 
many systemic and local factors.1617
The purpose of this study was 
twofold — to compare the ability of 
ABI and transcutaneous oxygen 
tension (Ptc02) to reflect the .runoff 
status of vessels determined by an­
giography and to evaluate the abili­
ty of the two measurements and 
runoff to predict symptomatic re­
currence and graft failure.
Patients and Methods
Between November 1985 and 
January 1988, 105 consecutive pa­
tients underwent aortobifemoral by­
pass operations and received aor­
tobifemoral Dacron grafts. Back­
ground information on the patients
T a b le  1. C h a ra c te ris tic s  o f 1 0 5  P atien ts
W h o  U n d e rw e n t A o r to b ife m o ra l B ypass
V aria b le No. (% )
A ge, y r 6 3 .2  (m ean)
S ex
M 61 (5 8 .1 )
F 4 4  (4 1 .9 )
P re se n tin g  s y m p to m s
C la ud ica tion 61 (58 .1 )
S evere  is ch e m ia 4 4  (4 1 .9 )
D iabe tes 1 8 (1 7 .1 )
S m o k in g  h is to ry 1 0 2  (9 7 .1 )
H yp e rte n s io n 4 4  (4 1 .9 )
Is c h e m ic  h e a rt d isease 3 7  (3 5 .2 )
C a ro tid  d isease 1 5 (1 4 .3 )
P re v iou s  va s cu la r s u rg e ry 27  (2 5 .7 )
is presented in Table I. The data 
were collected prospectively by one 
research assistant.
All patients underwent angiogra­
phy preoperatively. Each angiogram 
was evaluated and scored according 
to the runoff at the distal anasto­
mosis. This was done for each limb 
separately and according to stan­
dards suggested by Rutherford and 
colleagues.18 We defined poor run­
off as 50% or more occlusion in the 
runoff arteries at the site of distal 
anastomosis.
Of the 210 limbs, distal anasto­
moses in 128 (61%) were to the 
common femoral artery, in 2 (1%) to 
the common iliac artery, in 79 
(37.5%) to the deep femoral artery 
and in 1 (0.5%) to a previous femo- 
ropopliteal graft. Thirty-three 
(15.7%) limbs were subjected to 
extended profundaplasty. Sixty-nine 
(65.7%) proximal anastomoses were 
end-to-side and 36 (34.3%) were 
end-to-end.
Ankle-arm systolic blood-pres­
sure ratios (ABI) were measured for 
each limb in the resting supine 
position pre- and postoperatively. 
Ankle and arm systolic pressures 
were measured using a sphygmo­
manometer and a Doppler ultra­
sound velocity detector. Transcuta­
neous oxygen tension measure­
ments were made using a Contron 
Ptc02 monitor (Contron Instru­
ments, Everett, Mass.) with Clarke 
electrodes at room temperature. All 
measurements were done while the 
patient lay supine as the electrodes 
were placed on the dorsum of the 
foot and 10 cm below the knee on 
the symptomatically worse leg. 
Transcutaneous oxygen tension 
measurements were done before 
and up to 10 days after operation.
Complete data were missing on 
25 (11.9%) limbs because of death 
(six patients, 12 limbs), wound in­
fection or hematoma (3 limbs) or 
early graft thrombosis (10 limbs). 
Morbidity and mortality in the first
month postoperatively were consid­
ered as complications. Postopera­
tively, patients were seen at 1, 3 
and 6 months and at 1 and 2 years.
Three (2.9%) were lost to follow­
up. Long-term operative outcome 
was evaluated from the cumulative 
rates of death, amputation, graft 
patency and symptomatic recur­
rence. For primary patency rates, 
the first occlusion postoperatively, 
in spite of future interventions, was 
considered as graft failure. Symp­
tomatic recurrence was defined as 
any symptoms related to vascular 
occlusive disease that occurred dur­
ing follow-up.
Two statistical packages were 
used to analyse the data: SAS19 and 
BMDP.20 Angiography scores were 
divided into poor versus good run­
off, and the means of the postopera­
tive ABI and Ptc02 measurements 
according to the runoff status were 
calculated. We compared these two 
means using a comparison meth­
od.21 We further calculated the 
means for the difference between 
postoperative and preoperative 
Ptc02 and ABI, according to the 
runoff status, and compared them.
In order to compare the prognos­
tic power of the diagnostic tests, a 
Cox proportional-hazards survival 
analysis22 was used. A stepwise se­
lection process based on a comput­
ed significance probability (maxi­
mized partial-likelihood ratio), en­
tered or removed variables from the 
regression equation. We tested the 
independent correlation of the tests 
with the time to occurrence of graft 
failure, symptoms or death. The 
relative risk for each diagnostic test 
was expressed as the exponent of 
the coefficient of the test in the 
hazard equation. The p values re­
ported correspond to the impor­
tance of the test in predicting in­
creased risk for graft failure, symp­
tomatic recurrence or death, after 
taking into account all the other 
significant predictors.
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Results
The operative death rate was 
5.7%, amputation rate was 0%, 
early patency rate was 94.3% and 
early symptomatic relief (by limbs) 
was 98%. At 2-year follow-up the 
cumulative death rate was 15.5%, 
amputation rate 0%, cumulative 
patency 92.8% and the cumulative 
symptomatic relief dropped to 
77.3%.
Postoperative ABI and Ptc02 for 
Good Versus Poor Runoff
The difference in mean ABI for 
good versus poor runoff was signifi­
cant at 0.17 (p < 0.05) (Table II). It 
was also significant (p < 0.05) for 
Ptc02BK (below the knee) at 6.3 
mm Hg but not for Ptc02DF (dor­
sum of foot).
Differences Between Postoperative 
and Preoperative Ptc02 and ABI
Neither Ptc02 measures demon­
strated a significant difference in 
the mean increases for the two 
runoff categories (Table II), but ABI 
showed a significantly (p < 0.05) 
higher mean increase for good ver­
sus poor runoff of 0.11.
Predictors o f  Symptomatic 
Recurrence and Graft Failure 
(Tables III and IV)
A stepwise regression analysis se­
lected three variables as independ­
ent and additive predictors of symp­
tomatic recurrence during the fol­
low-up period: runoff, the preoper­
ative Ptco2BK and postoperative 
Ptco2DF. The presence of poor run­
off had a predictive value superior 
to that of the other significant 
variables (relative risk, 2.5; 95% 
confidence interval, range from 1.2 
to 5.4). A preoperative Ptc02BK 
score of less than 40 mm Hg was 
associated with a relative risk for 
symptomatic recurrence of 2.3 (95%
confidence interval, range from 1.1 
to 4.9). Postoperative Ptc02DF also 
made a significant, independent 
contribution in the regression mod­
el, but we could not find an abso­
lute level that would be associated 
with a substantial relative risk (> 
1). Variables like postoperative 
Ptc02BK, preoperative Ptc02DF and 
preoperative and postoperative ABI 
were not significant predictors of 
symptomatic recurrence.
The most significant predictor of 
graft failure was preoperative ABI. 
An index of less than 0.4 was 
associated with a relative risk for 
graft failure of 6.1 (95% confidence 
interval, range from 1.6 to 23.6). 
Postoperative ABI of less than 0.5 
was associated with a relative risk 
of 3.2 (95% confidence interval, 
range from 0.9 to 11.8). Poor run­
off was associated with a relative 
risk of 3.0 (95% confidence interval, 
range from 0.9 to 9.7). The contri­
butions of the last two variables to
the regression model were close to 
but not quite statistically significant 
at the p = 0.05 level.
Runoff, ABI and Ptc02 were not 
significant predictors of short- or 
long-term death rates.
Discussion
Ankle-brachial index and trans­
cutaneous oximetry are two nonin- 
vasive vascular measurements that 
evaluate physiological entities 
which are interdependent but not 
identical. Transcutaneous oxygen 
tension is a measure of peripheral 
oxygen delivery which is partially 
dependent on the hemodynamics in 
larger arteries. Clinically, the severi­
ty of ischemia is best correlated 
with the amount of oxygen supply 
to the tissue, which is best estimat­
ed by Ptc02. Oxygenation is a few 
physiological steps ahead of blood 
pressure in the actual function of 
living tissues. The amount of blood
T a b le  II. M ean  P o s to p e ra tive  M e a s u re m e n ts  and In c re a ses  o f A nk le -B ra ch ia l In d ex  (A B I) and 
T ra n sc u ta n e o u s  O xygen  T e n s io n  (P tco 2) A cco rd in g  to  R u n o ff
M ea s u re m e n t
R unoff
Good Poor D iffe rence
P tc o 2BK, m m  Hg
P os to p 59 .5 5 3 .2 6 .3 *
Increase 1 3 .4 * 8 .7 * 4 .7
P tc o 2DF, m m  Hg
P os to p 5 2 .6 4 7 .5 5.1
Increase 1 4 .6 * 6 .8 7 .8
ABI
P os to p 0 .7 8 0.61 0 .1 7 *
Increase 0 .2 5 * 0 .1 4 * 0 .1 1 *
* p  <  0 .0 5 .
B K  =  b e lo w  th e  knee, DF =  d o rs u m  o f fo o t .
T a b le  II I .  P re d ic to rs  o f  S y m p to m a tic  R ecurrence
R elative 9 5 %  confidence
V a r ia b le p va lue risk interval
R u n o ff 0 .0 1 7 2 .5 1 . 2 - 5 . 4
P tc o 2BK preop 0 .0 2 9 2 .3 1.1 - 4 . 9
P tc o 2DF po s to p 0 .031 1 .03 1 . 0 - 1 . 0 5
T a b le  IV . P re d ic to rs  o f  G ra ft Fa ilure
R elative 9 5 %  confidence
V a r ia b le p va lue risk interval
A B I p reop 0 .0 0 3 6.1 1 . 6 - 2 3 . 6
A B I p o s to p 0 .0 6 3 .2 0 . 9 - 1 1 . 8
R u n o ff 0 .0 7 3 .0 0 .9  -  9 .7
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that gets to the skin depends on 
arteriolar and capillary function, 
which is not always predictable 
from blood pressure in large arter­
ies. In diabetics, Ptc02 correlates 
better with peripheral tissue isch­
emia than ABI, which is usually 
high due to arterial calcifica­
tion.72324 Researchers who tried to 
correlate Ptc02 with blood pressure 
were usually disappointed to find 
far from perfect linear correla­
tion.25-26 This again confirms the 
concept that Ptc02 and ABI do not 
measure the same thing.
The runoff arterial status is a 
well-recognized factor in the post­
operative prognosis of patients who 
undergo aortobifemoral bypass.27-28 
We found that postoperative ABI 
was significantly different for good 
versus poor runoff, and Ptc02BK 
also showed a significant difference, 
but the actual value (6.3 mm Hg) 
was not impressive. We have fur­
ther shown that the mean increase 
in post- over preoperative ABI was 
significantly (p < 0.05) higher for 
limbs with good (0.25) versus poor 
(0.14) runoff, but Ptc02 increases 
did not differ significantly.
Our results agree with those 
from the study of Rutherford and 
colleagues,28 which showed that in 
the majority of limbs with poor 
runoff, the ABI increased by less 
than 0.2 after aortobifemoral by­
pass grafting. The majority of limbs 
with good runoff had an ABI in­
crease of more than 0.2. The ABI, 
therefore, reflects runoff status bet­
ter than Ptco2. This is consistent 
with the fact that ABI assesses the 
hemodynamic status of relatively 
large arteries, which is directly re­
lated to runoff, whereas Ptc02 mea­
surement depends also on smaller 
calibre vessels and other local fac­
tors that are independent of runoff.
The excellent ability of ABI to 
reflect runoff status gives it an 
important role in the postoperative 
follow-up. It can be used to evaluate
distal progression of disease or dis­
tal acute occlusions and to deter­
mine the success of procedures like 
thrombectomy, endarterectomy and 
angioplasty.
Using the Cox regression analy­
sis, we were able to demonstrate the 
predictive validity of runoff, Ptc02 
and ABI on the outcome of surgery. 
Using death rate as the dependent 
variable, ABI, Ptc02 and runoff 
showed no significant predictive 
ability.
Transcutaneous oxygen tension 
and runoff were significant predic­
tors of symptomatic recurrence. 
Limbs with poor runoff had a rela­
tive risk of 2.5 for symptomatic 
recurrence. The cut-off point cho­
sen for preoperative Ptc02BK as a 
predictor of symptomatic recur­
rence was 40 mm Hg. Limbs with 
lower scores ran a relative risk of 
2.3. Ankle-brachial index and the 
other Ptc02 measurements (except 
for postoperative Ptc02DF) were not 
significantly associated with symp­
tomatic recurrence.
Symptomatic recurrence does not 
necessarily mean recurrence of 
symptoms identical to or worse 
than those in the preoperative peri­
od. Any symptoms related to vascu­
lar disease were included in this 
category. The symptom could be 
caused by distal progression of the 
disease, disease in the graft itself or 
other hemodynamic factors. This 
concept of symptomatic recurrence 
adds valuable information for the 
management of patients and does 
not necessarily overlap with graft 
failure, amputation or death rate. 
For example, graft failure was quite 
low at 2-year follow-up (7.2%), 
whereas symptomatic recurrence 
was much higher (22.7%).
Other studies28-31 have also 
shown an important association be­
tween poor runoff and persistent 
symptoms after aortobifemoral by­
pass. The occurrence of persistent 
symptoms in patients with poor
CJS,
runoff ranged from 20% to 57%.
Preoperative ABI was the best 
predictor of graft failure with a 
relative risk of 6.1 for patients with 
scores of less than 0.4. However, it 
should be mentioned that 86% of all 
graft occlusions occurred early, and 
the postoperative ABI was not al­
ways measured before these early 
occlusions. Therefore, the predic­
tive significance of postoperative 
ABI might have been much higher.
It is of interest that the preopera­
tive ABI was a better predictor of 
graft occlusion than runoff. Trans­
cutaneous oxygen tension was not 
a significant predictor of graft oc­
clusion. Other studies27-28 also docu­
mented a significant association be­
tween poor runoff and graft failure 
in patients who underwent aor­
tobifemoral bypass.
Conclusions
We have shown that the postop­
erative ABI was better associated 
with the runoff status, determined 
by preoperative angiography, than 
Ptc02. Ankle-brachial index in­
creases were also better associated 
with the runoff status than Ptc02 
increases. Transcutaneous oxygen 
tension and runoff were significant 
predictors of symptomatic recur­
rence, while ABI was a significant 
predictor of graft failure. Both 
Ptc02 and ABI are valuable noninva- 
sive vascular measurements that 
offer different insights with differ­
ent predictions regarding manage­
ment and prognosis of vascular dis­
ease.
We thank United States Catheters and 
Instruments International (USCI) for 
their support of this study.
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continued from page 427
The authors note in their preface 
that some o f the contributors received 
short notice before submitting their 
contributions. Twenty-three chapters, 
including those on liver resection, duo­
denal atresia, malrotations and hypos­
padias, have no references at all. The 
only reference in the chapter on hy­
dronephrosis is the original Anderson 
and Hynes article of 1949; alternative 
reconstructive procedures are not men­
tioned. In some instances the content 
may not be in logical order. For exam­
ple, the treatment of inguinal hernias is 
hundreds of pages displaced from the 
management of undescended testicles.
The book is well bound; unfortunate­
ly one 4-page leaf in the review copy 
was missing. The artwork is clear. The 
size and weight o f the book indicate 
that it is intended for library use rather 
than transportation.
It is not clear from the content 
whether the book is supposed to be a 
textbook or an atlas, nor is it apparent 
to which type of physician the book is 
directed. Of the 87 chapters, I found 20 
that would be satisfactory and useful 
for a general surgeon and only 29 that 
would be o f use to a resident. Most of 
the textbook is obviously aimed at the 
specialist pediatric surgeon, but the 
lack of detail in the descriptions of 
some of the operative procedures, such 
as anorectal malformations, and the 
lack of discussion of other procedures, 
such as diaphragmatic hernia, make 
this book o f doubtful use to a well- 
trained pediatric surgeon.
When compared with other pediatric 
surgical texts, this book cannot be 
highly recommended. Its major use will 
be as a resource atlas in a pediatric 
hospital library. The combination of 
some subjects being dealt with clearly 
and completely and others superficially, 
detracts from the appeal of this exter­
nally attractive textbook.
Steven Rubin, MD, FRCSC
Children's Hospital o f  Eastern Ontario,
401 Smyth Rd.,
Ottawa, Ont.
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium) 
a semi synthetic cephalosporin antibiotic, results from inhibition of cell wall 
synthesis.
Indications and Clinical Uses
Treatm ent: CLAFORAN (cefotaxime sodium) may be indicated for the treatment 
of infections caused by susceptible strains of the designated micro-organisms 
in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by 
Streptococcus pneumoniae (formerly Diplococcus pneumoniae), other streptococci 
(excluding enterocci, e.g. S. faecalis), Straphylococcus aureus (penicillinase and 
non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella 
species (including K  pneumoniae), Proteus mirabilis, indole positive Proteus, Ser- 
ratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor­
rhea caused by N. gonorrhoeae including penicillin resistant strains. 
B acte rem ia /S e p ticem ia : caused by Escherichia coli, unspecified Klebsiella 
strains and Serratia marcescens.
Skin in fec tions : caused by Staphylococcus aureus (penicillinase and non­
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli, 
Proteus mirabilis and indole positive Proteus.
Intra-abdominal in fec tions: caused by Escherichia coli, and unspecified Kleb­
siella species.
Gynecological in fec tions: including pelvic inflammatory disease, endometritis 
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus 
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostiep- 
tococcus strains and some strains of Bacteroides fragilis In several cases, although 
clinical cures were achieved, bacteriological follow up was not available. 
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN 
has been used with some success in wound and intra-abdominal infections against 
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas. 
In the treatment of infections encountered in immunosuppressed and granulo­
cytopenic patients, results of therapy with CLAFORAN have not been impressive. 
CLAFORAN should not be considered in the treatment of enterococcal infections, 
i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order 
to isolate and identify the causative organisms and to determine their suscep­
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re-evaluated once these results 
become available.
Prophylactic U se: The administration of CLAFORAN perioperatively (preoperative 
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec­
tions in patients undergoing elective surgical procedures (e.g. abdominal or vaginal 
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified 
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased 
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative 
use of CLAFORAN may also reduce the incidence of certain postoperative infections. 
Effective use for elective surgery depends on the time of administration (see Dosage 
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation 
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin) 
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden­
tification of the causative organism so that appropriate therapy may be instituted. 
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to 
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics. 
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether 
the patient has had previous hypersensitivity reactions to cefotaxime, 
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution 
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including 
CLAFORAN should be administered with caution to any patient who has 
demonstrated some form of allergy, particularly to drugs. If an allergic reaction 
to CLAFORAN occurs, the drug should be discontinued and the patient treated 
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or 
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins 
(and other broad spectrum antibiotics); therefore, it is important to consider its 
diagnosis in patients who develop diarrhea during the administration of CLAFORAN. 
This colitis can range from mild to life-threatening in severity 
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor­
mal flora of the colon and may permit overgrowth of Clostridium difficile or other 
Clostridia. It has been established that a toxin produced by Clostridium difficile 
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace­
ment with a suitable specific antibiotic. Moderate to severe cases should be manag­
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis 
is not relieved by discontinuance of CLAFORAN administration or when it is severe, 
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis 
(e.g. vancomycin) or other suitable therapy may be indicated. Other possible causes 
of colitis should also be considered (see Adverse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals 
with a history of lower gastrointestinal disease particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently, 
use of the drug in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child bearing potential requires that the anticipated 
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be 
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible 
organisms. Constant evaluation of the patient's condition is essential. If super­
infection occurs, therapy should be discontinued and appropriate measures taken. 
Although CLAFORAN rarely produces alterations in kidney function, evaluation 
of renal status is recommended, especially in severely ill patients receiving high 
doses.
Patients with markedly impaired renal function should be placed on the special 
dosage schedule recommended under Dosage and Administration, because nor­
mal dosage in these individuals is likely to produce excessive and prolonged serum 
antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment 
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing 
substances but not with the use of specific glucose oxidase methods. 
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are: 
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflam­
mation with intravenous administration. Pain, induration and tenderness after in­
tramuscular injection. Gastrointestinal (1.7%): Colitis, diarrhea, nausea and 
vomiting. Symptoms of pseudomembranous colitis can appear during or after 
CLAFORAN treatment. Hem ic and Lymphatic System (< 1 % ): Mild, reversi 
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some 
patients developed positive direct Coomb’s test during treatment with CLAFORAN. 
Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient 
elevations in SGOT, SGPT, serum LDH and serum alkaline phosphatase levels 
have been reported. K idney ( <  1%); Increased serum creatinine and BUN have 
occasionally been observed. Central Nervous System (0.2%); Headache. 
Symptoms and Treatment ot Overdosage 
Since no case of overdosage has been reported to date with CLAFORAN, no 
specific information on symptoms or treatment is available. Treatment of over­
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in­
travenously after reconstitution (see Table with recommended mode of reconstitution 
according to route of administration).
Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative 
organisms, severity of the infection and condition of the patient.
Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated
Gonorrhea
1 1 g IM (single dose)
Uncomplicated
infections
2 1 g every 12 hours 
IM or IV
Moderately 
severe to severe 
infections
3-6 12 g every 
8 hours IM or IV
Very severe 
infections (e.g. 
septicemia)
6-8 2g  every 
6-8 hours IV
Life-threatening
infections
up to 12 2g every 
4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated 
surgery, recommended doses are as follows.
(a) 1 g IM or IV administered ’/2  to 1V2 hours prior to the initial surgical incision 
to ensure that adequate antibiotic levels are present in the serum and tissues 
at the start of surgery
(b) 1 g IM or IV administered 1V2 to 2 hours following the first dose; for lengthy 
operative procedures, additional intraoperative doses may be administered, if 
necessary, at appropriate intervals (IV 2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period. 
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. 
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours 
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 m g/kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, 
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid­
ed into 4 to 6 equal doses, or up to 180 m g/kg /day for severe infections. 
For body weights 50 kg or more, the usual adult dosage should be used. 
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72 
hours after the patient defervesces or after evidence of bacterial eradication has 
been obtained; a minimum of 10 days of treatment is recommended for infec­
tions caused by Group A beta-hemolytic streptococci in order to guard against 
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical 
appraisal is necessary during therapy of chronic urinary tract infections and may 
be required for several months after therapy has been completed; persistent in­
fections may require prolonged treatment. Doses less than those recommended 
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m* 
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on 
sex, weight, and age of the patient) may be used to convert these values into 
creatinine clearance.
Males: Weight (kg) x  (140 -  age) Females: 0.85 x above value 
72 x  serum creatinine
Administration
Intramuscular: CLAFORAN should be injected well within the body of a relatively
large muscle such as the upper outer quadrant of the buttock (i.e. gluteus max- 
imus); aspiration is necessary to avoid inadvertent injection into a blood vessel. 
Intravenous: The intravenous route is preferable for patients with bacteremia, 
bacterial septicemia, or other severe or life-threatening infections, or for patients 
who may be poor risks because of lowered resistance resulting from such 
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, 
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be 
injected over a period of 3 to 5 minutes. Using an infusion system, it may also 
be given over a longer period of time through the tubing system by which the 
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type 
needles are preferred for this type of infusion. However, during infusion of the 
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad­
ministration of other solutions at the same site.
Reg'd TM of Abbott Laboratories.
Reconstitution
For Intramuscular U se : CLAFORAN should be reconstituted with Sterile Water 
for Injection or Bacteriostatic Water for Injection in accordance with the volumes 
recommended in the following table.
Reconstitution Table
Intramuscular
Volume to be 
Added to
Vial (mL)‘
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial 2 2.2 230
1 g vial 3 3.4 300
2 g vial 5 6.0 330
‘ shake to dissolve.
For direct intravenous injection (bolus) a n d /o r  continuous intravenous 
in fu s io n : 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL 
of Sterile Water for Injection. Reconstituted solution may be further diluted with 
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table
Intravenous
Volume to be 
Added to 
Vial (mL)*
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial 10 10.2 50
1 g vial 10 10.4 95
2 g vial 10 11.0 180
‘ shake to dissolve.
Solutions fo r IV In fu s io n : CLAFORAN is compatible with the following infu­
sion fluids:
-  Sterile Water for Injection
-  0.9% NaCI injection
- 5% dextrose injection
- 0.9% NaCI and 5% dextrose injection
- 0.45% NaCI and 5% dextrose injection
- 0.2% NaCI and 5% dextrose injection
- Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer’s injection
- Lactated Ringer's solution
- Lactated Ringer's with 5% dextrose injection 
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic. 
Stab ility o f Solution
S to ra ge : Solutions of CLAFORAN range from light yellow to amber, depending 
on concentration and the diluent used. The solutions tend to darken depending 
on storage conditions and should be protected from elevated temperatures and 
excessive light.
“ Reg'd TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution 
maintains satisfactory potency for 24 hours at room temperature (25°C) and for 
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu­
tions may be further diluted with 50 to 1000 mL of the recommended infusion 
fluids in Viaflex" intravenous bags. Such solutions maintain satisfactory poten­
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration 
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for 
up to 24 hours at room temperature and 48 hours under refrigeration (reference 
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special In s tru c tions : Parenteral drug products should be inspected visually 
for particulate matter and discoloration prior to administration. Solutions of 
CLAFORAN range from light yellow to amber, depending on concentration and 
diluent used. The dry powder as well as solutions tend to darken, depending 
on storage conditions.
Inco m patib ilities: Solutions of CLAFORAN must not be admixed with 
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad­
ministered to the same patient, they must be administered separately and not 
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above 
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, 
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as 
acid on a dry basis).
S torage: CLAFORAN in the dry state should be stored at room temperature, 
protected from light and heat.
Product monograph available on request 
Reference
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©Registered Trademark 
of Roussel Uclaf, Paris
ROUSSEL 4 L
ROUSSEL CANADA INC.
MONTREAL. QUEBEC S B *  m .
ORIGINAL ARTICLES
Expanded Polytetrafluoroethylene 
Prostheses as Secondary Blood Access 
Sites for Hemodialysis: Pathological 
Findings in 29 Excised Grafts
Sheny Canizales, MD; Jamal Charara, PhD; Francis Gill, BSc;
Robert Guidoin, PhD; Paul-Emile Roy, MD; Philippe Bonnaud, MD;
Gilles Laroche, MD, FRCSC; Michel Batt, MD; Paul Roy, MD;
Michel Marois, MD; Allan Downs, MD, FRCSC; Carlo Picetti, MD; Serge Contard, MD
The popularity of expanded polytetrafluoroethylene (PTFE) arteriovenous fistulas 
for hemodialysis access is increasing. The low infection rate, low thrombogenicity 
and low body reactivity make it an important blood access for patients on routine 
hemodialysis.
The authors examined 29 PTFE graft fistulas surgically excised from patients on 
hemodialysis for one or more of the following complications: infection 7, 2 with 
associated hemorrhage; thrombosis 9; aneurysm 11, 3 with associated thrombosis; 
stenosis 5, 3 with associated thrombosis; hemorrhage 4 and arterial steal 2. The 
explanted prostheses were reinforced Gore-tex in 20, Gore-tex thin wall in 1, Impra 
I in 4, Impra II in 3 and Vitagraft in 1.
It was also noted that the implants failed in the short term mainly because of 
infection, in the medium term mainly because of thrombosis and stenosis, and in the 
long term usually because of aneurysm.
La popularite du teflon microporeux (PTFE) comme derivation arterio-veineuse 
pour l’hemodialyse est maintenant tres repandue. Sa resistance a l’infection, sa 
faible thrombogenicite et l’absence d’antigenicite permettent de considerer ce 
materiau comme une alternative de choix pour permettre Faeces iteratif au sang 
chez les patients traites pour hemodialyse chronique.
Les auteurs ont obtenu 29 specimens en PTFE preleves lors de l’exerese 
chirurgicale. L’ablation avait ete requise pour corriger les defaillances suivantes: 7 
infections dont 2 avec hemorragie; 9 thromboses; 11 formations anevrysmales dont 
3 avec thrombose; 5 stenoses dont 3 avec thrombose; 4 hemorragies et 2 
hemo-detournements. Les protheses explantees sont: 20 reinforced Gore-tex, 1 
Gore-tex thin wall, 4 Impra I, 3 Impra II et 1 Vitagraft.
Les interventions chirurgicales a court terme furent necessaires suite a l’appari- 
tion d’infections, a moyen terme suite aux stenoses et aux thromboses, et a long 
terme principalement suite aux formations anevrysmales.
From the Biomaterials Unit, Hopital St-Frangois d ’Assise, and Department o f  Surgery and 
Department o f  Pathology, Universite Laval, Quebec, PQ
Supported by grants from the Medical Research Council o f  Canada and the Hopital St-Franfois 
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T he increased longevity of pa­tients with end-stage renal fail­
ure through long-term hemodialysis 
has resulted in a need for alterna­
tive means o f circulatory access. 
Repeated and routine access to the 
circulation was initially permitted 
by the external arteriovenous 
shunt1 and the radial-cephalic fistu­
la,2 which is technically simple to 
construct, is well accepted by most 
patients and is associated with 
minimal complications and the best 
long-term patency of all available 
methods o f angioaccess.34 Howev­
er, the increasing number o f pa­
tients whose vessels are inadequate 
following evolutive complications 
has promoted a search for second­
ary procedures.5 These have includ­
ed saphenous vein autografts to the 
arm, biological grafts such as the 
bovine carotid artery heterograft 
and the modified human umbilical 
cord vein graft, and synthetic grafts 
such ?s Dacron and expanded 
PTFE.
The use o f  saphenous vein has 
not pnved as rewarding in these 
circumstances as for peripheral vas­
cular reconstruction.6 Also, it is 
preferable to  preserve the vein in 
case it is needed for peripheral 
arterial surgery or aortocoronary 
bypass grafting. The homologous 
vein is m ore  appealing because it is
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highly resistant to infection and is 
easy to puncture. The results, how­
ever, are often erratic, harvesting 
from a cadaver is very demanding 
and quality control of stripped veins 
is questionable.7 8
Although chemically processed 
bovine heterografts have been used 
successfully by some inves­
tigators,9-11 their use has frequently 
been associated with complications 
such as thrombosis, aneurysms, 
lipid uptake and infection.12-15
The umbilical vein has seen limit­
ed use,1617 and sufficient data are 
not available to draw conclusions.
Whereas experience with Dacron 
graft for hemodialysis access has 
been scanty,18 expanded PTFE has 
been successfully employed as an 
arteriovenous fistula. It appears to 
be a more valuable alternative. Ad­
vantages are that it is easy to use 
and can occasionally survive local­
ized infections.19-28 Blood access is 
highly demanding since the grafts 
are challenged by needle punctures 
two to three times a week. It is, 
therefore, not surprising that the 
prosthetic material sometimes fails 
and patients have to be reoperated 
upon because of complications.
In this study we report our re­
sults with 29 PTFE grafts, used for 
vascular access, collected from 27 
patients at reoperation.
Patients and Methods
The 29 arterial grafts were surgi­
cally excised at seven different cen­
tres in Canada (three), Italy (one) 
and France (three) from 27 patients 
(10 men and 17 women) whose 
mean age at implantation was 46 
years (range from 25 to 72 years). 
The average duration of implanta­
tion was 23.6 months (range from 
0.4 to 75.8 months). The most 
frequent complications requiring re­
moval of the graft were aneurysmal 
dilatation 11 (38%), thrombosis 9 
(31%) and infection 7 (24%). Steno­
sis 5 (17.2%), hemorrhage 4 
(13.8%) and arterial steal 2 (6.9%) 
were less frequent (Table I).
Of the 29 expanded PTFE pros- 
theses, 20 were reinforced Gore-tex, 
1 was Gore-tex thin wall, 4 were 
Impra I, 3 Impra II and 1 a Vita- 
graft.
The morphologic and pathologic 
characteristics and the structural 
changes of the prostheses were in­
vestigated according to the follow­
ing protocol.29 After excision, ideal­
ly, the grafts were opened longitu­
dinally, carefully rinsed with hepari­
nized saline, fixed in a buffered 
solution of 1.5% glutaraldehyde and 
shipped immediately to the Bi-
Table I. Clinical Data of Patients Who Had Polytetrafluoroethylene Prostheses
Age at Duration ot
Case
no. Sex
implantation,
yr
Year of 
implantation Prosthesis Location Configuration
implantation,
mo Complications
01 M 25 Gore-tex Infection
02* F 46 1977 Gore-tex Right thigh Loop 48.3 Aneurysm
03t M 46 1982 Impra I Right forearm Straight 1.3 Thrombosis
04 F 61 Gore-tex Right arm Straight 9.9 Thrombosis, false aneurysm
05 F 43 1981 Gore-tex Left forearm Loop 12.0 Stenosis, thrombosis
06 F 53 1982 Gore-tex Right thigh Straight 2.5 Infection
07 F 47 Gore-tex Left arm Straight 34.9 Thrombosis, aneurysm
08 F 30 1983 Gore-tex Left forearm Loop 8.9 Thrombosis
09 F 62 1982 Gore-tex Left arm Straight 23.1 Stenosis
10 F 60 1980 Impra I Left forearm Straight 41.2 Stenosis
11f M 48 1982 Impra I Right forearm Straight 6.4 Hemorrhage, infection
12 M 26 1984 Impra II Left forearm Loop 14.9 Aneurysm
13 M 30 1983 Impra II Left forearm Loop 9.2 Hemorrhage
14 M 26 1980 Impra I Forearm Straight 29.7 Aneurysm
15 F 60 1982 Impra II Right forearm Straight 20.0 Hemorrhage, infection
16 F 62 1978 Gore-tex Right arm 57.4 Aneurysm
17 F 51 1982 Gore-tex Right forearm Loop 8.9 Infection
18* F 54 1977 Gore-tex Loop 75.8 Aneurysm
19 M 43 1979 Gore-tex Left arm Straight 66.0 Thrombosis, aneurysm
20 F 40 1979 Gore-tex Left arm Straight 69.6 Aneurysm
21 F 36 1985 Gore-tex Left forearm Straight 0.4 Thrombosis
thin wall
22 M 44 1985 Gore-tex Left arm Straight 2.9 Thrombosis
23 F 38 1985 Gore-tex Right arm Straight 7.0 Infection
24 M 66 1987 Gore-tex Left arm Straight 2.0 Arterial steal
25 F 40 1987 Vitagraft Loop 0.5 Hemorrhage, infection, aneurysm
26 M 25 1982 Gore-tex Right arm Loop 59.4 False aneurysm
27 F 52 1985 Gore-tex Right forearm Straight 25.1 Stenosis
28 M 52 1986 Gore-tex Right forearm Loop 17.9 Thrombosis, stenosis
29 F 72 1987 Gore-tex Left arm Straight 3.4 Arterial steal
*, f  =  same patient.
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omaterials Laboratory at the Hopi- 
tal St-Franqois d’Assise in Quebec 
City. The prostheses were examined 
macroscopically and photographed. 
Representative areas of the internal 
and external capsules were selected 
for pathological investigation. Each 
area was divided into two subspeci­
mens. One was post-fixed in a Per- 
fix solution, dehydrated with 
ethanol and clarified with toluene 
before embedding in paraffin. Sec­
tions, 4 jxm thick, were stained in 
the following order: Weigert’s, Mas­
son’s trichrome, Brenn and Brown, 
and Dhal stains for viewing by light 
microscopy. The second part was 
post-fixed in carboxyhydrazide and 
osmium tetroxide for examination 
by scanning electron microscopy. 
Dehydration was obtained by im­
mersing the specimens in a series of 
solutions of ethanol of graded con­
centration, culminating in absolute 
ethanol. The specimens were dried 
by the critical point method using 
liquid carbon dioxide as the transfer 
medium. Specimens were then gold- 
palladium coated and examined in a 
JSM 35CF microscope (Jeol Inc.,
Peabody, Mass.) at 15 to 20 kV 
accelerating voltage.
The tissues adhering to the re­
maining parts of the prostheses 
were removed by boiling in a 5% 
sodium bicarbonate solution for 5 
minutes; they were then cooled 
slowly for 24 hours with magnetic 
agitation. The prosthesis was then 
immersed at least twice in a diluted 
commercial bleach solution at room 
temperature for 2 hours each time. 
Again the specimens were examined 
macroscopically and photographed. 
Representative specimens from the 
intact, the anastomotic and the 
punctured regions were also pre­
pared for scanning electron micros­
copy to evaluate iatrogenic damage 
to the graft.
The external capsules of the ex- 
planted prostheses were classified 
as follows: 1 — no encapsulation, 2
— a thin fibrous coating, 3 — an 
intermediate fibrous coating and 4
— a thick fibrous coating. The fatty 
external deposits were graded from 
1 to 4: 1 — no deposits, 2 — light 
deposits, 3 — intermediate deposits 
and 4 — abundant deposits.
Resus
Mamcopic Observations
Th t i m e  o f explantation for indi- 
vidus c a s e s  is shown in Fig. 1. It 
show t h a t  thromboses and aneu-
FIG. 2. Aneurysmal dilatation of rein­
forced Gore-tex graft implanted as 
forearm loop for 75.8 months; external view show s extreme dilatation result­
ing from repeated puncturing in limit­
ed areas.
FIG. 3. Thrombosed reinforced Gore- 
tex graft implanted as forearm loop 
fistula for 8.9 months. Lack of external 
encapsulation left repeated puncture 
area clearly visible in absence of any healing.FIG. 1. Evolutive complications of polytetrafluoroethylene (PTFE) fistulas after different durations of implantation.
CJS, VOL. 32. NO. 6, NOVEMBER 1989 435
canizales, et  a l .
rysmal formations (Fig. 2) may 
occur at any time, but infections 
and hemorrhages are observed 
within the first 2 years of implanta­
tion.
The main cause of aneurysmal 
dilatation is repeated punctures of 
the same area (Fig. 3). The needle 
injures the prosthesis wall, severing 
the graft fibres and weakening the 
wall; this is followed by leakage of 
blood and formation of the aneu­
rysm. Therefore, only the develop­
ment of fibrous tissue around and 
inside the graft wall could maintain 
its patency as an impervious blood 
conduit (Fig. 4).
The degrees of encapsulation and 
external fatty deposits in the cap­
sule of the explanted grafts are 
presented in Table II. These data 
clearly demonstrate that both thick­
ening of the capsule and progres­
sive incorporation of fatty deposits 
increased with the time of implanta­
tion.
Histologic Findings
Histologic examination demon-
FIG. 4. Segments of reinforced Gore- 
tex graft implanted as straight fistula 
in arm for 34.9 months. Graft was 
excised because of aneurysmal forma­
tion and occlusion due to excessive 
banding to ensure hemostasis. Holes 
in middle are result of repeated punc­
tures in same area, as illustrated in 
view of specimen after tissue diges­
tion, indicating that integrity of graft 
wall was only maintained by fibrous tissue.
strated that 9 of the 29 prostheses 
were dilated by dehiscence of the 
synthetic structure. In addition, 
areas of repeated puncture were 
observed (Fig. 5). In some cases, 
the luminal surface opposed to the 
puncture holes was probably 
scratched by the needle (Fig. 6). 
When the needle goes deeply 
through the graft, it may provoke 
scratching and irregularities along 
the opposite luminal surface. The 
mechanical stability of the wall 
graft did not seem to be altered 
much by this procedure. The needle 
punctures affected severely the 
structure of the reinforced Gore-tex 
graft, especially its outer wrap, 
which was frequently detached. 
Nevertheless, the healing process of 
a puncture hole showed connective 
tissue penetrating the hole and 
seemed to be in continuity with the 
partially vascularized fibrous con­
nective tissues of the outer capsule 
of the graft.
In the non-dilated prostheses, we 
noted some parietal thrombosis and 
in one of these cases the prosthesis 
was severely infected. Moreover, se­
verely infected areas were detected 
in three non-thrombosed grafts. 
Some grafts, however, were excised 
because of infection without evi­
dence of bacteremic colonization.
External encapsulation was ob­
served in 15 cases but we could not 
establish a clear relation between 
the rate of collagen within this 
external capsule and the patency 
period (Fig. 7).
In three cases we noted the pres­
ence of foreign-body reactions asso­
ciated with the intense production
of collagen. It seems that this kind 
of reaction could contribute to the 
formation of the external capsule. 
Bacteremic colonization was also 
noted within the graft interstices.
Tissue proliferation into the graft 
interstices was also observed. In 
some cases this layer was detached 
during the patent period of the 
graft. However, in one case the 
proliferation became thicker as it 
reached the external capsule and 
tended to behave like an atheroscle­
rotic injury.
Finally, low amounts of choles­
terol and lipid deposits were found 
on the luminal surfaces of many 
grafts (Fig. 8).
Discussion
Polytetrafluoroethylene is manu­
factured in the form of powder 
which is mixed with a lubricant to 
produce a paste of extruded Teflon 
and then shaped into a tube at 
room temperature. Expanded PTFE 
is processed by mechanical stretch­
ing of the plain tube of extruded 
Teflon, which results in an ultra­
structure of solid PTFE nodes inter­
connected by fine fibrils of PTFE. It 
is further stabilized by sintering at 
high temperature. Node size and 
shape and fibril length can be con­
trolled by changing the components 
of the process. The speed at which 
the expanded tube is cooled after 
sintering controls its physical prop­
erties.30
The technique of expanding 
PTFE was ultimately refined and 
applied to the development of many
Table II. D egrees o f E n ca p su la tion  and F a tty  D e p os its  V e rsu s  P a tency  P eriod
Fatty deposits
Encapsulation in the capsule Duration of
degree (range 1 - 4) im plantation, mo
1 -  N one 1.5 1.9
2  -  T h in 1.9 7 .8
3  -  In te rm e d ia te 1.9 2 6 .4
4  -  T h ic k 3 .3 3 2 .9
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models of PTFE prostheses (Gore- 
tex, Impra, Vitagraft). However, the 
strength testing of the earlier Gore- 
tex and Impra models revealed that 
circumferential strength was inade­
quate, leading to aneurysmal dila­
tions. Gore-tex has had a thin film 
consisting of expanding PTFE ap­
plied to its outer surface, whereas 
the Impra graft has had its radial 
strength enhanced by an increase in 
wall thickness.31 Although PTFE 
has become the material of choice 
for synthetic graft for dialysis ac­
cess, with cumulative patency rates 
exceeding those of most other
grafts,2132 this material is still not 
perfect.
The most common problem in 
our series was aneurysm formation, 
caused by needle injury which 
breaks down the wall of the pros­
thesis. The resultant leakage of 
blood forms a perigraft hematoma, 
which becomes organized and leads 
to the formation of an aneu­
rysm.1433 Moreover, after a certain 
period of time, and depending on 
the size of the puncture hole and 
the number of punctures in a given 
area, the integrity and impervious­
ness of the prosthetic material relies
only on fibrous tissue. The wall of 
the resulting blood conduit is there­
fore unable to withstand blood pres­
sure and results in predictable aneu­
rysmal formation. Nevertheless, this 
is quite reasonable if one considers 
that during a 6-year period at three 
hemodialysis sessions a week with 
two needle punctures each time, the 
graft will be punctured over 1800 
times. A better understanding of 
the failure mechanism of this graft 
under nosocomial fragmentation of 
the wall by needle puncture is re­
quired to extend the duration of 
access.
FIG. 5. Scanning electron micrograph of reinforced Gore-tex 
graft, after tissue digestion, implanted as forearm loop fistula 
for 8.9 months, illustrates disruption of prosthetic wall 
(original magnificat:on X 20).
FIG. 7. Optical micrograph of reinforced Gore-tex graft 
implanted as forearm loop fistula for 8.9 months. External 
capsule is as thick as graft wall. Intense collagen proliferation 
is evident within this capsule (Weigert’s stain, original 
magnification X 200).
FIG. 6. Scanning electron micrograph of Impra I graft, after 
tissue digestion, implanted as forearm fistula for 41.2 months. 
Needle points are evident (original magnification X 20).
FIG. 8. Scanning electron micrograph showing lipid uptake 
on luminal surface of Vitagraft implanted as loop fistula for 
0.5 months (original magnification X 1000).
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Needle puncture for hemodialysis 
is very demanding for the vascular 
access. The role of the nurses and 
the patient in maintaining a patent 
access is extremely important.1924 
For example, the recommended 
angle of insertion of 45° is impor­
tant to minimize the risk of false 
aneurysm or separation of the outer 
layer.34 Separation may occur if the 
angle of insertion is too acute. This 
separation can sometimes be useful. 
During the insertion of the needle 
at an acute angle, it slides between 
the prosthetic wall and the outer 
layer. When the needle is removed, 
the outer layer may act as a flap 
covering the hole and provide faster 
hemostasis. The procedure is clear­
ly to be avoided as a general prac­
tice because it impairs the mechani­
cal integrity of the graft, but we 
believe that this principle could be 
applied in the design of a special­
ized prosthesis for vascular access. 
Moreover, rotation of the needle 
after insertion is also recommended 
to prevent scratching of the luminal 
surface opposite the puncture site.34 
Polytetrafluoroethylene is a difficult 
material to puncture because of its 
high resistance to penetration, and 
this, combined with the free motion 
after the tip of the needle has 
penetrated the wall, makes scratch­
ing hard to avoid. Even if this 
scratching does not impair the me­
chanical stability of the wall, it 
increases the thrombogenicity of 
the surface. However, the risk of 
aneurysm formation can be reduced 
by avoiding repeated punctures in 
the same area.33
The evolutive complications of 
the grafts are well distributed over 
time. Thrombosis, however, may 
occur at any time during the paten­
cy period. It has been noted that 
the primary cause of thrombosis is 
mishandling of the fistula by dialy­
sis personnel.35 Hemostatic banding 
or unintentional obstruction of the 
graft by the sleeping patient may
also cause thrombosis. A concerted 
effort at communication between 
physician and technician has dimin­
ished preventable mishaps.24
Although PTFE grafts have 
shown good resistance to infection 
in experimental situations, they are 
at risk from infection both by con­
tamination during the initial opera­
tion and by subsequent inoculation 
of bacteria during the needle punc­
ture for dialysis. Therefore, infec­
tion could likely affect the graft at 
any time during the implantation 
period. However, in our report in­
fection developed mainly in the first 
year of dialysis treatment. The low 
incidence of infection after 1 year is 
explained by the fact that a well- 
incorporated graft is not as suscep­
tible to bacteremic challenge as a 
freshly-implanted one.36 Some bac­
teria can form a biofilm, which can 
adhere to smooth surfaces.37 This 
phenomenon may explain why the 
nonincorporated graft is more sus­
ceptible to infection. We believe, 
therefore, that the graft should be 
allowed to mature for at least 15 
days after insertion so that incorpo­
ration can take place.
Stenosis is one of the common 
causes of prosthetic failure, occur­
ring primarily near the venous anas­
tomosis. Possible mechanisms in­
clude the development of venous 
fibrous intimal hyperplasia of the 
vein just proximal to the anastomo­
sis, probably secondary to turbu­
lence and high-flow localized in­
growth from the anastomosis it­
self.26 Diffuse areas of stenosis may 
also develop within the graft, pre­
sumably because organized laminal 
clot accumulates at frequently used 
puncture sites.38 However, this 
complication seems to be independ­
ent of the choice of material.39 It 
has been noted in bovine grafts40 
and it is found in PTFE grafts.32 We 
found that stenosis can occur 1 
year after the insertion, unlike 
other reports33 in which stenosis
seemed to occur at any time.
The low amount of lipid and 
cholesterol is easily explained by 
the fact that these patients do not 
always suffer from advanced athero­
sclerosis unlike patients who re­
quire peripheral vascular surgery.
Conclusions
Our results suggest that the ex­
panded PTFE prosthesis is the sub­
stitute of choice among currently 
available prostheses. Nevertheless, 
PTFE is still not the ideal substi­
tute. The complications leading to 
failure of the vascular access site 
are primarily aneurysm formation 
and thrombosis. The most obvious 
advantage of this expanded PTFE is 
its ability to resist infection and to 
withstand repeated needle puncture.
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•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium for 
in jection) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN® OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SENSITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN®. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis  may 
respond to drug discontinuance alone. In more 
severe cases, m anagem ent may in c lu d e  
sigm oidoscopy, appropriate bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and 
cilastatin sodium for injection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient's condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have been 
reported with PRIMAXIN® especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS TR A TIO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN® 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm ent (see DOSAGE AND A D M IN IS ­
TRATION - Dosage in Patients w ith  Renal 
Insufficiency).
Use in Pregnancy
The use of PRIMAXIN® in pregnant women has not 
been studied, therefore, PRIMAXIN® should be 
used during pregnancy only if clearly needed. Use 
of this drug in women of childbearing potential 
requires that the anticipated benefits be weighed 
against possible hazards.
Reproduction studies with bolus I.V. doses suggest 
an apparent intolerance to PRIMAXIN® (including
emesis, inappetence, body weight loss, diarrhea 
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. Inother studies, PRIMAXIN® 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in 
milk. If the use of PRIMAXIN® is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN® is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN® and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically 
added to other antibiotics. PRIMAXIN® has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN® with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determine causal relationship of adverse ex­
periences to therapy with PRIMAXIN®.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN® were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly, probably, or d e fin ite ly  related to 
PRIMAXIN® were:
Gastrointestinal
Incidence (%)
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 
pseudomembranous colitis
0.2
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures
(see PRECAUTIONS)
0.2
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia 
Special Senses
<0.1
transient hearing loss in
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a tin in e  c le a ra n c e s  o f 
<5 mL/min/1.73 m2 «0 .08 mL/s/1.73 m ') should 
not receive PRIMAXIN® unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The pa tien t shou ld  rece ive 
PRIMAXIN® after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r  pa tien ts  on he m od ia lys is , 
PRIMAXIN® is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN® in 
patients undergoing peritoneal dialysis.
TABLE 2
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN® 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined 
by the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN® 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
MAXIMUM DOSAGE OF PRIMAXIN® 
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/mln/1.73 m* 
(mL/s/1.73 m2)
DOSE
(g)
DOSAGE
INTERVAL
(h)
MAXIMUM
TOTAL
DAILY
DOSAGE
(g)
Mild
impairment 31-70
(0.52-1.17)
0.5 6-8 1.5-2
Moderate
impairment 21-30 
(0.35 - 0.50)
0.5 8-12 1-1.5
Severe*
impairment 0-20
(0-0.33)
0.25 - 0.5 12 0.5-1.0**
Patients w ith  creatin ine  clearance o f 6 to  
20 mL/min/1.73 m2 (0.1 - 0.3 mL/s/1.73 m2) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lower) every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
*x The highest dose is only recommended fo r 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, /rmol/L)
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
TABLE 1
ADULT DOSAGE OF PRIMAXIN®
I.V. Administration
Severity 
of infection
Dose
(mg of imipenem)
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections 
due to less 
susceptible 
organisms 
or life threatening 
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
x Primarily some strains of Ps. aeruginosa.
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, /tmol/L)
PRIMAXIN® is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Dosage in Infants and Children
The recommended to ta l d a ily  dosage of 
PRIMAXIN® in children and infants 3 months of age 
and older is 60 to 100 mg/kg of body weight divided 
into 4 equal doses given at six hour intervals. The 
higher dosages should be used for infants and 
young children. The total daily dosage should not 
exceed 2 grams. Clinical data are insufficient to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
Contents of the vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium  C h loride  
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN® range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN® has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS 
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture 
in vials containing im ipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
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Concomitant Vascular Procedures in 
Conjunction With Myocardial 
Revascularization: All or None? A Report 
of a Case
Fredrick B.Y. Hoy, MD; Anthony Brody, MD; Robert C. Gomez, MD
Patients with coronary artery atherosclerosis usually have concomitant peripheral 
vascular lesions. The authors describe the case of a 65-year-old woman who had 
multiple symptomatic lesions: severe stenosis of the left main coronary artery and 
the carotid arteries, a large abdominal aortic aneurysm and bilateral renal artery 
occlusion. To manage these and to avoid myocardial infarction and cerebrovascular 
accident at operation, concomitant procedures were performed as follows: coronary 
artery bypass grafting, aneurysm resection, carotid endarterectomy and 
revascularization of the larger kidney. Although the patient’s hospital stay was
prolonged, there was no major morbidity and her recovery was good. She returned 
to a normal life-style, requiring only hemodialysis on an outpatient basis.
Les patients souffrant d'atherosderose coronaire ont habituellement des lesions 
vasculaires peripheriques concomitantes. Les auteurs decrivent le cas d’une femme 
de 65 ans qui presentait de multiples lesions symptomatiques: une importante 
stenose du tronc coronarien gauche et des carotides, un gros anevrisme de l’aorte 
abdominale et une occlusion bilaterale des arteres renales. Afin de traiter ces lesions 
tout en evitant l'infarctus du myocarde ou un accident cerebrovasculaire durant 
l’operation, les interventions concomitantes suivantes ont ete pratiquees: pontage 
aortocoronarien, resection d’anevrisme, endarterectomie carotidienne et revasculari­
zation du rein le plus gros. Bien que la patiente ait eu une hospitalisation
prolongee, il n ’y eut pas de morbidite importante et son retablissement fut 
satisfaisant. Elle put retourner a une vie normale, n’ayant besoin que d’une 
hemodialyse en externe.
N umerous reports have outlined the management of patients 
who have coronary artery disease 
and significant peripheral vascular 
lesions, including extracranial ca­
rotid stenoses, abdominal aortic an­
eurysms, aortoiliac occlusive dis­
ease and renal artery stenoses. We 
describe a case in which the patient 
had multiple, serious, symptomatic 
lesions requiring concomitant re­
pair.
Case Report
A 65-year-old woman was admit­
ted for management of refractory 
hypertension, increasing renal in­
sufficiency and congestive heart 
failure. She had been hypertensive 
for 30 years and was unresponsive 
to oral antihypertensive agents. She 
had also been complaining of short­
ness of breath on exertion for 5 
years. She had a history of angina 
pectoris, paroxysmal nocturnal dys­
pnea, orthopnea, swelling of her 
ankles, and had had previous ad­
missions for congestive heart fail­
ure. She also had experienced four 
episodes of right amaurosis fugax.
She weighed 104.5 kg and had a 
blood pressure of 200/130 mm Hg. 
Many drugs, including Zaroxolyn, 
Catapres, Lasix, Procardia, Capot­
en, Nipride, Aldactone and Labeta- 
lol had been used alone or in combi­
nation without effectively control­
ling her blood pressure. Her serum 
creatinine level was 389 /umol/L 
and blood urea nitrogen was 22.8 
m m ol/L urea.
Aortography demonstrated a 
9-cm, fusiform, infrarenal, abdomi­
nal aortic aneurysm and occluded 
renal arteries, which demonstrated 
distal reconstitution (Fig. 1). Both 
kidneys were small. Renal scanning 
confirmed the small size of the 
kidneys, especially the left. There
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was decreased function bilaterally. 
Renal vein renin levels were 
markedly elevated in both renal 
veins.
Because of her history of angina, 
coronary angiography was also per­
formed. This revealed 80% stenosis 
of the left main coronary artery. 
The right coronary artery had no 
marked stenosis. 2D echocardiogra­
phy revealed left ventricular hyper­
trophy with good contractility.
Noninvasive carotid studies per­
formed because of her symptoms of 
amaurosis fugax, suggested an oc­
clusion of the left common carotid 
artery and a hemodynamically sig­
nificant right carotid lesion. Carotid 
angiography confirmed the occlu­
sion of the left common carotid 
artery. In addition, there was a 75% 
ulcerated stenosis at the origin of 
the right internal carotid artery and 
an occluded right external carotid 
artery.
Following these investigations, 
her serum creatinine level rose fur­
ther to 645 ^trnol/L and her blood 
urea nitrogen to 30.7 mmol/L 
urea. Hemodialysis was started. In 
view of her refractory hypertension,
FIG. 1. Abdominal aortogram shows 
large aortic aneurysm and occluded 
renal arteries with distal reconstitu­
tion.
we believed that the major threat to 
this woman’s life was her large 
abdominal aortic aneurysm. Howev­
er, because of the severe stenosis of 
her left main coronary artery and 
angina, she was considered to be at 
high risk for a myocardial infarction 
during cross-clamping of the aorta. 
Furthermore, because of her history 
of amaurosis fugax, she would be at 
serious risk for a cerebrovascular 
accident at the time of cardiopulmo­
nary bypass. After a nephrology 
consultation, it was decided that if 
the patient remained stable during 
surgery, an attempt should be made 
to revascularize the larger right 
kidney in the hope of preserving 
renal function and allowing easier 
control of blood pressure.
The laparotomy was made in the 
midline from the sternal notch to 
the pubis. The patient was found to 
have a large thin-walled abdominal 
aortic aneurysm arising below the 
left renal vein. The larger right 
kidney measured 6 cm in greatest 
length.
The right carotid artery was ex­
posed and when the patient was 
heparinized it was opened. A heavi­
ly calcified, stenotic, ulcerated 
plaque was endarterectomized from 
the right common and internal ca­
rotid arteries. The right common 
carotid artery was closed, but the 
neck incision was left open and 
cardiopulmonary bypass instituted. 
Saphenous vein grafts were then 
placed to the left anterior descend­
ing and circumflex coronary arter­
ies. The patient was weaned from 
cardiopulmonary bypass, but the 
cannulas were left in place.
The abdominal aortic aneurysm 
was then resected. It was 10 cm in 
diameter, thin-walled and had no 
intraluminal clot. A preclotted knit­
ted Dacron tube was used to replace 
the abdominal aorta. Blood in the 
pericardial and peritoneal cavities 
was returned to the heart-lung ma­
chine and retransfused. A saphe­
nous vein graft was then placed 
from the aortic graft to the right 
renal artery. The cannulas were 
then removed from the heart. The 
heparin effect was reversed with 
intravenously administered prot­
amine sulfate. Hemostasis was se­
cured and all incisions were closed.
Postoperatively, the patient re­
mained stable with respect to her 
cardiac, respiratory and central ner­
vous systems. She continued to 
require hemodialysis and her post­
operative stay was prolonged by her 
reluctance to ambulate and her in­
ability to sustain adequate enteral 
nutrition. Permanent vascular ac­
cess for dialysis was established 29 
days postoperatively. At the time of 
discharge, 55 days after the opera­
tion, she was fully ambulatory. Her 
blood pressure was 120/70 mm Hg 
on Vasotec (Frosst, Dorval, PQ) 
only. She weighed approximately 
91 kg.
At her 6-month follow-up, she 
was fully active. She required out­
patient hemodialysis three times 
weekly. Her blood pressure was well 
controlled on one oral antihyperten­
sive agent.
Comment
Because atherosclerosis is a gen­
eralized disease process, patients 
with coronary artery disease would 
be expected to have significant con­
comitant peripheral vascular le­
sions.12 In addition, myocardial in­
farction is the leading cause of early 
and late death after carotid endar­
terectomy23 or abdominal aortic an­
eurysm repair.45
Our patient had multiple prob­
lems: (a) angina upon minimal exer­
tion due to severe left main coro­
nary artery stenosis, (b) transient 
ischemic attacks due to severe ca­
rotid lesions, (c) a large blood-filled 
abdominal aortic aneurysm and (d) 
uncontrolled hypertension and renal
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failure resulting from bilateral renal 
artery occlusions.
Reis and Hannah6 and others57-9 
have advocated combined coronary 
artery bypass and abdominal aneu­
rysm resection in patients with 
symptomatic coronary artery dis­
ease and large or tender aneurysms.
The incidence of cerebrovascular 
accident in those who have symp­
tomatic extracranial carotid lesions 
and undergo coronary artery by­
pass has been reported in the range 
of 10%.10 Accordingly, in this group 
of patients, combined coronary by­
pass and carotid endarterectomy 
has been recommended.10-12
It was our opinion that the most 
immediate threat to our patient was 
her large abdominal aneurysm, but 
in view of her symptomatic severe 
coronary artery disease she was also
at high risk of myocardial infarction 
and thus would require concomitant 
coronary artery bypass and aneu­
rysm resection. Having made that 
decision, we further believed that a 
cerebrovascular accident was highly 
likely at the time of cardiopulmo­
nary bypass because of her carotid 
artery anatomy and symptoms. Ac­
cordingly, concomitant coronary ar­
tery bypass, carotid endarterectomy 
and abdominal aneurysmectomy 
were planned. In addition, if the 
procedure was progressing well, an 
attempt would be made to revas­
cularize the larger kidney to pre­
serve remaining renal function and 
make refractory hypertension more 
amenable to medical therapy. De­
spite a prolonged postoperative hos­
pital stay, there was no major mor­
bidity from the combined proce­
dure. The patient returned to a 
normal active life-style aside from 
requiring hemodialysis as an out­
patient.
References
1. Tomatis LA, F ierens EE, Verbrucge 
GP: Evaluation of surgical risk in pe­
ripheral vascular disease by coronary 
arteriography: a series of 100 cases. 
Surgery 1972; 71: 429-435
2. Ennix CL jr, Lawrie GM, Morris GC jr, 
et al: Improved results of carotid endar­
terectomy in patients with symptomatic 
coronary disease: an analysis of 1,546 
consecutive carotid operations. Stroke 
1979; 10: 122-125
3. Hertzer NR, Lees CD: Fatal myocardial 
infarction following carotid endarterec­
tomy: three hundred thirty-five patients 
followed 6-11 years after operation. 
Ann Surg 1981; 194: 212-218
4. Toal KW, Jacocks MA, Elkins RC: 
Preoperative coronary artery bypass 
grafting in patients undergoing abdomi­
nal aortic reconstruction. Am J Surg 
1984; 148: 825-829
5. Reul GJ jr, Cooley DA, Duncan JM, et 
al: The effect of coronary bypass on the 
outcome of peripheral vascular opera­
tions in 1093 patients. J Vase Surg 
1986; 3: 788-798
6. Reis RL, Hannah H iii: Management of 
patients with severe, coexistent coro­
nary artery and peripheral vascular dis­
ease. J Thorac Cardiovasc Surg 1977; 
73: 909-918
7. Dalton ML jr, P arker TM, Mistrot JJ, 
et al: Concomitant coronary artery by­
pass and major noncardiac surgery. J 
Thorac Cardiovasc Surg 1978; 75: 621 — 
624
8. Korompai FL, Hayward RH, Knight 
WL: Noncardiac operations combined 
with coronary artery bypass. Surg Clin 
North Am 1982; 62: 215-224
9. Ruby ST, W hittemore AD, Couch NP, 
et al: Coronary artery disease in patients 
requiring abdominal aortic aneurysm re­
pair. Selective use of a combined opera­
tion. Ann Surg 1985; 201: 758-764
10. Jones EL, Craver JM, Michalik RA, et 
al: Combined carotid and coronary oper­
ations: when are they necessary? J Tho­
rac Cardiovasc Surg 1984; 87: 7-16
11. Berkoff HA, Turnipseed WD: Patient 
selection and results of simultaneous 
coronary and carotid artery procedures. 
Ann Thorac Surg 1984; 38: 172-175
12. Perler BA, Burdick JF, W illiams GM: 
The safety of carotid endarterectomy at 
the time of coronary artery bypass sur­
gery: analysis of results in a high-risk 
patient population. J Vase Surg 1985; 2: 
558-563
SESAP VI Critique
Item 222
Most patients with a superficial femoral artery occlusion have limited 
disease; reconstitution of the popliteal artery above or below the knee 
joint is demonstrated on arteriography. These patients usually complain 
of intermittent claudication without rest pain or tissue loss (ulcer or 
gangrene). Operation for claudication is usually reserved for patients 
whose symptoms are disabling and who have participated in exercise 
conditioning and stopped smoking.
When the occlusive disease extends below the popliteal artery, the 
patency rate after bypass is lower. When infrapopliteal bypass is 
required, the primary indication for operation should be threatened limb 
loss. Clinical criteria of threatened limb loss include gangrene, an 
ischemic ulcer, cyanotic toes, and ischemic rest pain. Disabling intermit­
tent claudication is not limb threatening and should be managed by 
infrapopliteal bypass only in selected patients, after nonoperative 
therapy has failed.
0
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Giant Fibroepithelial Polyps of the 
Female Urethra: Two Case Reports and 
Review of the Literature
Susan Dian Goldberg, MD, FRCSC;* Linda Sugar, MD, FRCPCt
Fibroepithelial polyps are one of the less common obstructive lesions of the female 
urethra. The authors describe two cases of giant fibroepithelial polyps in paraplegic 
women. Both patients had a history of long-term indwelling catheterization to 
manage neurogenic bladder. The chronic irritation caused by the catheters was 
thought to be responsible for the development of the polyps. Resection is required 
in these cases to relieve the urethral obstruction and eliminate the possibility of 
malignant disease.
Les polypes fibro-epitheliaux represented l’une des causes les moins frequentes 
d’obstruction de l’uretre chez la femme. Les auteurs decrivent deux cas de polypes 
fibro-epitheliaux geants chez des femmes paraplegiques. Les deux patientes 
presentaient une longue histoire de catheterisme a demeure pour cause de vessie 
neurogene. On croit que l’irritation chronique causee par le catheter est a l’origine 
du developpement des polypes. Dans ces cas, la resection est necessaire pour 
soulager l’obstruction et eliminer la possibility d’une maladie maligne.
In this paper we describe two cases of giant fibroepithelial pol­
yps, seen in two paraplegic women 
as obstructive mass lesions. In both 
instances, the patient’s neurogenic 
bladder was managed by placement 
of an indwelling urethral catheter. 
Chronic irritation secondary to the 
indwelling catheter was thought to 
be the main cause of the lesions in 
both cases.
Case Reports
Case 1
A 65-year-old woman had two 
large white polypoid lesions pro­
truding from the urethral meatus. 
Paraplegic as a result of a motor 
vehicle accident, she had had an 
indwelling catheter to manage her 
neurogenic bladder for 10 years.
The large polypoid lesions made 
repeated catheter changes increas­
ingly difficult. Cystoscopy was per­
formed to elucidate the nature of 
the lesions. It revealed minimally 
inflamed bladder mucosa, a normal 
bladder neck, and two, white, 
fleshy, polypoid lesions, 0.7 and 
0.75 mm in diameter, distal to the 
urinary sphincter (Fig. 1). Excision- 
al biopsy of the lesions demonstrat­
ed that they were composed of 
nonkeratinizing squamous epitheli­
um overlying an inflamed fibrovas- 
cular stroma (Fig. 2).
FIG. 1. Case 1. Close-up of urethral 
meatus demonstrating polyp.
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FIG. 2. Case 1. Histologic detail of polyp. Nonkeratinizing squamous epithelium 
overlies mildly inflamed stroma (hematoxylin and eosin, original magnification X 
100) .
Case 2
On routine physical examination, 
a 36-year-old paraplegic woman was 
noted to have a large white polyp­
oid urethral lesion. Her neurogenic 
bladder had been treated with an 
indwelling catheter 7 years after 
injury in a motor vehicle accident. 
Cystoscopy, performed to define the 
nature of the lesion, revealed a 
minimally inflamed, heavily trabecu- 
lated bladder with a single, large, 
white, polypoid lesion distal to the 
bladder neck, obstructing the uri­
nary outlet (Fig. 3). Excisional biop­
sy revealed a polyp, 8 mm in diame­
ter, consisting of nonkeratinizing 
squamous epithelium overlying a 
mildly inflamed fibrovascular core.
Discussion
The female urethra is a fibromus- 
cular tube 3 to 5 cm in length and 
lined by stratified transitional epi­
thelium, originating from the uri­
nary bladder proximally and squa­
mous epithelium of vulvar origin 
distally.1 Although urethral carun­
cles are the most common protuber­
ant lesion of the female urethra, 
less common lesions presenting as 
urethral masses include hemangi­
omas, varices, mucosal prolapse, 
meatal tags, condylomas, papillo­
mas, periurethral cysts, adenomas, 
carcinomas and fibroepithelial pol­
yps.1
Presenting signs and symptoms 
include pain, dysuria, hematuria, 
bloody discharge, itching and inter­
mittent urinary obstruction.
In a review1 of 394 cases of 
urethral tumours, clinically inter­
preted as caruncles, 376 lesions 
were classified as urethral carun­
cles. Seven lesions were categorized 
as benign urethral papillomas asso­
ciated with chronic inflammatory 
changes, and nine lesions were 
found on pathological evaluation to 
be malignant. Six of the malignant
FIG. 3. Case 2. Urethral meatus with 
view of fibroepithelial polyp.
lesions were categorized as squa­
mous cell carcinomas, the remain­
ing three cases represented Bowen’s 
disease. The average age at presen­
tation in those who had a malignant 
lesion was 55 years.1
Both our patients had a history 
of long-term indwelling catheteriza­
tion to manage neurogenic bladder. 
The associated chronic irritation 
was thought to be responsible for 
the development of inflammatory 
polyps at the urethral meatus. Re­
sultant overgrowth of squamous 
epithelium led to the development 
of the large white fleshy lesions 
seen protruding from the urethral 
opening. Resection of the lesions 
is advised to rule out malignant 
disease and to relieve the obstruc­
tion caused by the lesions.
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Surgical Wound Infections: a 63-Month 
Survey in a Developmental Institution
R. Lampard, MD, MSc, MBA
Michener Centre, a developmental institution of 1200 residents, instituted a 
nosocomial infection control program in October 1983, which included surgical 
wound monitoring.
Of the 336 clean and clean-contaminated operations performed in the next 63 
months, there were 15 wound infections attributable to the surgeon; another 7 
occurred which were directly attributable to the patient’s postoperative behaviour. 
Six of the seven occurred in severely retarded patients. The wound infection rate 
dropped during the surveillance period from 23% to 4.1% or less.
Careful preselection of patients for elective surgery and studious attention to 
postoperative nursing care are necessary to achieve these rates or to reduce them 
further, particularly amongst severely retarded patients.
Le Centre Michener, un etablissement voue au developpement de 1200 beneficiaires, 
a mis sur pied, en octobre 1983, un programme de controle des infections 
nosocomiales qui comprenait la surveillance des infections de plaies.
Sur 336 operations “propres” ou “propres avec contamination” effectuees au 
cours des 63 mois qui ont suivi, on a denombre 15 infections de plaies attribuables 
au chirurgien; 7 autres etaient directement attribuables au comportement postopera- 
toire du patient. Six de ces sept sont survenues chez des patients profondement 
retardes. Au cours de la periode de surveillance, le taux d’infection de plaie a chute 
de 23% a 4.1% ou moins.
Une preselection soigneuse des patients pour la chirurgie non urgente et une 
attention serieuse portee aux soins infirmiers postoperatoires sont necessaires si 
Ton veut atteindre de tels taux ou les reduire davantage, surtout lorsqu’il s’agit de 
patients souffrant d’arrieration mentale profonde.
The study of wound infection dates back to the mid-1800s 
when the basic principles of body 
resistance, routes of transmission 
and antisepsis were postulated and 
confirmed by Pare, Semmelweis and 
Lister respectively.12 These princi­
ples were not widely accepted until 
the 20th century.
With the discovery of the penicil­
lins and sulfanilamides in the 1930s 
and the general availability of these
drugs later, the emphasis was on 
treatment rather than prevention of 
infection. Nevertheless, studies 
shortly after World War II revealed 
that 5.7% of hospitalized patients 
had nosocomial infections.3
The identification of mutant 
strains of Staphylococcus aureus, 
which were penicillin resistant, sti­
mulated renewed emphasis on the 
value of prevention.4
In the 1970s, the Centres for
Disease Control in Atlanta recom­
mended the establishment of infec­
tion control committees, and the 
hiring of surveillance nurses and 
hospital epidemiologists. In 1974, 
they initiated a study of the efficacy 
of nosocomial infection control to 
assess the effectiveness of these 
programs.3 It was discovered that 
during the period 1970 to 1976, 
hospitals with infection control pro­
grams reduced their nosocomial in­
fection rates by 32%, but those 
without such programs showed an 
increase of 18%. The value of these 
programs was not only demonstrat­
ed but reaffirmed.5
Implementation of the Program
The Michener Centre is a provin­
cial institution for the mentally re­
tarded, having approximately 1200 
residents. Although disease rates 
there have been identified and cal­
culated since the early 1970s, ex­
tension of the monitoring program 
to include a monthly list of all 
nosocomial and postoperative 
wound infections was not begun 
until 1983, when a part-time infec­
tion control nurse was hired. With 
the help of the manual Guidelines 
for Prevention o f Surgical Wound 
Infections6 and provincial infection 
control guidelines,7 a customized 
infection control manual was drawn 
up to help identify, classify, isolate 
and prevent infection. Demonstra­
tions were given of good hygiene 
techniques. Individual cases were 
referred to the infection control 
nurse, who visited the site to ensure 
that aseptic techniques were being
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followed. All antibiotic choices were 
analysed against organism sensitivi­
ties to ensure that the correct 
choice was made or, if necessary, 
that the antibiotic chosen was 
changed. Any patient with a postop­
erative wound infection was exam­
ined by the infection control nurse 
and the infection was classified in 
accordance with the four-stage clas­
sification developed by the United 
States National Research Council in 
1964 (Table I).8
Results
In the 63 months since the sur­
vey started, 336 clean and clean- 
contaminated and 20 contaminated 
and dirty operations have been per­
formed. There were 21 infections, 
15 in the clean and clean-con­
taminated group (Table II). In 98% 
of cases the operation was per­
formed by surgeons at the nearby 
regional hospital; in the remainder, 
the patients were referred to teach­
ing hospitals 230 km away. All 
patients were returned early after 
operation to the 26-bed infirmary at 
the Michener Centre, thus allowing 
7- and 30-day follow-up.
Early in the study, it became 
apparent that some wound infec­
tions were caused by the patient, 
who was disturbed by the operation 
and contaminated the wound by 
removing the dressings, scratching 
and picking at the incision and 
sutures, and in other ways interfer­
ing with the healing process. These 
infections could not be considered 
as “surgeon induced”, so they were 
excluded from the series (Table III). 
There were seven (32%) such cases, 
six of them occurring in severely 
retarded patients. This represented 
2% of all operations (7 of 356).
A drop in postoperative wound 
infection rates is usually achieved 
within 6 months of the institution 
of a surveillance program. At the
Michener Centre it took only 3 
months for the rate to drop marked­
ly from 23% and reach a plateau of 
2.8% to 4.7%. The rate then re­
mained almost constant for the next 
35 months. However, it continues 
to be higher than the rate for the 
nearby regional hospital (Table IV), 
suggesting that the residents of the 
Michener Centre may be contribut­
ing to this higher rate. Neverthe­
less, the difference in the two rates 
has decreased from 22.4% in 1983 
to 2.5% in 1988.
Comments
The wound infection data are 
reviewed monthly and any unusual 
findings are brought to the atten­
tion of the surgeon involved or the 
family physician. Otherwise, a sum­
mary of wound infection rates for 
each surgeon and the cumulative 
rates for all surgeons (Table V) are 
circulated annually.
The type of surgery performed at 
the Michener Centre differs from 
that done in normal hospitals.
Table I. US National Research Council Classification of Postoperative Wound Infections8
Class of infection Description
Clean
Clean-contaminated
Contaminated
Dirty
Nontraumatic
Elective
Primary closure
No entry into gastrointestinal or respiratory tract
No break in sterile technique
Entry into gastrointestinal or respiratory tract
Entry into biliary or urinary tract
Break in sterile technique
Operation performed into or through vaginal mucosa
Surgery performed in presence of acute inflammation
Fresh traumatic wounds
Spillage from gastrointestinal tract
Major break in sterile technique
Presence of pus
Perforated viscus
Old or dirty traumatic wounds
Table II. Postoperative Surgical Wound Infections at Michener Centre, 
October 1983 to December 1988
Year
No. of 
operations
No. of 
infections'
Patient’s
functional
levelf
1983 (Oct - Dec) 13 3 Moderate
1984 84 4
Profound
Moderate
Profound
1985 63 2
Profound
Profound
Profound
Severe
1986 58 2
Severe
Moderate
1987 69 2
Severe
Profound
1988 49 2
Moderate
Borderline
Severe
Clean and
clean-contaminated
operations 336 15
Contaminated and dirty
operations 201 5
'Excluding those attributed to resident behaviour.
tlQ  levels of mental functioning were as follows: borderline =  68-85, mild =  52-67, moderate
=  36-51, severe =  20--35, profound =  <20.
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SURGICAL WOUND INFECTIONS
Major abdominal surgery and gyne­
cologic procedures are less com­
mon. Orthopedic and ophthalmo­
logic procedures are much more 
common.
The excess morbidity caused by 
patient interference postoperatively 
represented 32% of all postoperative 
wound infections (7 of 22 cases).
Table III. Postoperative Wound Infections 
Attributed to Resident Behaviour
Year
No. of 
patients
Patient’s functional 
level
1983 0 -
1984 1 Profound
1985 4 Profound
1986 0
Severe
Moderate
Profound
1987 1 Severe
1988 1 Severe
Table IV. Clean and Clean-Contaminated 
Surgical Wound Infection Rates (%) at 
Michener Centre and Red Deer Regional 
Hospital
Year
Michener
Centre
Red Deer 
Regional Hospital
1983 23.1 1.69*
1984 4.7 1.98'
1985 3.2 1.90
1986 3.4 1.92
1987 2.8 1.77
1988 4.1 1.51
'Estimated.
However, this represented only 2% 
(7 of 356) of all operations. Patients 
with severe or profound functional 
limitation had more infections than 
those with lesser limitation (Table 
VI). Patients with a severe or pro­
found functional level now undergo 
additional assessment by the family 
physician about their suitability for 
operation. Although the desired 
surgical outcome has almost always 
been achieved, the additional medi­
cal opinion has resulted in several 
operations being cancelled or post­
poned until surgical indications 
were more compelling.
Conclusions
The most important conclusion 
to be drawn from this study is that 
postoperative wound infection rates
for the Michener Centre population 
approximate those in general hospi­
tals through (a) good patient selec­
tion for operation, (b) regular and 
repeated use of the same group of 
consulting surgeons and (c) care 
and treatment by nurses experi­
enced in dealing with retarded pa­
tients. As emphasized in the study 
on the efficacy of nosocomial infec­
tion control,3 a program that effec­
tively monitors infection control 
policies and practices must be in 
place before these competitive re­
sults can be achieved.
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NOTICES
Abstract Submissions for the 1990 
Royal College Meeting
The 1990 Royal College meeting will be 
held in Toronto, Ontario, from Sept. 
1 4 -1 7 , 1990. In January 1990, the 
Annual Meeting Committee will invite 
all Fellows and members of participat­
ing societies to submit abstracts of 
scientific papers for consideration by 
the specialty review panels for the 1990 
program.
The abstract submission forms will 
be distributed to all Fellows as an insert 
to the January 1990 Annals. Watch for 
your copy.
Please note that the deadline for 
receipt of the abstracts, accompanied by 
the processing fees will be Mar. 9, 
1990.
continued on page 466
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A N T IB IO T IC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycin C, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the 7a position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia 
spp.)
5 - Lower respiratory tract infections
6 - Bone and Joint in fections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b il ity  of the causative organ ism (s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and 
non-producing strains)
Escherichia coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas 
spp., most strains of enterococci, many strains 
of Enterobacter cloacae, and methicillin- 
re s is ta n t s ta p h y lo c o c c i and L is te r ia  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post- 
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal surgery 
when there is a significant risk of postoperative 
infection or where the occurrence of post­
operative infection is considered to be especially 
serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
©Trademark Merck & Co., Inc./ 
Merck Frosst Canada Inc., R.U.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally 
reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate treatment may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cepha­
losporins, penicillins or otherdrugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of partial cross-allergenicity between cepha- 
mycins and the other beta-lactam antibiotics, 
penicillins and cephalosporins. Severe reactions 
(including anaphylaxis) have been reported 
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported 
w ith  v ir tu a lly  a ll a n t ib io tic s  in c lu d in g  
MEFOXIN®. This colitis can range from mild to 
life threatening in severity. Antibiotics should 
therefore be prescribed with caution in indi­
viduals with a history of gastrointestinal disease, 
particularly colitis. It is important to consider a 
diagnosis of pseudomembranous colitis  in 
patients who develop diarrhea in association 
with antibiotic use. While studies indicate that a 
toxin produced by Clostridium difficile is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling’s solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration. 
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing  concom itant adm in is tra tion  of 
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should be taken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
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Use in Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pru ritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on A D M IN IS TR A T IO N  and 
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as m alnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending. 
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by 
severity of infection, susceptib ility  of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Daily Frequency
Infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or i.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher
dosage (e.g. gas
gangrene)
'Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or g lom erulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with impaired Renal Function
MEFOXIN® may be used in patients w ith 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min
DOSE FREQUENCY
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment 29-10 1-2 g every 12-24 h
Severe
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In patients undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete
monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
At present there  is in s u ff ic ie n t data to  
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations for adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g administered in tram uscu larly or in tra ­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and th ird 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2 g doses 
should be given intravenously or intramus­
cularly four hours and eight hours after the first 
dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored 
below 30°C. The dry m ateria l as well as 
solutions tends to darken, depending on storage 
conditions; product potency, however, is not 
adversely affected.
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Effect of Hypothermia and Cardioplegia 
on Intramyocardial Voltage and Myocardial 
Oxygen Consumption
R.W. Landymore, MD, FRCSC; A.E. Marble, PhD, PEng
Intramyocardial voltage and myocardial oxygen consumption were measured in the 
fibrillating heart between the temperatures of 37°C and 25°C and in the arrested 
heart after infusion of potassium cardioplegic solution in 10 adult mongrel dogs. 
Electrical activity from the myocardium was recorded using specially designed 
plunge electrodes, and intramyocardial voltage was monitored by an in-line 
voltmeter. Myocardial oxygen consumption gradually decreased from 5.8 ± 0.6 ml 
0 2/m in at 37°C to 2.3 ± 0.5 ml 0 2/m in at 25°C. In contrast, hypothermia did not 
cause a similar decrease in intramyocardial voltage which remained within a range of 
1.8 ± 0.5 mV to 2.4 ± 0.5 mV between the temperatures of 37°C and 25°C. The 
infusion of potassium cardioplegic solution resulted in a dramatic decrease in 
voltage to 43 ± 5 and myocardial oxygen consumption fell to 0.5 ± 0.3 ml 
0 2/m in. Our data demonstrated that the mean voltage of the fibrillating heart 
remains constant between the temperatures 37°C and 25°C and myocardial oxygen 
consumption decreases with hypothermia, which suggests that voltage does not 
correlate with the level of myocardial oxygen consumption. Myocardial oxygen 
consumption and intramyocardial voltage, however, decrease dramatically when 
cardioplegia is instituted.
Chez 10 chiens batards adultes, on a mesure le voltage intramyocardique et la 
consommation d’oxygene du myocarde sur le coeur en fibrillation maintenu a des 
temperatures de 37°C et de 25°C et sur le coeur a l’arret apres perfusion d’une 
solution cardioplegique de potassium. L’activite electrique du myocarde a ete 
enregistree a l’aide d’electrodes de conception speciale, et le voltage intramyocardi­
que a ete monitorise a l’aide d’un voltmetre en ligne. La consommation myocardique 
d’oxygene a baisse progressivement de 5.8 ± 0.6 ml d’0 2/m in a 37°C jusqu’a 2.3 ± 
0.5 ml d’0 2/m in a 25°C. Par opposition, l’hypothermie n’a pas cause une baisse 
similaire du voltage intramyocardique, lequel est demeure dans l’intervalle de 1.8 ± 
0.5 mV a 2.4 ± 0.5 mV entre les temperatures de 37°C et de 25°C. La perfusion 
d’une solution cardioplegique de potassium a entraine une baisse spectaculaire du 
voltage de 43 ± 5 g \ ,  et la consommation myocardique d’oxygene a chute de 0.5 ± 
0.3 ml d’0 2/min. Ces resultats demontrent que le voltage moyen du coeur en 
fibrillation demeure constant entre 37°C et 25°C et que la consommation d’oxygene 
du myocarde s’abaisse dans des conditions d’hypothermie; ceci indique que le 
voltage n’est pas relie au niveau de consommation d’oxygene du myocarde. La 
consommation myocardique d’oxygene et le voltage intramyocardique baissent 
toutefois de fafon spectaculaire quand une cardioplegie est mise en route.
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Induction of myocardial arrest with cold potassium cardioplegic 
solution decreases myocardial ener­
gy requirements by lowering myo­
cardial temperature and preventing 
electromechanical activity. Al­
though cardioplegia initiates a rapid 
electromechanical arrest, small- 
amplitude electrical potentials may 
be recorded from the myocardium, 
using specially designed plunge 
electrodes, within 10 to 15 minutes 
after the infusion of potassium car­
dioplegic solution when there is no 
visual mechanical activity and when 
the electrocardiogram is isoelec­
tric.1-2 These small-amplitude elec­
trical potentials have a fundamental 
frequency of 3.0 Hz and may persist 
for more than 30 minutes before 
electromechanical activity resumes.1 
Although the importance of small- 
amplitude electrical activity during 
cardioplegic arrest is uncertain, pre­
liminary investigations in our labo­
ratory suggest that such activity is 
associated with impaired functional 
recovery of the myocardium after 
90 minutes of ischemia.3 To estab­
lish the relationship between in­
tramyocardial voltage and myocar­
dial metabolism we designed a 
study to measure oxygen consump­
tion (a) in the fibrillating heart 
between the temperatures of 37°C  
and 25°C, (b) during small-ampli­
tude electrical activity and (c) in the 
cardioplegic-arrested heart.
Materials and Methods
Ten, adult, mongrel dogs, weigh-
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ing between 21 to 25 kg, were 
sedated with 1 ml of Innovar. Anes­
thesia was induced and maintained 
with Somnutol. Ventilation was pro­
vided with a Bird Mark 7 (Bird 
Corp., Palm Springs, Calif.) pres­
sure-regulated ventilator.
The left femoral artery was can- 
nulated with a no. 14F USCI arteri­
al cannula (C.R. Bard Inc., Billerica, 
Mass.) for cardiopulmonary bypass, 
and venous return was provided 
with two 34 USCI cannulas. The 
cava were snared and the left ventri­
cle was vented. Cardiopulmonary 
bypass was established with a Med­
tronic impellar pump (model 
1835-00U) driven by a Medtronic 
circulatory assist console (model 
1810) that would deliver nonpul- 
satile flow at a rate of 2.5 
L/min-mr2 (Medtronic Inc., Circu­
latory Systems Division, Roseville, 
Miss.).
The right atrium was opened 
while the dog was on bypass and a 
no. 12F USCI catheter was inserted 
into the coronary sinus and brought 
out directly through the wall of the 
atrium for measurement of coro­
nary sinus flow. A snare was passed 
externally around the coronary
sinus to prevent migration of the 
catheter and to ensure that the 
effluent from the catheter repd on 
chart paper with specially con­
structed plunge electrodes. The 
thermistor probes were calibrated 
before each experiment with a mer­
cury thermometer.
Oxygen saturation was monitored 
continuously with two Oxy-Sat me­
ters (SM-0100; Bentley Laborato­
ries, Irvine, Calif.). Oxygen sensing 
equipment was positioned in the 
arterial circuit and also placed in 
line with the coronary sinus drain­
age. Myocardial oxygen consump­
tion (MV02) was measured at two- 
degree intervals between the tem­
peratures of 37°C and 25°C and 
was calculated from measurements 
of oxygen saturation, coronary 
sinus flow (CSF) and hemoglobin 
(Hb) according to the following for­
mula: MV02 (ml/min) = (% arterial 
saturation — % venous saturation)
X Hb X 1.34 X CSF (ml/min). 
d on
chart paper with specially con­
structed plunge electrodes. The 
thermistor probes were calibrated 
before each experiment with a mer­
cury thermometer.
Oxygen saturation was monitored 
continuously with two Oxy-Sat me­
ters (SM-0100; Bentley Laborato­
ries, Irvine, Calif.). Oxygen sensing 
equipment was positioned in the 
arterial circuit and also placed in 
line with the coronary sinus drain­
age. Myocardial oxygen consump­
tion (MV02) was measured at two- 
degree intervals between the tem­
peratures of 37°C and 25°C and 
was calculated from measurements 
of oxygen saturation, coronary 
sinus flow (CSF) and hemoglobin 
(Hb) according to the following for­
mula: MV02 (ml/min) =  (% arterial 
saturation — % venous saturation) 
X Hb X 1.34 X CSF (ml/min).
Myocardial temperature was then 
increased to 30 °C and cardiac ar­
rest was initiated by infusing potas­
sium cardioplegic solution directly 
into the oxygenator.4 Crystalloid 
cardioplegic solution containing 25 
mmol/L of potassium3 was infused 
directly into the oxygenator until 
complete cardiac arrest was ob­
tained. Cardiac arrest was defined 
by the absence of visual mechanical 
activity and loss of electrical activity 
on the surface electrocardiogram 
and from the plunge electrodes. 
Intramyocardial voltage and myo­
cardial oxygen consumption were 
measured in the arrested heart and 
were monitored continuously until 
gross electromechanical activity re­
sumed.
The results are reported as the 
arithmetic mean ± the standard 
error of the mean.
Results
Intramyocardial voltage and myo­
cardial oxygen consumption are il­
lustrated in Fig. 1. Intramyocardial 
voltage during ventricular fibrilla­
tion varied between 1.8 ±  0.5 mV 
and 2.4 ± 0.5 mV between the 
temperatures of 37°C and 25°C. 
The mean intramyocardial voltage
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FIG. 1. Mean intramyocardial voltage and myocardial oxygen consumption (MV02) 
during hypothermia and cardioplegic arrest. ± =  standard error of mean.
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did not decrease as the core temper­
ature was lowered. In contrast, 
myocardial oxygen consumption 
gradually decreased from 5.8 ± 0.6 
ml 0 2/m in at 37°C to 2.3 ± 0.5 ml 
0 2/m in  at 25°C. The infusion of 
cardioplegic solution resulted in a 
dramatic decrease in both the in- 
tramyocardial voltage and myocar­
dial oxygen consumption. Voltage 
recorded in the arrested heart mea­
sured 43 ±  5 mV and myocardial 
oxygen consumption decreased to 
0.5 ± 0.3 ml 0 2/min. Intramyocar- 
dial voltage and myocardial oxygen 
consumption remained low until the 
onset of ventricular fibrillation.
Small-amplitude electrical poten­
tials were recorded from the myo­
cardium just before the onset of 
ventricular fibrillation. However, 
the transition from a complete ar­
rest to ventricular fibrillation was so 
rapid that we could not measure 
coronary sinus flow, and, thus, 
could not calculate myocardial oxy­
gen consumption during the pres­
ence of the small-amplitude fibrilla­
tion waveforms.
Discussion
Infusion of potassium cardiople­
gic solution into the ascending 
aorta will initiate a rapid electrome­
chanical arrest but may not main­
tain a complete electrical arrest. 
Independent investigators12 have 
recorded small-amplitude electrical 
potentials from the myocardium 
with specially designed plunge elec­
trodes after the infusion of the 
cardioplegic solution when the 
heart is quiescent and the elec­
trocardiogram is isoelectric. Small- 
amplitude electrical activity origi­
nates in the HIS bundle and is 
conducted to the ventricles within a 
few minutes.5 This activity is char­
acterized by the onset of small- 
amplitude fibrillation waveforms 
which have a mean voltage two to
three times greater than the cardio­
plegic arrest potential, which usual­
ly lies between 10 and 40 n V .6 
These small-amplitude electrical po­
tentials are usually recorded within 
5 to 15 minutes after the infusion 
of cardioplegic solution and may be 
present for more than 30 minutes 
before the resumption of electrome­
chanical activity.6 Earlier investiga­
tions in our laboratory suggested 
that the presence of small-ampli­
tude electrical activity may be asso­
ciated with impaired recovery of 
myocardial function after ischemic 
arrest.3 To explore further the rela­
tion between intramyocardial volt­
age and myocardial metabolism we 
measured myocardial voltage and 
oxygen consumption in the fibrillat- 
ing heart between the temperatures 
of 37°C and 25°C in the cardiople­
gic arrested heart and, finally, we 
attempted to measure myocardial 
oxygen consumption and intramyo­
cardial voltage during small-ampli­
tude electrical activity.
Our observations indicate that 
myocardial oxygen consumption 
gradually decreases as the tempera­
ture of the fibrillating heart is low­
ered from 37°C to 25°C. Because 
Buckberg and colleagues7'8 demon­
strated that hypothermia decreased 
myocardial energy requirements by 
lowering myocardial oxygen con­
sumption, we expected that moder­
ate hypothermia would have similar 
effects on the magnitude of the 
fibrillation waveforms, since hypo­
thermia is known to reduce the 
contractile force of the myocardi­
um. However, moderate hypo­
thermia did not reduce the rtiean 
voltage of the fibrillation waveforms 
between the temperatures of 25°C 
and 37°C, indicating that the volt­
age of the fibrillating heart does not 
correlate directly with the level of 
myocardial oxygen consumption.
Cardiac arrest was initiated by 
infusing the cardioplegic solution 
into the oxygenator rather than
into the ascending thoracic aorta. 
This was necessary in order to 
preserve coronary sinus flow, so 
that myocardial oxygen consump­
tion could be calculated. Cardio­
plegia induced an electrical and me­
chanical arrest in all animals. Ven­
tricular fibrillation and plunge-elec­
trode activity ceased after the car­
dioplegic solution was infused and 
intramyocardial voltage decreased 
from 2.1 mV in the fibrillating heart 
at 30°C to 40 jtv. The cessation of 
electromechanical activity was asso­
ciated with a marked reduction in 
myocardial oxygen consumption, 
and both voltage and myocardial 
oxygen consumption remained low 
until the spontaneous onset of ven­
tricular fibrillation. Small-amplitude 
electrical potentials were recorded 
from the plunge electrodes just be­
fore ventricular fibrillation resumed 
but because the transition between 
the arrested state and electrome­
chanical activity was so short that 
we could not measure coronary 
sinus flow and thus calculate myo­
cardial oxygen consumption during 
small-amplitude electrical activity.
Brandt and associates4 monitored 
the electrical status of the myocar­
dium during cardioplegic arrest 
using an identical experimental 
model. They never recorded electri­
cal activity from the plunge elec­
trodes after the infusion of the 
cardioplegic solution, which led 
them to conclude that cardioplegia 
always initiated and maintained a 
complete electrical arrest. Our data 
and Brandt’s observations4 comple­
ment each other but are in contrast 
to numerous earlier investiga­
tions, i^-3.5.6,9,io which indicated that 
small-amplitude electrical potentials 
may be recorded from the myocardi­
um within 10 to 15 minutes after 
infusion of the cardioplegic solu­
tion. Cardiac arrest for these ex­
periments1-3'5'6910 was induced by 
infusing potassium directly into the 
aortic root. Infusion of cardioplegic
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solution into the clamped ascending 
thoracic aorta almost completely 
abolishes coronary flow, which pre­
vents rapid fluctuations of intracel­
lular potassium. The gradual de­
cline of intracellular potassium as­
sociated with this technique results 
in a slow transition between the 
arrested myocardium and the onset 
of gross electromechanical activity. 
Thus, small-amplitude electrical po­
tentials may develop and persist for 
more than 30 minutes before ven­
tricular fibrillation resumes. In con­
trast, infusion of cardioplegia into 
the oxygenator preserves coronary 
flow and presumably causes rapid 
washout and decline of intracellular 
potassium, leading to the sudden 
onset of ventricular excitation.
The metabolic significance of 
small-amplitude electrical activity is 
not fully understood, although an 
earlier investigation3 suggested that 
such activity was associated with 
postischemic depression of left ven­
tricular function. Unfortunately, we 
were unable to calculate myocardial 
oxygen consumption during small- 
amplitude electrical activity. Howev­
er, we measured the voltage of the 
fibrillating heart during hypo­
thermia and following the induction 
of potassium cardioplegia. Interest­
ingly, the mean voltage of the myo­
cardium during ventricular fibrilla­
tion remained relatively constant as 
myocardial temperature was low­
ered. Considering that myocardial 
oxygen consumption progressively 
decreases with hypothermia, one 
must assume that voltage does not 
correlate directly with the level of 
myocardial oxygen consumption. 
Therefore, the increase in the rest­
ing potential associated with the 
onset of small-amplitude activity 
may indicate increased myocardial 
oxygen consumption but may not 
directly reflect the level of myocar­
dial metabolism. The significance of 
small-amplitude electrical activity 
during cardioplegic arrest remains
uncertain, requiring further clarifi­
cation to determine its effects on 
myocardial metabolism and preser­
vation.
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THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in­
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram­
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin­
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the 
infections listed below when caused by susceptible strains of the designated 
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ­
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; 
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains); 
Staphylococcus aureus (including penicillinase-producing but excluding 
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epider- 
midis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia 
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to 
Pseudomonas infections of the urinary tract, a good clinical response accompanied 
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus 
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides 
sp. (including 8 . fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. 
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains); 
Escherichia coli; Bacteroides sp. (including 8 . fragilis); Klebsiella sp.; and Serratia 
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli; 
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci 
but including Group A 6-hemolytic Streptococcus pyogenes); Proteus mirabilis; 
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including 8. fragilis); Peptococcus 
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto­
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to 
identify the causative organisms and to determine their susceptibilities to cefti­
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility 
studies are known. However, modification of the treatment may be required once 
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have 
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group 
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hyper­
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM 
should be given cautiously to penicillin-sensitive patients. Antibiotics, including 
CefizoxTM, should be administered with caution to any patient who has demon­
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi­
zoxTM occurs, its administration should be discontinued. Serious acute hyper­
sensitivity reactions may require epinephrine and other emergency measures. 
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other 
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis­
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may 
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte and protein supplementation as 
indicated. When the colitis is not relieved by drug discontinuance or when it is 
severe, consideration may be given to the administration of oral vancomycin or 
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in 
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti­
zoxime sodium) has produced alterations in renal function. Renal status should be 
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible 
organisms including species originally sensitive to the drug. Careful observation of 
the patient is essential. If superinfection occurs during therapy, appropriate 
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of 
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, 
patients with impaired renal function (i.e., creatinine clearance <1.32 mL/s or 
^79 mL/min) should be placed on a special dosage schedule recommended under 
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to 
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and 
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM 
concomitantly with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The 
use of CefizoxTM jn pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus. The pharmacokinetics 
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies 
performed in rats and rabbits have revealed no evidence of impaired fertility or harm 
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not 
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and 
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations 
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi­
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to 
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age 
has not been established. In children six months of age and older, treatment with 
CefizoxTM has been associated with transient elevated levels of eosinophils, 
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related 
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age- 
dependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction
Incidence
<1%
Incidence 
>1% but <5%
Hypersensitivity: Rash
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no 
specific information available on symptoms or treatment. In cases of suspected 
overdosage, supportive therapy should be instituted according to symptoms. Serum 
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly 
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the 
patient, severity of the infection and susceptibility of the causative organism(s). The 
intravenous route may be preferable for patients with bacterial septicemia, or other 
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at 
least 48 hours after evidence of bacterial eradication has been obtained. For 
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is 
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams admin­
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500 mg q12h, IVorIM
Other Sites 2-3 1 g q8h or q12h, IV or IM
Severe or 
Refractory
3-6 1 g q8h, IV or IM, to 
2g q8horq12h, IVorIM*
Life-Threatening 9-12 3or4gq8h  IV
*When administering 2 g intramuscularly, the dose should be divided and injected 
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas 
aeruginosa and because many strains are only moderately susceptible to CefizoxTM, 
higher dosage may be appropriate when urinary tract infections are caused by 
these organisms. Other therapy should be instituted if the response is not prompt.
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Adults with Impaired Renal Function: In patients in whom the creatin ine clearance 
is 1.32 m U s (79 mL/min) or less, the dosage of CefizoxTM  must be reduced. Follow­
ing an initial loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing 
schedule presented in Table 2 should be followed in patients with reduced renal 
function.
TABLE 2
Renal
Function
Creatinine 
Clearance 
mL/s mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to 
severe impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hem odialysis
patients*
00.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
*ln patients undergoing hem odialysis no additional supplemental dosing is 
required. DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT 
RECEIVES THE DOSE AT THE END OF THE DIALYSIS. When started 24 hours after 
administration of 1 g of CefizoxTM, hemodialysis has been shown to reduce serum 
levels by 50%.
When only the serum creatinine level is available, creatinine clearance may be 
calculated from the following formulae (for patients 18 years and over only). The 
serum creatinine level should represent renal function at the steady state.
Males:
Creatin ine Clearance Weight (kg )x(140-age)
(mL/min) 72 x serum creatinine (mg/100 mL)
Creatin ine Clearance Weight (kg) x 140 - age)
(mL/s) ~~ 49 x serum creatinine ( /xmol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50mg/kg IVorIM q6horq8h, IVorIM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious 
infections.
ADMINISTRATION
Intramuscular: The reconstituted solution of CefizoxTM should be injected well 
within the body of a relatively large muscle, such as the gluteus. When administer­
ing 2 g IM doses, the dose should be divided equally and then injected into different 
large muscle masses.
Intravenous: Injection (bolus): The reconstituted so lution of CefizoxTM should be 
injected slow ly over 3 to 5 minutes, d irectly or through the tubing system by which 
the patient is receiving another com patib le intravenous solution. During administra­
tion o f the solution containing CefizoxTM, it is desirab le to temporarily discontinue 
adm inistration of the other solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of 
CefizoxTM should be administered over a 20 to 30 m inute period.
NOTE: CefizoxTM so lutions should not be physically mixed with any other drug. 
There is a known incompatibility with am inoglycoside antib iotics. Therefore, they 
should not be physically mixed with CefizoxTM so lutions nor adm inistered at the 
same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium (6R-[6<», 7B(Z)]]-7 -[[(2 ,3 -d ihydro -2-im ino-4-th iazo ly l) 
(m ethoxyim ino)acetyl]am ino]-8-oxo-5-th ia-1-azab ilcyclo[4.2.0] o c t-2 -e n e -2 -  
carboxylate
Structural Formula:
Molecular Formula: C 13 H  i2 N 5 0 s S 2 N a  
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow  crysta lline powder.
Composition: CefizoxTM vials contain ceftizoxime sodium (expressed in terms 
of free acid). The sodium content o f each gram of CefizoxTM  is approximately 
60
mg (2.6 mEq sodium ion).
So lutions of CefizoxTM range from colourless to pale yellow, depending upon the 
diluent and volume used. The solution should be d iscarded if it becom es cloudy. 
The pH of freshly reconstituted so lutions usually ranges from 6.0 to 8.0.
A  solution of 1 g CefizoxTM in 13 mL Sterile Water for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 G R AM  and 2 GRAMS)
For intramuscular Injection: Reconstitute with Sterile  Water for Injection or B a c ­
teriostatic Water for Injection.
Reconstitution Table for Standard Vials - I.M. Injection
Vial Diluent to be
Approximate
Available
Approximate
Average
Size Added to Via l Volume Concentration
1 g 3.0 mL 3.7 m L 270mg/mL
2 g 6.0 m L 7.4 m L 270mg/mL
Shake well until d issolved.
For Intravenous Injection: Reconstitute  only with Sterile  Water for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Vial Diluent to be
Approximate
Available
Approximate
Average
Size Added to V ia l Volume Concentration
1 g 10 m L 10.7 m L 95 mg/mL
2g 20 m L 21.4 m L 95 mg/mL
Shake well until dissolved.
For Intravenous Infusion: Reconstitute  as for intravenous injection. Further 
dilute the reconstituted so lution to 50 to 100 m L with one of the “ So lu tions for 
Intravenous Infusion" (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection 
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated R inger’s Injection
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile  Water for Injection
5% Dextrose in Lactated R inger’s  Injection O NLY  when reconstituted with 
4% Sodium Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: A ll reconstituted so lu tions and those further diluted should be used 
within 24 hours if stored at room temperature or w ithin 48 hours if refrigerated. 
These storage lim its are from the tim e o f the initial reconstitution.
Incompatibility: CefizoxTM should  not be added to blood products, protein 
hydrolysates or am ino acids. CefizoxTM should not be mixed together w ith an 
am inoglycoside.
DOSAGE FORMS
Availability: CefizoxTM is  availab le  as a sterile powder in Standard V ia ls  o f 
1 gram or 2 grams, contain ing ceftizox im e as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature 
(15°-30°C).
FOOTNOTES
'As indicated in the manufacturer's product monograph Cefizox, Smith Kline & French Canada Ltd . 1988.
2As indicated in the manufacturer's product monograph cefoxitin, Merck Sharp & Dohme Canada, 1985 
3Lou M.A. et a l.: 14th International Congr. Chemother.. Kyoto, Japan, June 1985, pp 2378-2379.
4Neu H.C., Chin N X  : The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics 
Chemioterapia 1985;4:271-277.
5Fu K .P . Neu H.C.: Antibacterial activity of ceftizoxime. a B-lactamase-stable cephalosporin Antimicrob. Agents 
Chemother 1980;12:583-590
6Thornsberry C .: Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics 
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ORIGINAL ARTICLES
Evaluation of Autotransfusion in Aortic Reconstruction
Alan M. Graham, MD, FRCSC; Tom Burdon, MD; James F. Symes, MD, FRCSC
A new intraoperative autotransfusion system was prospectively evaluated in 30 
major aortic reconstructions. After systemic heparinization of the patient, blood is 
collected in a cardiotomy reservoir and immediately reinfused (up to 500 ml/min).
The amount of autotransfused or banked blood necessary to maintain the 
hemoglobin at 100 g/L  during and for 24 hours after surgery was monitored and 
coagulation profiles, renal function and complications were recorded.
The amount of autotransfused blood averaged 1414 ml and the number of packed 
red blood cells transfused over 24 hours averaged 1.9 units. Of the 30 patients, 24 
required 2 units of homologous blood or less over 24 hours; 8 patients received no 
homologous transfusions and another 8 only 1 unit. There was no significant 
change postoperatively in serum creatinine or fibrinogen levels or in the 
prothrombin and partial thromboplastin times; the platelet count fell from 264 X 
109/L  preoperatively to 182 X 109/L  postoperatively (p < 0.05), but this was not 
clinically relevant. The free plasma hemoglobin level rose substantially, but 
perioperative urine output was good. There were no complications attributable to 
autotransfusion.
The use of the autotransfuser during major vascular surgery provides a safe, 
effective means to minimize the loss of clotting factors, preserve blood-bank 
resources and eliminate the risk of disease transmission from homologous blood. By 
allowing rapid reinfusion when blood loss is excessive, this system can prevent 
prolonged hypotension in patients at increased cardiac risk.
Un nouveau systeme d’autotransfusion peroperatoire a ete evalue de maniere 
prospective lors de 30 reconstructions aortiques majeures. Apres heparinisation 
generate du patient, le sang a ete recuelli dans un reservoir de cardiotomie et 
reinjecte immediatement (jusqu’a concurrence de 500 ml/min). Qu’il soit 
autotransfuse ou qu’il provienne de la banque de sang, on a surveille la quantite de 
sang necessaire pour maintenir Themoglobine a 100 g/L  pendant l’operation et 
durant les 24 heures suivantes. On a aussi enregistre les profils de coagulation, les 
indices de fonction renale et les complications rencontrees.
La quantite moyenne de sang autotransfuse a ete de 1414 ml, a laquelle s’ajouta 
1.9 unites d’hematies concentrees pour 24 heures. Des 30 patients, 24 eurent besoin 
de 2 unites de sang autologue ou moins, sur 24 heures; 8 patients ne re^urent 
aucune transfusion de sang autologue et 8 autres re$urent 1 unite seulement. On 
n’a observe aucune modification postoperatoire significative de la creatininemie, des 
taux de fibrinogene ou des temps de prothrombine ou de cephaline. Le compte 
plaquettaire a chute de 264 X 109/L  avant T operation, a 182 X 109/L  apres (p <
0.05), un changement sans importance clinique. Le taux d’hemoglobine plasmatique 
libre a augmente de fa?on marquee mais le debit urinaire peroperatoire est demeure 
bon. On n’a releve aucune complication attribuable a l’autotransfusion.
L’emploi de ce systeme d’autotransfusion au cours des chirurgies vasculaires 
majeures offre un moyen sur et efficace de minimiser la perte des facteurs de 
coagulation, reduit la demande sur la banque de sang et elimine le risque de 
transmission des maladies venant du sang homologue. En permettant la 
retransfusion rapide du sang quand les pertes sont excessives, ce systeme peut 
prevenir une hypotension prolongee chez des patients ayant un risque cardiaque 
eleve.
Elective
A utotransfusion, the collection and reinfusion of a patient’s 
own blood, although not a new 
concept, has only recently been ap­
plied to areas other than open-heart 
surgery. Concern with regard to the 
transmission of infectious agents in 
blood products, however, has rekin­
dled an awareness of the possible 
dangers of homologous transfusion. 
Hepatitis remains the most serious 
infection after transfusion. In Cana­
da, non A-non B hepatitis contami­
nates between 2% and 5% of all 
transfusion products, and as many 
as 17% in the United States. Human 
immunodeficiency virus, which can 
result in the fatal acquired immune 
deficiency syndrome, is also effec­
tively transmitted by transfusion.1 
These serious complications have 
stimulated the development of new 
methods that would minimize or 
avoid homologous blood transfu­
sion, such as autologous blood 
transfusion, intraoperative hemodi- 
lution and collection and reinfusion 
apparatus.
Reconstruction of the abdominal 
aorta for occlusive and aneurysmal 
disease may, in complicated cases, 
require the transfusion of substan­
tial quantities of homologous blood.
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AUTOTRANSFUSION IN AORTIC SURGERY
Since many of these procedures 
require urgent or emergency sur­
gery, autologous blood collection is 
not possible. Furthermore, nor­
movolemic hemodilution is not pos­
sible in many patients who undergo 
aortic surgery because of their con­
comitant cardiac disease.
With these considerations in 
mind we have developed and used 
an autotransfusion system. It is 
similar to a system used at the 
University Health Center of Pitts­
burgh.2 Thirty consecutive patients 
who underwent aortic reconstruc­
tion were assessed.
Methods
Over a 6-month period, 30 pa­
tients scheduled to undergo elective 
aortic surgery were studied. Includ­
ed were 16 patients who had aneu­
rysmal disease of the aorta and iliac 
arteries, 11 who had aortoiliac oc­
clusive disease, 1 who had an ili­
Tab le  1.
Procedures Carried Out in 30 Patients
No. patients
Aneurysmal disease
Aortic aneurysm repair -
infrarenal 7
Aortic and iliac artery
aneurysm repair 6
Aortobifemoral bypass
(aneurysmal and
occlusive disease) 2
Aortoiliac aneurysm with
bilateral renal artery
bypass 1
Occlusive disease
Aortobifemoral bypass graft
+
extended profundaplasty 5
single renal artery bypass 3
bilateral common femoral
aneurysms 2
nephrectomy 1
Miscellaneous
Thoracoabdominal aneurysm
repair with reimplantation
of celiac, superior
mesenteric and renal
arteries 1
Coarctation (adult) repair 1
lleofemoral pseudoaneurysm
repair 1
ofemoral pseudoaneurysm, 1 who 
had adult coarctation of the thorac­
ic aorta and 1 who had thoracoab­
dominal aneurysm with reimplanta­
tion of the celiac, superior mesen­
teric and both renal arteries (Table 
I ) .
For all patients, intraoperative 
blood loss, the quantity of blood 
autotransfused and the requirement 
for homologous transfusion of 
blood products to maintain a hemo­
globin at 100 g /L  were document­
ed. In addition, pre- and postopera­
tive renal function, perioperative 
urine output, pre- and postoperative 
coagulation profile (prothrombin 
and partial thromboplastin times, 
platelet and fibrinogen levels), free 
plasma hemoglobin level and surgi­
cal outcome were assessed. The 
preoperative cardiac status of all 
patients according to the New York 
Heart Association classification was 
noted; 19 were in class I and 11 in 
class II (3 patients in the latter class 
underwent aortocoronary bypass 
before aortic surgery).
The autotransfusion system (Fig. 
1) was used only while the patient 
was heparinized. The anticoagulat­
ed blood is collected in a cardioto- 
my reservoir that contains a mi­
croaggregate filter. A one-quarter 
inch line is connected to the reser­
voir, inserted in an occlusive roller 
pump and attached to a heat ex­
changer. The blood is filtered 
through a 105 lira filter screen, 
which is proximal to the heat- 
exchanger outlet. A 20 /um blood 
transfusion filter is inserted distal to 
the heat-exchanger outlet.
The blood can be either recir­
culated to the cardiotomy reservoir 
through an extension line or re­
turned to the patient through a 
large-bore intravenous line. Blood 
temperature is monitored with a 
temperature probe within the heat 
exchanger. The temperature is kept 
constant at 37 °C with a water 
source. A pressure-monitoring de­
vice is also attached to the heat 
exchanger. Blood aspiration at the 
field depends on wall suction regu­
lated in the range of 50 to 75 mm 
Hg. The system is primed with 200 
ml of heparinized saline before aspi­
ration of blood.
Results
There were two postoperative 
deaths, one from a myocardial in­
farction on postoperative day 6 and 
one from a cerebrovascular accident 
on postoperative day 5. There were 
no complications associated with 
the autotransfusion system and no 
patient had major hemorrhagic 
morbidity.
The mean time the autotransfus­
er was used was 108 minutes 
(range from 45 to 220 minutes) and 
the volume of blood autotransfused 
averaged 1414 ml (range from 200 
to 4100 ml).
The total blood-bank requirement 
for the 30 patients was 54 units of 
packed cells, 4 units of fresh-frozen 
plasma and 20 units of platelets 
(Table II). The average number of 
packed cells transfused to maintain 
a hemoglobin of 100 g /L  during 
operation and within the first 24 
hours postoperatively was 1.9
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units, the requirements ranging 
from no transfusion in eight pa­
tients and only 1 unit in another 
eight to 7 units in two patients. The 
last two patients were unusual and 
presented difficult problems. One 
was an elderly man who had chron­
ic disseminated intravascular coagu­
lation and a large, heavily calcified 
abdominal aneurysm. The other was 
a middle-aged woman who had a 
thoracoabdominal aneurysm involv­
ing all major intra-abdominal ves­
sels; it was associated with a large 
intraoperative blood loss because of 
heavy calcification of the aortic wall 
at the anastomotic sites.
Of the 30 patients, 24 (80%) 
required 2 units or less of packed 
red cells (Table III). Excluding three 
patients who required large transfu­
sions, the total number of homolo­
gous units given to maintain a 
hemoglobin of 100 g /L  was only 
35 for 27 patients. This is an 
arbitrary figure; had we decided on 
a hemoglobin level of 80 g /L  as 
others have,3 73% of patients would 
have required no homologous 
blood.
The major complication of auto­
transfusion has been suggested to 
be hemolysis, with its resultant 
renal dysfunction. We monitored 
renal function closely by measuring 
serial serum creatinine levels. The 
mean serum creatinine level preop- 
eratively was 132.6 /tmol/L (range 
from 70.7 to 229.8 #tmol/L). The 
level just before discharge from 
hospital was 123.8 / j . n 10I/L  (range 
from 61.9 to 256.4 /imol/L) (Table 
III). Hourly urine output in the
T a b le  II. Amount of Packed Red Cell
Transfusions Needed to Maintain
Hemoglobin Level at 10 g/L
No. units No. pa tien ts
0 8
1 8
2 6
3 5
5 1
7 2
initial 24 hours after operation av­
eraged 1.57 m l/kg. No patient was 
oliguric, but some had received 
mannitol and lasix intraoperatively, 
which may have had an effect on 
the outputs.
There was no significant change 
in the prothrombin time (11.0/11.4  
s preoperatively versus 11 .3 /11 .5  s 
24 hours postoperatively), the par­
tial thromboplastin time (31.7/32.0  
preoperatively versus 32 .2 /31 .7  s) 
and the fibrinogen levels (3.47 g /L  
versus 3.22 g/L ). However, the 
patient who had chronic DIC preop­
eratively in association with an aor­
tic aneurysm4 had a rise in the 
fibrinogen level from a preoperative 
level of 0.88 g /L  to 1.76 g /L  48 
hours after aneurysmectomy. Free 
plasma hemoglobin was measured 
in a number of patients, and al­
though urinary function was unal­
tered the free plasma hemoglobin 
levels were elevated from a mean (± 
SD) preoperative value of 56 ±  19 
g /L  to 117 ±  31 g /L  (p < 0.01, 
paired f-test).
The number of platelets de­
creased in the first 24 hours post­
operatively to 182 X  109/L  from 
264 X  109/L  preoperatively. Al­
though this change is numerically 
significant (p < 0.05), it was not 
clinically relevant.
Discussion
The vascular surgeon’s patients 
have often undergone previous vas­
cular procedures and require reop­
eration due to progression of ath­
erosclerosis and graft failure. Inher­
ent in these procedures is the fre­
quent need for homologous blood 
transfusion. Further, availability of 
compatible blood is sometimes lim­
ited due to previous isoimmuniza­
tion. Demands on homologous 
donor blood have increased as the 
number of complex surgical proce­
dures has escalated. Transmission 
of infectious disease is now of para­
mount interest to the general pub­
lic. Other adverse effects include 
isoimmunization, hypocalcemia, aci­
dosis and hypothermia. All of these 
issues have forced the surgical com­
munity to become more aware of 
the need to use autologous blood 
whenever possible.
Autotransfusion has been used 
successfully without complication 
in many centres.5-7 In fact, Cutler3 
reported that 76% of patients who 
underwent elective aortofemoral 
grafting avoided intraoperative ho­
mologous blood transfusion. He 
used hemodilution to a hematocrit 
of 25% in patients at low cardiac 
risk and to 30% in higher risk 
patients, in association with auto­
transfusion. By comparison, 26% of 
our patients received no transfu­
sions, and an equal percentage re­
ceived only 1 unit of packed cells 
without the aid of hemodilution; 
73% would not have required any 
transfusion had we accepted a he­
matocrit of 25%. Landow8 recently 
reviewed perioperative hemodilution 
and suggested that healthy patients 
from 2 to 60 years of age could 
undergo hemodilution to 25%, and 
that patients with diabetes, claudi-
T a b le  II I .  Laboratory Data Before and After Autotransfusion
M ea s u re m e n t P reop era tive Postoperative
Creatinine, ^mol/L 132.6 123.8
Fibrinogen, g/L 3.47 3.22
Prothrombin time, s 11.0/11.4 11.3/11.5
Partial thromboplastin time, s 31.7/32.0 32.2/31.7
Platelets, X 109/L 264 182*
Hemoglobin, g/L 134 114
*p < 0.05 by Student's paired f-test.
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cation or heart disease should not 
undergo hemodilution at all. Our 
patients generally belonged to the 
last two groups.
At present, there are simple and 
complex systems available for auto­
transfusion. The Solcotrans system 
(Solco Basle Inc., Rockland, Mass.) 
is a simple system composed of 
plastic reservoirs containing prede­
termined amounts of citrate-phos­
phate-dextrose (CPD); the reser­
voirs are connected to suctioning 
devices, allowing collection of blood 
from the operative field. When the 
container is full, it is passed from 
the operative field to the anesthetist 
who infuses the fluid by gravity or 
pressure.
Both Sorenson (Sorenson Re­
search, Division of Abbott Labora­
tories, Salt Lake City, Utah) and 
Thoratec9 systems are disposable 
suction and collection devices. Ci­
trate-phosphate-dextrose, as the an­
ticoagulant, and blood are mixed at 
the tip of disposable atraumatic 
aspiration wands, blood is collected 
in disposable plastic containers 
which may have external pressure 
applied to accelerate reinfusion. It is 
difficult in these systems to regu­
late the ratio of CPD to blood and 
therefore good control of an­
ticoagulation is difficult.
Cell washing autotransfusion sys­
tems are presently available for clin­
ical use. In these, the blood is 
aspirated, plasma and red cells are 
separated, the red cells are washed 
and resuspended and are then rein­
fused by gravity. These systems are 
more complex and costly but have 
been widely used.10'11 Rapid reinfu­
sion during the period of high- 
volume blood loss, as can occur 
during aneurysmectomy, is not pos­
sible with these systems and there­
fore hypotension may occur with its 
attendant cardiac risk.
The Bentley autotransfusion de­
vice was popularized by Klebanoff 
in 1979.12 It is essentially a modi­
fied cardiotomy reservoir used with 
a roller pump, allowing blood to be 
reinfused under pressure. The Bent­
ley system has been associated with 
a risk of air embolism from the 
device. The problem in most of the 
reports was that the autotransfu­
sion system was not appropriately 
attended.1314 Most transfusion de­
vices now rely on gravity or exter­
nal compression on collapsible con­
tainers for reinfusion. The disadvan­
tage of this is the inability to auto­
transfuse rapidly and thereby avoid 
hypotension.
Our device is relatively inexpen­
sive and has the capacity to warm 
shed blood and to provide rapid 
reinfusion. Our device, although de­
pendent on a skilled technician, can 
deliver scavenged blood at a rate of 
up to 500 ml/min. This has proven 
invaluable in situations of complex 
aortic reconstructions when rapid 
volume loss has occurred. The sur­
geon can proceed more effectively, 
with less haste, knowing that blood 
lost is being immediately returned 
and that the hemodynamics are sta­
ble.
The possible physiologic compli­
cations of autotransfusion such as 
microemboli, sepsis, free hemoglo­
bin and nephrotoxicity resulting 
from hemolysis and with coagulopa­
thy have been reviewed by Jacobs 
and Hsieh.15 Although the clinician 
must be aware of these, few prob­
lems have been documented with 
the autotransfusion systems in use 
today.16 Of the measurements we 
made, the only significant change 
was in the number of platelets (264 
X 109/L to 182 X 109/L) and in 
the free plasma hemoglobin. The 
decrease in platelets appeared to 
have no identifiable clinical rele­
vance. The rise in free plasma he­
moglobin is also of little concern if 
the patient’s urine output is suf­
ficient to avoid tubular damage.
Our system is particularly advan­
tageous to the patients at high
cardiovascular risk, who may have 
cardiac disease in addition to their 
vascular problems and tolerate peri­
ods of hypotension and hypoxia 
poorly. The ability of the system to 
reinfuse large volumes of warm 
blood quickly minimizes the cardio­
vascular complications.
Conclusions
The autotransfusion system we 
used requires a trained attendant 
but has proven to be a safe and 
effective means of maintaining a 
stable hemodynamic situation in pa­
tients who undergo aortic recon­
struction even when there is large 
volume blood loss. It is particularly 
suitable for high-risk patients who 
would tolerate volume loss poorly. 
Further, the adverse effects of 
transfusion of homologous blood 
such as the transmission of infec­
tious disease, isoimmunization, hy­
pocalcemia, acidosis and hypo­
thermia can be minimized with the 
autotransfusion of shed blood. Up 
to 73% of patients could undergo 
aortic surgery without the transfu­
sion of homologous blood.
We thank F. Burdon, J. Carbonneau 
and J.G. Robitaille for the service of the 
autotransfuser and M. Grant for help in 
preparing the manuscript.
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TECHNIQUES OF PERCUTANEOUS 
GASTROSTOMY. Edited by Jeffrey L. 
Ponsky. 127 pp. Illust. Igaku-Shoin 
Medical Publishers, Inc., New York; 
W.B. Saunders Company Canada Lim­
ited, Toronto, 1988. $71.50. ISBN 
0-89640-139-1.
Since Ponsky’s initial description in 
1981, the use of percutaneous endo­
scopic gastrostomy has increased great­
ly. This text, a collection of 14 brief 
chapters, begins with a discussion of 
historical perspectives and indications 
for gastrostomy. This is followed by a 
brief description of the various surgical 
gastrostomies, then three chapters de­
tailing the different techniques of per­
cutaneous endoscopic gastrostomy (the 
“pull”, “push” and “introducer” meth­
ods).
One chapter details the use of percu­
taneous endoscopic gastrostomy in chil­
dren, in whom this technique was ini­
tially developed. There are chapters on 
percutaneous placement of jejunosto- 
mies and complications of percutaneous 
gastrostomy. In one chapter the nurse’s 
role is discussed, and in another the 
three techniques of percutaneous endo­
scopic gastrostomy placement are com­
pared. A cryptic chapter deals with the 
technical aspects of tube feeding and 
the liquid diets.
There is considerable overlap of in­
formation and illustrations in these 
chapters. There are a number of typo­
graphic errors. Furthermore, the radi­
ologic technique of percutaneous gas­
trostomy without endoscopy, which is 
also being used widely, is never men­
tioned.
This book gives a good coverage of 
the percutaneous gastrostomy methods 
and will be valuable to surgeon-endo­
scopists, residents and gastroenterolo­
gists who are just becoming familiar 
with this technique. However, the book 
is brief, relatively expensive and does 
not provide enough new information for 
those who have had experience with 
this technique as it developed.
Mervyn Deitel, MD, FRCSC
Professor o f Surgery,
Professor o f Nutritional Sciences,
University o f Toronto,
St. Joseph's Health Centre,
Toronto, Ont.
ANORECTAL MALFORMATIONS IN 
CHILDREN: UPDATE 1988. Edited by 
F. Douglas Stephens and E. Durham 
Smith. 604 pp. Illust. Alan R. Liss, 
Inc., New York, 1988. $150.00 (US). 
ISBN 0-8451-1070-5.
This book has everything you ever 
wanted to know about anorectal malfor­
mations, and more! It is currently the 
definitive textbook on this subject. 1 
cannot imagine any pediatric surgeon 
being without it or not using it as a
reference text on this multifaceted, diffi­
cult congenital pediatric problem. This 
anomaly first appears in the newborn 
and is usually a problem for life. It is a 
problem that also hangs around the 
pediatric surgeon’s neck like the pro­
verbial albatross. However, in this text, 
we have all the up-to-date theories, 
investigations, operations and results, 
pro and con, to bring clarity to a 
perplexing scene.
The book is aptly dedicated “to all 
parents, doctors, nurses, and others 
who work to improve the quality of life 
for people born with anorectal anoma­
lies”. Contributions (the editors state) 
were received either as complete chap­
ters or as parts of chapters, or were 
incorporated into the text of chapters 
by the author-collators. The contribu­
tors include most of the members of the 
1984 Wingspread Workshop, which 
was attended by internationally recog­
nized authorities in the field. In such a 
multiauthored book, all the different 
opinions are expressed, and the reader 
is then left to accept or reject such 
views.
This text is of interest only to work­
ers in this field and, for them, the book 
is a must!
Sigmund H. Ein, MD, FRCSC, FAAP, 
FACS
Division o f General Surgery,
Hospital for Sick Children,
Toronto, Ont.
M5C 1X8
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Internal Carotid Artery Aneurysm and 
Marfan’s Syndrome
David A. Latter, MD, FRCSC;* Michael A. Ricci, MD;* R.D.C. Forbes, MD, FRCPC;t 
Alan M. Graham, MD, FRCSC*
Aneurysms of the extracranial carotid artery are most commonly caused by 
atherosclerosis or trauma but may also have unusual causes, such as Marfan’s 
syndrome. Although aneurysmal changes in the extracranial carotid vessels usually 
are due to extension of aortic dissection into the carotid system, isolated aneurysms 
may occasionally complicate Marfan’s syndrome. The authors report a case of 
Marfan’s syndrome in which the patient, a 45-year-old woman, presented with an 
asymptomatic mass in the right side of the neck at the level of the carotid 
bifurcation. An isolated internal carotid artery aneurysm was identified. The 
aneurysm was resected using an interposition vein graft over an outlying shunt. 
Histologic examination confirmed the typical cystic medial necrosis with loss of 
elastic fibres and an increase of mucoid material in the media. The patient’s recovery 
was smooth and at 2-year follow-up there were no signs of recurrent aneurysm 
formation.
Les anevrismes de l’artere carotide externe sont le plus souvent causes par 
l’atherosclerose ou un traumatisme, mais ils peuvent aussi avoir une cause 
inhabituelle comme le syndrome de Marfan. Bien que l’anevrisme de la carotide 
externe soit generalement du a l’extension d’une dissection aortique dans le systeme 
carotidien, des anevrismes isoles peuvent occasionnellement venir compliquer le 
syndrome de Marfan. Les auteurs decrivent un cas de syndrome de Marfan au cours 
duquel la patiente, agee de 45 ans, a presente du cote droit du cou, une masse 
asymptomatique, au niveau de la bifurcation carotidienne. Un anevrisme isole de la 
carotide interne fut identifie. L’anevrisme fut reseque par interposition d’une greffe 
veineuse sur une derivation peripherique. L’examen histologique confirma la 
necrose kystique typique de la media, avec perte des fibres elastiques et une 
augmentation du material muqueux dans la media. La guerison de la patient fut sans 
accroc et, a l’examen de controle apres 2 ans, il n’y avait aucun signe de recidive 
d’anevrisme.
M arfan’s syndrome is an inherit­ed autosomal dominant disor­
der of connective tissue. It affects 
up to 60 people per million popula­
tion.1 It is characterized by defec­
tive collagen synthesis leading to 
ocular, skeletal and cardiovascular
abnormalities. Ocular manifesta­
tions include subluxation of the 
lens in 50% to 80% of patients. 
Skeletal abnormalities are those of 
dolichostenomelia (increased limb 
length compared with the trunk), 
arachnodactyly, joint laxity, scolio­
sis and high arched palates.1’2 Car­
diovascular abnormalities are the 
most important since they are the 
cause of death in 90% to 100% of 
patients with Marfan’s syndrome.3-5 
These abnormalities include mitral 
and aortic valvular disease, fusiform 
ascending aortic aneurysm and aor­
tic dissection.3 Although a compre­
hensive review3 of Marfan’s syn­
drome and its cardiovascular conse­
quences failed to discover a single 
case of carotid artery aneurysm in 
169 patients, isolated carotid aneu­
rysms are a rare but recognized 
complication.6-7 We describe one 
such case in this article.
Case Report
A 45-year-old woman was re­
ferred to our vascular service when 
a painless swelling in her right neck 
was discovered during a routine 
check-up. Definite hemispheric neu­
rologic symptoms were absent, but 
she did complain of an occasional 
“cloud-like” blurring of the visual 
field of her right eye which lasted a 
few seconds and was likely a symp­
tom of lens dislocation. She denied 
paresthesia, paralysis or loss of 
consciousness. She had mitral valve 
prolapse and was taking digoxin 
and nadolol for supraventricular ta­
chyarrythmias. Her family history 
revealed that her mother had suf­
fered from Marfan’s syndrome and 
died at the age of 45 years because 
of rupture of an aortic arch dissec­
tion.
She was a tall woman with the
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characteristic marfanoid body habi­
tus, long slender digits, a high 
arched palate and evidence of bilat­
eral lens dislocations. Her pulse rate 
and blood pressure were normal. 
The vascular system was normal on 
examination except for the right 
side of the neck where a well- 
demarcated 2 X 2-cm pulsatile mass 
was found. There was no associated 
bruit or thrill.
Investigations included abdomi­
nal ultrasonography, which was 
normal, and aortic arch aortogra­
phy (Fig. 1). The aortogram re­
vealed a saccular aneurysm, 2.5 cm 
in dimension, arising from the right 
internal carotid artery at its origin 
from the common carotid artery. 
The left external carotid artery ap­
peared to be slightly dilated but was 
not frankly aneurysmal. The aortic 
arch appeared normal. Under gener­
al anesthesia, the right internal ca­
rotid artery was exposed by a longi­
tudinal incision along the anterior 
border of the sternocleidomastoid 
muscle. The common carotid, exter­
nal carotid and internal carotid ar­
teries distal to the aneurysm were 
identified and controlled. Grossly, 
there was an aneurysm of the inter­
nal carotid artery, 2.5 cm in diame­
ter, originating at the bifurcation 
and extending for 2.5 cm up the 
internal artery (Fig. 2). The com­
mon carotid, external carotid and 
distal internal carotid vessels were 
entirely normal. A segment of sa­
phenous vein was harvested, sys­
temic heparinization was carried 
out, the respective arteries were 
clamped and the aneurysm was 
opened. An internal Inahara-Pruitt 
shunt was inserted into the com­
mon and internal carotid arteries 
with the saphenous vein reversed 
and placed over the distal limb of 
the shunt, to re-establish blood flow 
to the right hemisphere. The distal 
anastomosis was fashioned with 
running 6-0 Prolene suture. A por­
tion of the proximal anastomosis
was completed similarly, then the 
shunt was removed, the arteries 
were re-clamped and the proximal 
anastomosis was finished. The total 
ischemia time was 7 minutes. The 
heparin effect was reversed with 
protamine sulfate and the wound 
was closed in layers. Postoperative- 
ly, the patient became conscious 
immediately and had no neurologic 
deficits. Her postoperative course 
was uncomplicated. A duplex scan 
of the surgical site 2 years postop-
FIG. 1. Arch aortogram shows saccular 
aneurysm (arrow) of right internal ca­
rotid artery.
FIG. 2. Operative view of right inter­
nal carotid aneurysm. Large vessel 
loops are around internal carotid ar­
tery (left) and common carotid artery 
(right); smaller, coloured loops sur­
round external carotid and large silk 
stitch (arrow) marks superior thyroid 
artery.
eratively revealed a patent graft 
with no aneurysmal dilatation.
Histologic sections of the aneu­
rysm wall showed extensive cystic 
medionecrosis with marked medial 
elastic fibre fragmentation and dis­
solution (Fig. 3), associated with 
striking deposition of amorphous 
intercellular ground substance and 
the presence of prominent cystic 
areas (Fig. 4).
Discussion
Patients with Marfan’s syndrome 
usually die at an early age, due to 
cardiovascular events in 90% to 
100% of patients.3 Fusiform aneu­
rysms of the ascending aorta with 
subsequent aortic insufficiency and 
congestive heart failure, dissecting 
aortic arch aneurysms and mitral 
valve disease are the usual cardio­
vascular abnormalities which lead 
to death. Rarely, an isolated aneu­
rysm of the carotid artery is discov-
FIG. 3. Section of aneurysm site show­
ing fragmentation and loss of medial 
elastic fibres (elastic-van Gieson’s 
stain, original magnification X 250).
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ered in a patient with Marfan’s 
syndrome.67 In these patients, ca­
rotid artery aneurysms usually are a 
result of dissection of the aortic 
arch extending into the common 
carotid artery. Why fusiform as­
cending aortic aneurysms occur in 
some patients with Marfan’s syn­
drome and aortic dissection occurs 
in others, appears to be related to 
the status of the aortic media. Rob­
erts and Honig3 noted that in pa­
tients with a fusiform or saccular 
aneurysm of the aortic arch, histo­
logic analysis of the wall of the 
aorta revealed severe cystic medial 
necrosis. Conversely, in patients 
with aortic arch dissection, there is 
minimal or no evidence of cystic 
medial necrosis. This coincides with 
the pathologic features demonstrat­
ed in our patient. The saccular 
aneurysm was isolated to the proxi­
mal internal carotid artery and had 
severe cystic medial degeneration.
Simple, true, dissecting aneu­
rysms are not prone to thromboem­
bolic complications and can be 
treated medically with anticoagula­
tion, allowing the port of re-entry to 
heal with a minimal risk of 
stroke.8-9 Saccular or fusiform aneu­
rysms of the carotid artery, howev­
er, have an increased risk of throm­
bus formation and subsequent em­
bolization. The incidence of stroke 
in patients with these aneurysms, 
regardless of the cause, approaches 
50%.9 It is because of this high 
stroke rate that surgical treatment 
has evolved.
Surgery of carotid artery aneu­
rysms dates back to 1808 when Sir 
Astley Cooper first successfully 
treated a carotid artery aneurysm by 
ligation.10 Since then, surgical 
treatment has matured greatly with 
a marked improvement in results.
Basic principles of carotid artery 
surgery must be applied to carotid 
aneurysm repair and a special effort 
made to minimize handling of the 
aneurysm to avoid embolization. 
Adequate proximal and distal con­
trol is necessary, and cerebral pro­
tection must be assured. Autoge­
nous vein is the material of choice 
for the interposition graft. Because
of the more extensive tissue dissec­
tion with a carotid aneurysm, local 
anesthesia is not advocated. The 
best method to monitor cerebral 
ischemia under general anesthesia 
is continuous electroencephalo- 
graphic monitoring with subse­
quent selective shunting.6 If this is 
not possible, then a carotid shunt 
should be used routinely.11
A useful technique is to place the 
vein graft over the distal end of the 
shunt before shunt placement. This 
allows the surgeon to do the distal 
anastomosis and part of the proxi­
mal anastomosis with an in-lying 
shunt. The shunt can then be re­
moved to allow completion of the 
proximal anastomosis with minimal 
ischemia time. This technique al­
lows the surgeon to work with 
good cerebral protection and at a 
relaxed pace to assure technical 
perfection.
Carotid artery aneurysms can be 
complex and their treatment must 
be individualized,12 but by adhering 
to basic principles and using the 
expanded knowledge gained from 
cases like this one, we will be able 
to treat these serious problems with 
a morbidity and mortality similar to 
that of elective carotid endarterecto­
my.
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NOTICES
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International Conference on 
Gallstones
An international conference on gall­
stones and their management is to be 
held in Jerusalem from Feb. 25  to Feb 
28 , 1990. The conference will cover 
diverse aspects of gallstone disease; 
epidemiology, natural history, patho­
genesis, biliary imaging, motility and 
particularly new therapeutic modalities, 
such as shock-wave lithotripsy, direct 
dissolution of gallstones, medical disso­
lution and endoscopic management. 
The role of surgery and the long-term 
problems of recurrence and prevention 
will also be discussed. The organizing 
committee comprises T. Gilat and S. 
Bar Meir from Israel, J. Geenan and W. 
Hogan from the United States, M. Clas­
sen from Germany and H. Dowling from 
the United Kingdom. For further infor­
mation contact; Gallstone Conference, 
Vered Congress, 15 Weizman St., Nes 
Ziona 7 0 400 , Israel; tel: 0 8 -4 0 0 7 7 7 , 8, 
9; 4 0 0 5 6 2 ; telex: 381 3 6 1  VERED IL; 
fax: 972-8-404142 .
Lederle Surgical 
Infectious Diseases 
Fellowship
Purpose
To support research in the broad area of 
surgical infections including critical care, 
metabolism, and nutrition as they relate to 
the septic surgical patient.
Successful applicants in 1989/90
Lederle congratulates the two recipients of 
last year’s fellowship.
Dr. Bill Fragiskos researching under 
Dr. M urray Girotti at the Toronto G eneral 
Hospital. This project relates to non-specific 
host defenses in subjects with anergic 
response to skin test antigens.
Dr. Tellado-Rodriguez researching under 
Dr. N icolas Christou at McGill University.
This project will investigate specific immu­
nological changes in patients suffering 
from blunt trauma.
These research projects will contribute 
to the rapidly growing understanding 
o f the com plexities of host defenses in 
resisting disease.
Applications are invited for 1990/91
Applications are invited for two fellowships, 
carrying a grant of $15,000 for one year 
to support a Canadian surgical trainee 
working in a Canadian laboratory.
The fellowship, which starts on 
July 1st, 1990, is offered by Lederle 
Laboratories in co-operation 
with the Canadian Association 
of General Surgeons.
Inquiries and applications 
should be sent to:
Dr. John Duff, Chairman, Projects Committee 
of tlie Canadian Suigical Research Fund 
Canadian Association of General Surgeons 
University of Western Ontario 
339 Windennere Rd, Box 5339 
London, Ontario N6A 5A5
466 CJS. VOL. 32, NO. 6, NOVEMBER 1989
ORIGINAL ARTICLES
Objective Comparison of Manual 
Dexterity in Physicians and Surgeons
D. Squire, MD;* A.A. Giachino, MD, FRCSC;* A.W. Profitt, MD, FRCSC;t C. Heaney, OTJ
Recent interest in the assessment of manual dexterity of surgical residency 
applicants prompted an investigation of psychomotor skills in surgeons and 
physicians. The Purdue Pegboard and Minnesota Manual Dexterity tests were given 
to 57 subjects. Analysis of the data revealed no significant difference in 
dexterity between medical and surgical residents, suggesting that medical students 
do not select specialty training programs because of the presence or absence of 
manual skills. The data also revealed that surgical staffmen performed substantially 
worse than those in the other groups on some of the tests, possibly because of an 
older average age. The authors conclude from their data that manual dexterity tests 
should not be used in assessing candidates for surgical residency training positions.
L’interet recent pour revaluation de la dexterite manuelle des candidats a residence 
en chirurgie est a l’origine de cette etude portant sur les aptitudes psychomotrices 
des chirurgiens et medecins. Le panneau alveole Purdue et l’epreuve de dexterite 
manuelle Minnesota ont ete utilises pour tester 57 sujets. L’analyse des resultats n’a 
revele aucune difference d’aptitude entre les residents de medecine et ceux de 
chirurgie, ce qui indique que les etudiants ne choisissent pas leur programme de 
formation de speciality en fonction de la presence ou de l’absence de dexterite 
manuelle. Les donnees revelent egalement que les chirurgiens ont ete sensiblement 
pires que les autre groupes dans l’execution de certains tests, possiblement parce 
que leur age moyen etait plus eleve. Les auteurs concluent de ces resultats que les 
epreuves de dexterite manuelle ne devraient pas etre utilisees pour evaluer les 
candidats aux postes de residents en chirurgie.
W ith increasing competition for residency training positions, 
selection committees are striving to 
identify methods of choosing the 
most appropriate candidates. It is 
often assumed that a surgeon has
special manual skills and that surgi­
cal results are directly related to 
manual dexterity. Therefore, as an 
adjunct to the usual selection proc­
ess, several programs1 have begun 
assessing the manual skill of appli­
cants. We question the validity of 
this concept, and in this study we 
compared the manual dexterity of 
physicians and surgeons, including 
residents and attending staff. We 
attempted to answer the following 
questions:
•  Is there a difference in manual 
dexterity between physicians and 
surgeons?
•  Is surgical skill primarily de­
termined by manual dexterity?
•  Do medical students select 
specialties according to their skills?
•  Is it reasonable to skill-test 
surgical residency applicants?
Methods and Study Population
Two standardized tests of hand 
function, the Purdue Pegboard Test 
(Fig. 1) and the Minnesota Manual 
Dexterity Test were used to assess 
the subjects. The Purdue Pegboard 
consists of four subtests, each 
scored separately, plus a fifth de­
rived score. Each hand is tested 
separately, then both hands togeth­
er and finally a simple assembly of 
small objects is performed. Each 
test has a specific time limit and the 
score relates to the number of tasks 
performed in that time. The fifth, 
derived score is a sum of the first 
three (right hand, left hand, both 
hands).
The Minnesota Manual Dexterity 
Test has two parts: a turning test 
(Fig. 2) and a placing test (Fig. 3). 
In the turning test, a subject is 
timed as he turns two coloured
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discs and reinserts them into appro­
priate holes. In the placing test, the 
subject reinserts each disc into its 
appropriate hole. Each test is timed 
and performed five times. The first 
result is discarded as a practice and 
the remaining four are summed to 
give a cumulative score in seconds.
Twenty-six surgical residents, 18 
medical residents, 7 attending sur­
geons and 6 attending physicians 
participated in the study (Table I). 
The ages of the medical and surgi­
cal residents were similar while the 
surgical staff were slightly older 
than the medical staff. The data 
were analysed using a one-way anal­
ysis of variance, and modified f-tests 
where applicable.
Results
Purdue Pegboard
The results of testing the domi­
nant hand, the nondominant hand 
and both hands together showed 
that there was no significant differ­
ence between medical and surgical 
residents; the surgical staffmen’s 
scores were significantly (p < 0.01) 
lower than those of the other three 
groups. No groups bettered the 
average score of 10 000 American 
assembly workers2 (Figs. 4 to 6).
When the entire medical group 
was compared to the entire surgical 
group no significant difference in 
scores was noted.
The assembly subtest (Fig. 7) 
again showed no difference between 
the two groups of residents. Both 
the medical and surgical staff had 
lower scores but were not signifi­
cantly different from each other.
Minnesota Manual Dexterity Test
The two groups of residents re­
ceived nearly identical scores (96%) 
on the turning test and the medical 
staff excelled with a 99 percentile
FIG. 2. Minnesota Manual Dexterity Test: turning test.
FIG. 3. Minnesota Manual Dexterity Test: placing test.
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result, but the surgical staff per­
formed worst of all with a 77 
percentile average (Fig. 8). The
placing test (Fig. 9) gave similar 
results to the assembly subtest of 
the Purdue Pegboard (Fig. 7). The
Table I. Participants
Physicians Surgeons
Residents Staff Residents Staff
No. of subjects 18 6 26 7
Mean age, yr 28 42 29 46
residents were grouped around one 
mean and did better than the staff 
who recorded poorer scores but 
were similar to each other.
Discussion
Since its original design, the Pur­
due Pegboard has been extensively
FIG. 4. Results of Purdue Pegboard Test using dominant 
hand. Norm. = average score of 10 000 American assembly 
workers.2
!
FIG. 6. Results of Purdue Pegboard Test using both hands.
NUMBER OF PEQS
RESIDENTS STAFF RESIDENTS STAFF NORM.
FIG. 5. Results of Purdue Pegboard Test using nondominant 
hand.
NUMBER OF PIECES
RESIDENTS STAFF RESIDENTS STAFF NORM.
FIG. 7. Results of Purdue Pegboard, assembly test.
TIME (SECONDSI
FIG. 8. Minnesota Manual Dexterity Test. Results of turning 
test.
SU R G IC AL
32.0%  lie
RESIDENTS STAFF RESIDENTS STAFF
FIG. 9. Minnesota Manual Dexterity Test. Results of placing 
test.
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investigated and found to measure 
“the ability to make rapid con­
trolled manipulative movements of 
small objects where the fingers are 
primarily involved’’.2 In addition, 
the assembly subtest measures “the 
ability to make skillful controlled 
arm-hand movements of large ob­
jects” .2
The Minnesota Manual Dexterity 
Test was designed to measure na­
tive speed capacity of simple but 
rapid eye-hand coordination.3 The 
hand and wrist are primarily used in 
the turning test, and the placing 
test assesses large scale movements 
involving the elbow and shoulder. 
The assembly subtest of the Purdue 
Pegboard and the placing test of 
the Minnesota Manual Dexterity 
Test measure similar capabilities. 
Recognizing the validity of these 
tests, we now return to the original 
four questions.
•  Is there a difference in the 
manual dexterity of physicians and 
surgeons? With the exception of 
the turning test of the Minnesota 
Manual Dexterity Test, all tests 
showed no difference when the en­
tire medical group was compared to 
the entire surgical group. The rela­
tively poor performance of the sur­
gical staff on some tests was unex­
pected. If this was a valid observa­
tion then the concept that manual 
dexterity is paramount for success 
in surgery is unfounded. The poorer 
performance may have been a sam­
pling error due to the small number 
of the group or related to the 
slightly older average age of the 
surgical staff.
•  Is surgical skill determined 
primarily by manual dexterity? 
Since a group with no surgical 
skills (physicians) had manual dex­
terity ratings equivalent to those of 
their surgical colleagues, manual 
dexterity is not the primary determi­
nant of surgical skills. In 1984, 
Schueneman and colleagues1 stud­
ied 120 general surgical residents 
and attempted to correlate a subjec­
tive assessment of operative skills 
with various tests of neuropsy- 
chologic ability. They concluded 
that “pure psychomotor skill is not 
the major dimension in distinguish­
ing the proficient surgical perfor­
mance from the mediocre”.
•  Do medical students select 
specialties according to their skills? 
This does not appear to be the case, 
otherwise the two groups of resi­
dents would have shown some dif­
ference in the test results. For many 
years, dental schools used skill tests 
in an attempt to correlate manual 
dexterity with technical success in 
the profession. The chalk carving 
test, generally adopted by dental 
schools for the assessment of psy­
chomotor skills in 1949, has been 
abandoned in favour of a paper and 
pencil perceptual motor ability test,1 
which is at least as good, or better, 
a predictor of future technical 
grades.45 Debate continues about 
the reliability and predictive capaci­
ty of these two tests,4-8 and, after 
years of use, there is still no clear 
conclusion.
•  Is it reasonable to skill-test 
surgical residency applicants? We 
believe our study indicates that
medical students who become sur­
geons do not possess a higher level 
of manual dexterity than those who 
choose medicine, and that factors 
other than simple manual ability 
differentiate the proficient surgeon 
from the mediocre. From our re­
sults we cannot advocate the use of 
skill tests in assessing applicants 
for surgical residency programs.
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HISTORY OF SURGERY
T h e Life and Times of Guillaume 
Dupuytren
P. Wylock, MD
Guillaume Dupuytren’s good fortune was the time of his birth. He was a product of 
revolutionary change in France, and without it he would never have become a 
surgeon. From south central France he came to Paris to become a surgeon and 
reached his goal, literally, “on a crust of bread”. Dupuytren is remembered 
principally for the hand condition which bears his name; his other numerous and 
more-important contributions have been ignored. Never happy outside the operating 
room — or perhaps inside it either, due to his mania for perfection — this arrogant 
master surgeon constantly clashed with his colleagues, staff and the few friends he 
had. When he died at the age of 57 years, he had advanced surgery on many 
frontiers.
Guillaume Dupuytren beneficia de l’epoque de sa naissance. Ne avec les bouleverse- 
ments de la Revolution frangaise, il n’aurait jamais pu devenir chirurgien sans eux. 
Venant du centre sud de la France, il arriva a Paris pour devenir chirurgien et il y 
parvint malgre le plus grand denuement. On se rappelle surtout de Dupuytren pour 
l’affection de la main qui porte son nom; ses contributions nombreuses et plus 
importantes ont ete ignorees. Il n’etait jamais heureux hors de la salle d’operation et 
peut-etre pas davantage quand il etait dans son enceinte. A cause de sa manie de la 
perfection, cet arrogant mattre-chirurgien se disputait constamment avec ses 
colleges, le personnel et le peu d’amis qu’il avait. A son deces, a Page de 57 ans, il 
avait fait avancer la chirurgie sur plusiers fronts.
Contracture of the fingers and the palm was described in the 
early 17th century by Plater, a 
professor at Basel University. He 
was convinced that the manual ac­
tivities of one of his patients — a 
sculptor — had caused the flexor 
tendons to shrivel up after they had 
come loose from their connections 
deep in the palm.1 The same phe-
Accepted for publication July 18, 1989
nomenon was diagnosed in the 18th 
century by Astley Cooper and Alex­
is Boyer, among others. They both 
considered this disease incurable. 
Yet in the 19th century three fac­
tors presented the anatomist and 
surgeon Guillaume Dupuytren with 
an opportunity to have his name 
immortalized.2-3
•  On Dec. 5, 1831, he started
his anatomy course by saying that 
he would only discuss one patient 
and one disease. The patient was a 
40-year-old coachman named De- 
marteau.
•  He described the symptoms of 
this disorder in a present-day man­
ner. During the course, he demon­
strated a dissection of an old man’s 
hand, affected by a contracture, and 
proved that this deformation was 
caused neither by the tendons nor 
by the skin, but by a retraction of 
the palmar aponeurosis.
•  After this clinical and anatom­
ical demonstration, he went on to 
discuss another patient upon whom 
he had carried out a surgical correc­
tion. He had been observing this 
patient since 1811; his contracture 
had evolved in such a way that 
Dupuytren decided to operate, 
which he did on June 12, 1831, 
without using anesthetics. He made 
a transverse incision approximately 
3 cm long at the midpalmar fold, 
fifth ray, then a second incision at 
the proximal interphalangeal fold 
and a third at the base of the 
proximal phalanx. The incision of 
the palmar aponeurosis was accom­
panied by a “clearly audible crack”. 
The fingers were straightened and a 
bandage was applied. Healing was 
complete by July 2, and an exten­
sion splint was applied until Aug.
2 . 4-7
To conclude that historic day in 
December 1831, he operated on the
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hand of Jean Joseph Demarteau, 
who was neither a coachman nor 
the first patient he had treated for 
contracture.3-8
The Life Story of Guillaume 
Dupuytren
In that rich period of French 
medicine, the era of Larrey, Roux, 
Delpech, Bichat and Laennec, Du­
puytren was the most ambitious, 
the most aggressive and the most 
talented, maybe as a consequence of 
his “relatively” humble origin. He 
was born in 1777, the son of a 
not-particularly well-off lawyer. In 
1789, at the age of 12 years, he 
was taken to Paris to finish his 
studies. His family had a few sur­
geons in its ranks, hence his voca­
tion. In the 17th century a Michel 
Dupuytren had lived in Pierre-Buf- 
fiere, where he worked as a surgeon 
and at the same time kept a tobacco 
shop. Guillaume’s grandfather, 
Francois Dupuytren, had practised 
in the same town in 1759.
As a result of the fundamental 
changes brought about by the 
French Revolution, Guillaume had 
the opportunity to develop himself. 
He embarked on his medical studies 
and soon became an authority on 
anatomy.
At the age of 18 years, he suc­
cessfully passed the examination for 
prosector. Authorities such as Cho- 
part, Percy, Sabatier, Boyer and 
Desault were members of the exam­
ining board. He was put in charge 
of all autopsies at the famous Hotel 
Dieu hospital in Paris, where he 
performed almost 1000 autopsies 
annually. He became so competent 
that he was exempted from military 
service.
The Hotel Dieu hospital was situ­
ated on both banks of the River 
Seine, near the Notre Dame cathe­
dral. A hospital ward was built on 
the bridge linking the hospital
buildings. In those days the hospital 
had 1600 beds available but, in a 
period when anesthetics and an­
tiseptics were nonexistent, the 
death rate inevitably was very high. 
In this period Dupuytren suffered 
much hardship, so much so that the 
oil he needed to keep his lantern 
burning had to be prepared from 
the fat of corpses.
In 1801, at the age of 24 years, 
he became head of the anatomy 
department, and the following year 
he was appointed surgeon, second 
class. He became a doctor in medi­
cine in 1803. His thesis “Proposi­
tions sur quelques points d’anato- 
mie, de physiologie et d ’anatomie 
pathologique” was dedicated to 
Boyer. He was the founder in 1803 
of the “Societe Anatomique”. In 
1808, he obtained the prestigious 
appointment as member of the sur­
gical staff at the Hotel Dieu hospi­
tal.
In 1811 the position of professor 
of operative medicine became va­
cant. Dupuytren applied, together 
with three others — Roux, Marjolin 
and Tartra. The theoretical and 
practical examinations were ex­
tremely difficult. After fierce com­
petition, Dupuytren won, and on 
Feb. 10, 1812 he was appointed to 
the position. His thesis on lithoto­
my was considered a masterpiece. 
In 1815, at the age of 38, he 
became chief surgeon at the Hotel 
Dieu hospital, the highest surgical 
appointment in France. Dupuytren 
performed his duty with honour, 
thanks to his superior qualities, up 
until he died, in 1835, from a lung 
empyema resulting from tuberculo­
sis. Whilst Cruveilhier, Bouillaud 
and Broussais were discussing 
whether or not to drain this empy­
ema, Dupuytren himself held the 
opinion that it was better to die 
from the disease than from the 
operation.
Fellow surgeons and students 
from all over France gathered to
pay their last respects to him. His 
students carried his coffin to his 
final resting place in the Pere La- 
chaise cemetery as an ultimate 
homage to their master.9-10
Who Was Dupuytren?
Dupuytren had a noble and strik­
ing physique. He was a sturdy, 
solidly built man with a big head. 
On lithographs he is depicted as 
having a fine nose, a small mouth, 
which made him the target of ridi­
cule, dark penetrating eyes and a 
thick neck. He wore a lace collar, a 
waistcoat and a coat, the fashion of 
the day (Fig. 1).
Apparently, he was an arrogant 
and eccentric man, but he had the 
“gift of the gab” and he worked 
hard. According to one of his pu­
pils, he would stride through the 
corridors like a “god on earth”, 
pontificating and oblivious to the 
people around him. He enforced his 
authority by his sheer presence; 
everyone respected him and there
FIG. 1. Guillaume Dupuytren (1777- 
1835). (Reproduced from Delhoume L: 
Dupuytren (1777-1835), J.B. Bailliere 
et Fils, Paris, 1935.)
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would be a solemn silence whenever 
the master spoke. “Je me suis 
trompe quelques fois, mais je crois 
m ’etre trompe moins que Ies 
autres” (“I made some mistakes, 
but I think less than the others”) 
are famous words of Dupuytren.
As with so many geniuses, Du­
puytren was an awkward person, 
both toward his assistants and his 
patients, except children whom he 
liked very much. He was aggressive 
and insolent, probably out of self­
protection, as he feared that his 
reputation might be threatened by 
others.
He was not averse to intrigue or 
to ignoring other people’s work, 
nor did he have any qualms about 
plagiarizing. An early example of 
this was when he broke with one of 
his pupils, Rene Laennec, who ac­
cused him of being too self-cen­
tred.11 Rene Laennec would later 
invent the stethoscope. All this was 
quite harmless compared with the 
way he would manipulate his teach­
ers Boyer and Pelletan to further 
his personal ambitions. He managed 
to make Boyer his lifelong enemy 
by breaking off his engagement to 
Boyer’s daughter on the day before 
they were due to marry, Jan. 25, 
1810. Later he did marry and had 
one child, Adeline, but the marriage 
broke up in 1826. Boyer’s daughter 
later married Dr. Roux, Dupuytr- 
en's rival, not only in surgery but 
also in love. Roux eventually suc­
ceeded Dupuytren as chief surgeon.
Dupuytren’s Daily Schedule
Every day, before breakfast, Du­
puytren did his rounds of the 
wards, at 7:00 in the winter and 1 
hour earlier in summer. A bell was 
rung to announce his arrival, and 
he was met by the matron, “La 
Superieure”. Surrounded by his as­
sistants, students and foreign 
guests, he visited his patients, to
whom he was very rude. When he 
came to a bed he would start shout­
ing at the patient, sometimes grab­
bing the poor man by the nose and 
forcing him to sit on his knees 
before he was allowed to voice his 
complaints. (His assistants could 
judge by his mood whether he had 
won or lost money during the previ­
ous night’s gambling.)
At 9:00 the clinical lessons start­
ed. They usually lasted 1 hour. 
There followed clinical demonstra­
tions, which were often combined 
with anatomical demonstrations, 
the operating schedule being start­
ed in the same hall. In the after­
noon, Dupuytren had his private 
practice which allowed him to earn 
a fortune. He made acquaintance 
with some members of the nobility, 
among them Baron de Rothschild 
and Madame de Lavalette who be­
came his mistress. Every evening of 
the week for 20 years he insisted on 
visiting the new patients and those 
recently operated on.
In 1818, at the age of 40 years, 
Dupuytren performed 378 opera­
tions, reduced 178 fractures and 
opened up 300 abscesses. In that 
year some 2363 patients were ad­
mitted to hospital and of the 378 
patients he operated on, 228 recov­
ered. These are indeed impressive 
figures, especially in a period when 
anesthesia and antiseptics were un­
known.
Dupuytren’s Work
Dupuytren was not only known 
for his description of palmar fi­
bromatosis. He was a highly re­
spected anatomist, pathologist and 
physiologist. He is known as the 
most brilliant surgeon in the period 
before antiseptics and anesthesia 
were discovered. Moreover, he was 
a competent teacher.12
He was well known for his treat­
ment of bone cysts, aneurysms and
fractures. The bimalleolar ankle 
fracture is also referred to as Du­
puytren’s fracture. He performed 
mandibular resection for a sarcoma 
in 1812. He treated aneurysms by 
compression and performed a sec­
tion of the sternocleidomastoid 
muscle for torticollis. He success­
fully ligated the external iliac artery 
and subclavian artery. He also per­
formed cataract operations, lithoto­
mies and artificial anal reconstruc­
tions.13
Although he has often been ac­
cused of plagiarism, Dupuytren did 
make some clever observations; 30 
years (in 1831) before Langer, he 
described the directions of the lines 
of the skin and their meaning, and 
Langer later acknowledged this.14 
He also gave a detailed description 
of the anatomy of the facial and 
phrenic nerves. He classified burns 
into six different categories, and he 
advised treatment with silver nitrate 
solution (130 years before Moyer).15
Dupuytren also treated hernias. 
Nevertheless, we had to wait until 
anesthetics and antiseptics were dis­
covered before careful anatomic re­
covery could be accomplished as it 
is today. Before that, hernia repair 
had to be carried out swiftly be­
cause of the pain; moreover, it was 
a dangerous operation because sep­
sis occurred frequently. For this 
reason, only major hernias were 
treated, and in these cases the ana­
tomical proportions were usually 
completely distorted. A major liga­
tion was usually performed on the 
hernial sac. A visitor once observed 
how even Dupuytren cut into the 
bowel at the original skin incision 
during two subsequent demonstra­
tions. Dupuytren also misjudged 
the frequent death of young adults 
as a result of peritonitis. He 
thought the problem was at the 
cecum rather than at the appendix.
His experience with the injured 
of the Napoleonic Wars and the 
Revolution of 1830 led him to write
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with authority about trauma.1617
Dupuytren did not write much 
during his lifetime. His lecture 
notes come to us courtesy of his 
students and were edited as “legons 
orales”.
Contributions to Plastic 
Surgery
Dupuytren’s comments and con­
tributions to plastic surgery came 
from his broad directions in general 
surgery rather than from a specific 
inclination toward reconstructive 
surgery.1317
He performed cleft lip operations, 
but had problems with the premax­
illa in bilateral cleft lip patients. He 
showed the same impatience with 
the projecting premaxilla that he 
did with a troublesome patient.18 He 
performed columella reconstruction 
with a lip flap and reductions of 
fractures of the zygomatic bone.
France During the Life of 
Dupuytren
Dupuytren lived through a period 
of tremendous upheaval in France. 
At the time of his birth, Louis XVI 
(1754-1793) was still in power. 
The French Revolution and the 
storming of the Bastille on July 14, 
1789 was a milestone in French 
history. The States-General deposed 
the king and declared themselves 
the constitutional legislators. The 
feudal system came to an end and 
was replaced by a bourgeois democ­
racy. Medical colleges were freed 
from scholasticism and archaic prin­
ciples. “Practical” medicine was ad­
vocated instead of “theoretical” 
medicine. Education was ap­
proached clinically. For the first 
time, the medical colleges were 
opened to poorer students wanting 
to study medicine.
“Liberte, egalite, fraternite” were 
no idle words. Dupuytren was lucky
to have been born just before that 
period. He was an exponent of the 
revolutionary changes which had 
taken place in France and without 
which he never could have become 
a physician.19
In 1792, Louis XVI was deposed 
and a republic was established. The 
struggle between the Jacobins and 
the Girondins was at its fiercest. 
During that period the civil mar­
riage was introduced as separate 
from the church marriage.
Louis XVI was decapitated in 
1793, and his wife Marie-Antoinette 
suffered the same fate some 10 
months later. This period was domi­
nated by the reign of terror con­
ducted by Robespierre, and it was 
the heyday of the guillotine. In 
1795, a “Directoire” of five direc­
tors was installed. The Southern 
Netherlands were annexed by 
France.
In 1799, Napoleon Bonaparte 
seized power in a coup and became 
a consul. In 1804, he had himself 
crowned emperor and embarked on 
his campaigns of conquest. In 
1812, the Russian campaign was 
conducted and Moscow besieged. 
But the retreat of his “grande ar- 
mee” was a disaster. After Napo­
leon was exiled to Elba in 1814, 
Louis XVIII, brother of Louis XVI, 
became king of France. At the 
Congress of Vienna, in 1815, Bel­
gium and the Netherlands were 
united into one kingdom under Wil­
liam I.
Yet Napoleon returned for 100 
days. He deposed Louis XVIII and 
gathered a new army but was deci­
sively defeated at the Battle of 
Waterloo (on June 18, 1815).
Louis XVIII returned to power, to 
be succeeded in 1825 by King 
Charles X who attempted to re­
establish absolute monarchy. After 
the revolution in Paris in July 1830, 
Charles X was forced to abdicate in 
favour of the bourgeois king, Louis 
Philippe d’Orleans.
The real aim of the French Revo­
lution of 1789 was in fact not 
realized until 1830.
At that time Dupuytren was the 
court physician to Charles X, and 
he gave the exiled king financial 
support which amounted to 1 mil­
lion francs, a fortune in those days.
Dupuytren’s Students and 
Influence
Dupuytren had pupils from all 
over Europe, even from the United 
States. Medicine in France was in 
full bloom. The ground that had 
been lost in the 18th century was 
quickly regained during the 19th 
century, and French medicine had a 
great influence on European medi­
cal science. There was Corvisart, 
who rediscovered percussion; Bi­
chat, who established that our or­
gans are made up of tissue; Laen- 
nec, who discovered auscultation; 
Magendie, who pointed out that 
physiologic tests formed the corner­
stone of research and Claude Ber­
nard, who introduced determinism 
as the basis of biologic and physio­
logic research.
Apart from Dupuytren there were 
other talented French surgeons like 
Velpeau, Malgaigne and Nelaton. 
Comhere and Michaud are perhaps 
the best known Belgian pupils of 
Dupuytren.
What is not so well known is that 
Dupuytren’s fame had reached as 
far as the United States.2021 On the 
east coast the flourishing towns of 
Boston, New York, Philadelphia 
and Charleston were important 
trading centres. The gigantic fleet 
of packet boats, great three-mast 
sailing ships which established a 
regular connection between the old 
and new worlds contributed to this. 
Surgeons like J.C. Warren (1778- 
1855) and his son J.M. Warren 
(1811-1857) were pupils of Du­
puytren. They were both professors 
of surgical science at Harvard Uni­
versity. Along with other brilliant
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surgeons, they stood out at the 
beginning of a new and successful 
era in American medicine.
Conclusions
Guillaume Dupuytren was cer­
tainly not liked, but he was respect­
ed and admired by his colleagues as 
the “Napoleon” of French surgical 
science. He was both coarse and 
intriguing. Baron Pierre Percy 
(1754-1825), an eminent military 
surgeon, described him as “the first 
of surgeons and least of men” . 
Jacques Lisfranc (1790-1847), sur­
geon at the La Pitre hospital, called 
Dupuytren the brigand of the Hotel 
Dieu. The patients were terrified in 
his presence, yet at the same time 
they venerated him as a deity. The 
respect he got when he said in a 
cold manner “ I will cure you” was 
indescribable.
He remained cool-headed and 
calm when a patient died on the 
operating table, and when he felt 
that his time had come, he wished 
to die in the hands of God, without 
surgical treatment. Right up to the 
end he did not tolerate any competi­
tion.
Dupuytren was a controversial 
figure whose mottoes were: “riert 
n ’est tant a redouter pour un 
homme que la mediocrite” (“noth­
ing save mediocrity is to be feared”) 
and “peu lire, beaucoup voir, beau- 
coup faire” (“read little, see much, 
do much”).22
I gratefully acknowledge the assistance 
of Dr. Stan Monstrey.
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Canadian Association of General Surgeons 
Resident Research Award
The Canadian Fund for the Advancement of General Surgery will award a prize to 
the resident in general surgery submitting the best research paper.
Prize
1) Return Airfare, hotel expenses, and a per-diem allowance to present the work 
at the Annual Meeting of the Canadian Association of General Surgeons to 
be held in conjunction with the Annual Meeting of the Royal College of 
Physicians and Surgeons of Canada, Toronto, Ont., Sept. 14-17, 1990.
2) $500.
Eligibility
Any resident or fellow in general surgery. The research must have been performed 
during surgical training at a Canadian medical school.
Abstract and Brief Description
An abstract must be submitted to the Royal College, but CAGS must be 
designated as the first choice for presentation. The abstract must be 
accompanied by a brief expanded description of the work performed. This 
should be a maximum of two double-spaced pages and include the following 
headings: Title, Introduction, Materials and Methods, Results and Discussion. 
Applicants must also submit a letter confirming their status as a resident or fellow 
and indicating that the work is submitted for the resident research award 
competition.
Deadline 
Mar. 9, 1990.
Inquiries should be addressed to:
Dr. Gerald M. Fried
Chairman, CAGS Research Committee 
Montreal General Hospital 
1650 Cedar Avenue, #  9863 
Montreal, Quebec H3G 1A4
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
month before issue date. Regular classified rates (for each insertion): $45.00 for the first 40 words or less, additional words 60p each 
(additional $17.00 for frame). Special Display under 100 words, 2'/4 in. X 2 in., $110.00. $6.00 charge (first insertion only) for CJS box 
numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
VASCULAR SURGEON: MB -  Applications 
are invited for the geographic full-time posi­
tion of Vascular Surgeon, Department of Sur­
gery, University of Manitoba and Health Sci­
ences Centre. Candidates must have senior 
specialty qualifications in vascular surgery in 
the country of current practice and must be 
eligible for registration with the College of 
Physicians and Surgeons of Manitoba. Certifi­
cation in vascular surgery by the Royal Col­
lege of Physicians and Surgeons of Canada is 
preferred. Preference will be given to candi­
dates with training in, and a major commit­
ment to, research. Salary and academic rank 
will be commensurate with experience and 
qualifications. Both men and women are en­
couraged to apply. In accordance with Cana­
dian immigration requirements, this advertise­
ment is directed to Canadian citizens and 
permanent residents. Interested candidates 
should apply in writing, enclosing a curriculum 
vitae, to: Dr. R.J.W. Blanchard, Professor 
and Head, Department of Surgery, Health 
Sciences Centre, GC401-820 Sherbrook 
St., Winnipeg, MB Canada R3A 1 R9.
—S 8 9 - 4 2
CLINICAL BURN FELLOWSHIP: ON -  A
12-month clinical burn fellowship is available 
at the Toronto Regional Adult Burn Centre, at 
the Wellesley Hospital, beginning July 1, 
1990. The unit is a very well-staffed, new, 
ultra-modern, self-contained burn centre, with 
110 adult patients per year. Position totally 
funded. Clinical research available. Extensive 
research funding in place. Please contact: Dr. 
Walter Peters, Suite 224, Turner Wing, 
Wellesley Hospital, 160 Wellesley St. E., 
Toronto, ON M4Y 1J3. Tel: (416)
926-7790. - S 8 9 - 3 7
GENERAL SURGEON: ON -  Excellent op­
portunity exists in Sarnia/Lambton County to 
develop a lucrative private practice covering 
the full scope of general surgery. The Sarnia 
hospitals provide a total of over 350 active 
care beds with above-average support ser­
vices. An interest in trauma surgery would be 
useful in connection with patients admitted to 
the Sarnia General Hospital Level II Emergency 
Trauma Program. The city of Sarnia and
county of Lambton catchment area has a total 
population of 120 000. Superior recreation 
facilities for persons who enjoy sailing and 
other water sports, golf and curling, etc., are 
available. For further information call or write 
to: K.E. Dickie, MD, FRCSC, Chief of Sur­
gery, Sarnia General Hospital. 220 N. Mit- 
ton St., Sarnia, ON N7T 6H6. Tel: (519) 
332-0210 (office), or P.N. Mehta, MD, 
FRCSC, Chief of Surgery. St. Joseph's 
Hospital, 290 N. Russell St., Sarnia, ON 
N7T 6S3. Tel: (519) 336-7860 (office).
- S 8 9 - 3 6
TRANSPLANT FELLOWSHIP, UNIVERSI­
TY HOSPITAL, LONDON: ON -  University 
Hospital, London, Ontario has three openings 
for fellows in multi-organ transplantation, 
starting July 1, 1990. Our 2-year fellowship 
program includes experience in clinical and 
experimental transplantation. We expect to 
perform 40-50 heart, heart-lung and lung 
transplants; 70 liver transplants: 80 kidney 
transplants and 5 bowel transplants in 1990. 
Candidates who have completed their training
HEAD OF PEDIATRIC ORTHOPEDICS
British Columbia Children’s Hospital/ 
University of British Columbia 
Vancouver
British Columbia, Canada
British Columbia Children’s Hospital, a 240-bed ter­
tiary, multi-disciplinary and acute care hospital, serving 
a population of between 2-1/2 to 3 million people, fully 
affiliated with the University of British Columbia, Facul­
ty of Medicine, requires a Head for the Pediatric 
Orthopedic Department. The current Department of 
Pediatric Orthopedics comprises four pediatric ortho­
pedic surgeons, who are committed to maintaining a 
high standard of teaching for undergraduate medical 
students and residents in orthopedics as well as other 
specialties.
The successful candidate will have an FRCSC or 
equivalent; be eligible to practise medicine in British 
Columbia; will be recognized as a skilled surgeon and 
an outstanding teacher; will have superior leadership 
qualities and planning abilities with previous ex­
perience in a senior administrative position; and will 
maintain an active interest in clinical and laboratory 
research.
Interested candidates should forward their curriculum 
vitae to:
Hjalmar W. Johnson, MD, FRCSC 
Acting Head
Division of Urology, Department of Surgery
University of British Columbia
c/o Room 1L7, B.C. Children’s Hospital
4480 Oak Street, Vancouver, BC
V6H 3V4 S 8 9 -3 9
CAMP HILL ChiEF
MEDICAL department of
CENTRE SURGERY
Camp Hill Hospital •  Halifax Infirmary Hospital
Camp Hill Medical Centre, a 750-bed facility providing community, regional 
and provincial referral services, invites applications for the position of 
Chief of Surgery. The Centre represents the recent consolidation of Camp 
Hill and Halifax Infirmary Hospitals.
The combined Department of Surgery includes 17 surgeons providing 
general, thoracic, vascular, or orthopedic and plastic surgery and four oral 
surgeons comprising the Division of Dentistry, Oral and Maxillofacial 
Surgery. A total of 150 active treatment beds are located on the two sites. 
The Department is affiliated with teaching programs at Dalhousie 
University.
The Chief of Surgery will be responsible for providing academic and 
clinical leadership in the Department, developing programs at both 
h o sp ita ls , and p a rtic ip a tin g  in p lann ing  fo r a new 540-bed 
acute care facility.
The successful candidate will have an FRCSC, be eligible to practise 
medicine in Nova Scotia, be recognized as a skilled surgeon and teacher, 
have superior leadership qualities and planning abilities and have previous 
experience in an administrative position.
In accordance w ith Canadian im m igration requirem ents, th is  
advertisement is directed to Canadian citizens and permanent residents 
of Canada. Camp Hill Medical Centre is an equal opportunity employer.
Interested candidates should forward their curriculum vitae to:
Dr. S.F. Boudreau
Chairman of Surgical Search Committee 
Camp Hill Medical Centre 
1335 Queen Street 
Halifax, Nova Scotia
B3J 2H6 S 8 9 -4 0
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in anesthesia, internal medicine, general sur­
gery or pediatrics, and are eligible for educa­
tional or general licensure in Ontario, will be 
given priority. Submit resumes to: Dr. David 
R. Grant, Director, Transplant Unit, PO 
Box 5339, University Hospital, London, 
ON N6A 5A5. -S89-38
PLASTIC SURGERY SECTION HEAD:
MB -  Faculty of Medicine, University of 
Manitoba, invites applications for the po­
sition of Plastic Surgery Section Head. 
This contingent, geographic full-time posi­
tion includes a University of Manitoba 
appointment as Associate Professor in 
the Department of Surgery, Section of 
Plastic Surgery, and provides opportunity 
for private practice. Applicants must be 
eligible for registration with the College of 
Physicians and Surgeons of Manitoba and 
hold certification in plastic surgery by the 
Royal College of Physicians and Surgeons 
of Canada. Demonstrated academic ac­
complishments, administrative ability and 
expertise in the development of teaching 
and research programs and patient care 
required. Both men and women are en­
couraged to apply. Salary will be com­
mensurate with experience. In accordance 
with Canadian immigration requirements, 
this advertising is directed to Canadian 
citizens and permanent residents. Appli­
cants should forward their completed cur­
riculum vitae, together with names of 
three referees, to: Dr. R.G. Danzinger, 
Chairman, Search Committee, c/o De­
partment of Surgery, St. Boniface Gen­
eral Hospital, 409 Tache Ave., Winni­
peg, MB R2H 2A6. -S89-41
INTENSIVIST —  DIRECTOR ICU
Peel Memorial Hospital, a 500-plus-bed community hospital, is seeking an 
intensivist for its Intensive Care Unit. The intensivist must be prepared to take a 
leadership role in providing primary care to all ICU patients and must be able to 
work in a cooperative and collaborative manner with a backup team of internists, 
anesthetists and surgeons.
Responsibilities will include ensuring that appropriate policies and procedures for 
the effective operation of the ICU are established. The successful candidate will be 
the leader of a multi-disciplinary team committed to excellence in caring for 
critically ill patients.
Candidates must be qualified and interested in working with both medical and 
surgical ICU patients. In addition, there will be opportunity for the candidate 
to practise within his specialty outside the ICU setting.
Suitable candidates for this position will possess:
— Fellowship in Royal College of Physicians and Surgeons (respirology, 
cardiology, or other medical subspecialty, anesthesia, or surgery).
— Additional training in critical care medicine (minimum 1 year).
— Demonstrated skill and experience in critical care.
— Strong leadership skills.
— Excellent communication skills.
Preference will be given to candidates who would be considered eligible for 
certification as an intensivist through the Royal College of Physicians and 
Surgeons when this becomes available.
Peel Memorial Hospital is located in the rapidly growing community of Brampton,
35 km from Toronto. The hospital is an extremely busy community hospital 
which has adopted many innovative programs.
Interested and qualified candidates should submit their curriculum vitae to:
Dr. W. Lucas 
Chief of Staff 
Peel Memorial Hospital 
20 Lynch St.
Brampton, ON
L6W 2Z8 —S89-43
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Activity against a great majority of significant 
pathogens — for most patients, appropriate 
J m  bactericidal coverage with single-agent 
antibiotic: PRIMAXIN® I.v.
Clinical efficacy — Kager and Nord evaluated 
164 patients with intra-abdominal infections 
and observed 91% cure or improvement.1
Good tolerability profile — sim ilar to 
cefazolin/t Avoids the potential nephrotoxicity 
or ototoxicity experienced w ith the 
aminoglycosides.
No cross-resistance has been observed between 
imipenem and other beta-lactam antibiotics.5
PRIMAXIN® I.V. is not active against Corynebacterium group JK,
Fusobacterium varium, Mycobacterium spp., Chlamydia spp., Streptococcus 
faecium, Pseudomonas maltophilia, and some strains of: F cepacia,
P. pseudomallei, methicillin-resistant staphylococci, and Flavobacterium spp.
1. Kager, L , Nord, C.E.: lmipenem/cilastatin in the treatment of intra­
abdominal infections: A review of worldwide experience. Rev Infect Dis 
7(suppl 3): S518-S521, July-August 1985.
2. Calandra, G.B., Ricci, F.M., Wang, C„ Brown, K.R: Safety and tolerance 
comparison of imipenem/cilastatin to cephalothin and cefazolin,
J Antimicrob Chemother 12 (suppl D): 125-131, 1983.
3. Quinn, J.P et al.: Resistance to imipenem in Pseudomonas aeruginosa:
Clinical experience and biochemical mechanisms. Rev Infect Dis 10(4):
892-898, July-August 1988.
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CARDIOVASCULAR SUTURES
Improved Cardiovascular Needles
• Special highly adherent silicone 
lubricant further reduces 
resistance...first pass, last pass
• Securely attached to the suture
Needles Resist Bending
• New, stronger needle configuration
• Superior sharpness
• Lower penetration force reduces 
strain on needle -  minimizes 
bending and breaking
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